Physicians O
should O
be O
aware O
that O
PLP I-Effect
can O
occur I-Adverse_event.Trigger
after O
initiation O
of O
paclitaxel I-Treatment.Drug
. O

Heparin O
- O
dependent O
antibodies O
and O
thrombosis O
without O
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
. O

Treatment I-Potential_therapeutic_event.Trigger
of I-Potential_therapeutic_event.Trigger
lithium I-Drug
tremor I-Treat_Disorder
with O
metoprolol I-Treatment.Drug
. O

A I-Subject
54 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
, O
treated O
with O
amiodarone I-Treatment.Drug
, O
developed I-Adverse_event.Trigger
thyrotoxicosis I-Effect
. O

Gynaecomastia I-Effect
is O
a O
rarely O
reported O
adverse I-Adverse_event.Trigger
drug I-Adverse_event.Trigger
reaction I-Adverse_event.Trigger
due O
to O
isoniazid I-Treatment.Drug
therapy I-Treatment
. O

The O
authors O
performed O
a O
literature O
search O
using O
PubMed O
and O
the O
search O
terms O
" O
gemcitabine O
" O
and O
" O
radiation O
recall O
" O
to O
find O
prior I-Subject
cases I-Subject
of O
radiation I-Effect
recall I-Effect
attributed I-Adverse_event.Trigger
to O
gemcitabine I-Treatment.Drug
. O

Carbamazepine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
Diabetes I-Effect
mellitus I-Effect
. O

She I-Subject.Gender
displayed I-Adverse_event.Trigger
symptoms I-Effect
of I-Effect
ST I-Effect
8 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
introduction I-Treatment.Route
of I-Treatment
linezolid I-Treatment.Drug
. O

Naproxen I-Treatment.Drug
is O
a O
commonly O
used O
nonsteroidal O
anti O
- O
inflammatory O
drug O
( O
NSAID O
) O
whose O
side O
effects O
include I-Adverse_event.Trigger
tinnitus I-Effect
and I-Effect
transient I-Effect
hearing I-Effect
loss I-Effect
. O

The O
allopurinol I-Treatment.Drug
hypersensitivity I-Effect
syndrome I-Effect
is O
a O
rare O
adverse I-Adverse_event.Trigger
drug O
reaction O
. O

The O
pulmonary I-Effect
toxicity I-Effect
is O
probably O
induced I-Adverse_event.Trigger
by O
piritrexim I-Treatment.Drug
. O

BACKGROUND O
: O
Interferon I-Treatment.Drug
( I-Treatment
IFN) I-Treatment
- O
associated I-Adverse_event.Trigger
retinopathy I-Effect
is I-Effect
typically I-Effect
characterized I-Effect
by I-Effect
retinal I-Effect
hemorrhages I-Effect
and I-Effect
cotton I-Effect
wool I-Effect
spots I-Effect
at I-Effect
the I-Effect
posterior I-Effect
fundus I-Effect
, O
but O
visual O
function O
is O
usually O
maintained O
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
a I-Subject
liver I-Treat_Disorder
abscess I-Treat_Disorder
due I-Subject
to I-Subject
Entamoeba I-Treat_Disorder
histolytica I-Treat_Disorder
, O
in O
whom O
metronidazole I-Treatment.Drug
therapy I-Treatment
( I-Treatment
total I-Treatment
dose I-Treatment
, I-Treatment
21 I-Treatment.Dosage
g I-Treatment.Dosage
over I-Treatment
14 I-Treatment.Duration
days I-Treatment.Duration
) I-Treatment
was O
complicated I-Adverse_event.Trigger
by O
reversible I-Effect
deafness I-Effect
, I-Effect
tinnitus I-Effect
, I-Effect
and I-Effect
ataxia I-Effect
and I-Effect
who I-Effect
relapsed I-Effect
5 I-Effect
months I-Effect
later I-Effect
with I-Effect
a I-Effect
splenic I-Effect
abscess I-Effect
. O

We O
present O
a I-Subject
Japanese I-Subject.Race
male I-Subject.Gender
patient I-Subject
who I-Subject
underwent I-Subject
a I-Subject
living I-Subject
- I-Subject
donor I-Subject
kidney I-Subject.Sub_Disorder
transplantation I-Subject.Sub_Disorder
having O
received I-Potential_therapeutic_event.Trigger
tacrolimus I-Treatment.Combination.Drug
, I-Treatment
mycophenolate I-Treatment.Combination.Drug
mofetil I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
prednisolone I-Treatment.Combination.Drug
for O
immunosuppression I-Treat_Disorder
. O

Gold I-Drug
nephropathy I-Effect
due I-Adverse_event.Trigger
to O
auranofin I-Treatment.Drug
obscured O
by O
tolmetin I-Drug
pseudoproteinuria O
. O

We O
report O
three I-Subject.Population
cases I-Subject
of O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
torsades I-Effect
de I-Effect
pointe I-Effect
. O

Torsades I-Effect
de I-Effect
pointes I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
drug I-Treatment
interaction I-Treatment
between I-Treatment
disopyramide I-Treatment.Combination.Drug
and I-Treatment
clarithromycin I-Treatment.Combination.Drug
. O

We O
describe O
a I-Subject
patient I-Subject
who O
developed I-Adverse_event.Trigger
HUS I-Effect
after O
treatment O
with O
mitomycin I-Treatment.Drug
C I-Treatment.Drug
( I-Treatment
total I-Treatment
dose I-Treatment
144 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
) I-Treatment
due O
to O
a O
carcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
ascending I-Treat_Disorder
colon I-Treat_Disorder
. O

In O
this O
case O
, O
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
FU I-Treatment.Combination.Drug
increased I-Treatment
PHT I-Treatment.Combination.Drug
, I-Treatment
which I-Treatment
in I-Treatment
turn I-Treatment
may I-Treatment
have I-Treatment
increased I-Treatment
the I-Treatment
PB I-Treatment
concentration I-Treatment
, O
suggesting O
that O
when O
fluoropyrimidine O
antitumor O
agents O
are O
administered O
to O
patients I-Subject
receiving O
PHT O
in O
combination O
with O
other O
drugs O
, O
some O
measures O
should O
be O
taken O
in O
consideration O
of O
secondary I-Effect
effects I-Effect
of I-Effect
antitumor I-Effect
agents I-Effect
on I-Effect
other I-Effect
drugs I-Effect
that O
may O
possibly O
interact I-Adverse_event.Trigger
with O
PHT O
, O
including O
frequent O
monitoring O
of O
blood O
drug O
concentration O
. O

Severe I-Effect
loss I-Effect
of I-Effect
vision I-Effect
after O
removal O
of O
cataract O
caused I-Adverse_event.Trigger
by O
intravitreal I-Treatment
triamcinolone I-Treatment.Combination.Drug
in O
combination O
with O
photodynamic I-Treatment.Combination.Drug
therapy O
for O
exudative I-Treat_Disorder
age I-Treat_Disorder
- I-Treat_Disorder
related I-Treat_Disorder
macular I-Treat_Disorder
degeneration I-Treat_Disorder
. O

The O
CATAPULT O
I O
study O
shows O
that O
tirapazamine I-Treatment.Drug
enhances I-Effect
the I-Effect
activity I-Effect
of I-Effect
cisplatin I-Effect
in O
patients I-Subject
with I-Subject
advanced I-Treat_Disorder
NSCLC I-Treat_Disorder
and O
confirms O
that O
hypoxia O
is O
an O
exploitable O
therapeutic O
target O
in O
human O
malignancies O
. O

Cardiac I-Effect
arrest I-Effect
associated I-Adverse_event.Trigger
with O
sulprostone I-Treatment.Drug
use O
during O
caesarean O
section O
. O

Linear I-Effect
IgA I-Effect
bullous I-Effect
dermatosis I-Effect
occurring I-Adverse_event.Trigger
after O
carbamazepine I-Treatment.Drug
. O

Erythropoietin I-Treatment.Drug
is O
beneficial I-Potential_therapeutic_event.Trigger
in O
mitomycin I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
hemolytic I-Treat_Disorder
- I-Treat_Disorder
uremic I-Treat_Disorder
syndrome I-Treat_Disorder
. O

Erythropoietin O
is O
beneficial O
in O
mitomycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hemolytic I-Effect
- I-Effect
uremic I-Effect
syndrome I-Effect
. O

Hypothyroidism I-Effect
, O
occurring I-Adverse_event.Trigger
in O
up O
to O
11 I-Subject.Population
percent I-Subject.Population
of I-Subject
patients I-Subject
treated O
with O
amiodarone I-Treatment.Drug
, O
can O
also O
alter O
drug O
metabolism O
and O
sensitize O
the O
central O
nervous O
system O
, O
thus O
increasing O
the O
potential O
for O
toxicity O
. O

We O
report O
the O
first O
case O
of O
herpes I-Effect
esophagitis I-Effect
in I-Adverse_event.Trigger
a I-Subject
renal I-Treat_Disorder
transplant I-Treat_Disorder
patient I-Subject
treated O
with O
Cyclosporine I-Treatment.Combination.Drug
A I-Treatment.Combination.Drug
while I-Treatment
on I-Treatment
chronic I-Treatment.Combination.Drug
steroid I-Treatment.Combination.Drug
therapy I-Treatment
. O

Severe I-Effect
hepatocellular I-Effect
dysfunction I-Effect
following I-Adverse_event.Trigger
cyproterone I-Treatment.Drug
acetate I-Treatment.Drug
therapy O
. O

It O
is O
thought O
that O
the O
clinico O
- O
pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so O
- O
called O
" O
3 I-Effect
- I-Effect
week I-Effect
sulphasalazine I-Effect
syndrome I-Effect
" O
, O
a O
rare O
, O
but O
often O
fatal O
, O
immunoallergic I-Adverse_event.Trigger
reaction I-Adverse_event.Trigger
to O
sulphasalazine I-Treatment.Drug
. O

Two I-Subject.Population
patients I-Subject
with I-Subject
bipolar I-Treat_Disorder
affective I-Treat_Disorder
disorder I-Treat_Disorder
and I-Subject
a I-Subject.Sub_Disorder
history I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
bronchospastic I-Subject.Sub_Disorder
phenomena I-Subject.Sub_Disorder
experienced I-Adverse_event.Trigger
tremor I-Effect
during O
lithium I-Treatment.Drug
carbonate I-Treatment.Drug
therapy I-Treatment
. O

Acute I-Effect
renal I-Effect
failure I-Effect
most O
likely O
was O
secondary O
to O
the O
nephrotoxic I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
captopril I-Treatment.Drug
on O
chronically I-Subject.Sub_Disorder
hypoperfused I-Subject.Sub_Disorder
kidneys I-Subject.Sub_Disorder
. O

We O
report O
a O
case O
of O
radiotherapy I-Treatment
- I-Treatment
enhanced I-Treatment
aminoglutethimide I-Treatment.Drug
skin I-Effect
toxicity I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
metastatic I-Treat_Disorder
breast I-Treat_Disorder
cancer I-Treat_Disorder
. O

Clinicians O
should O
also O
be O
aware O
of O
the O
possibility O
of O
serotonin I-Effect
syndrome I-Effect
when O
encountering O
a I-Subject
patient I-Subject
taking I-Adverse_event.Trigger
serotonergic I-Treatment.Drug
drugs I-Treatment.Drug
who O
presents O
with O
characteristic O
symptoms O
of O
serotonin O
syndrome O
. O

Such O
a O
rapid O
and O
relentless O
progression O
of O
methyldopa I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
liver I-Effect
injury I-Effect
is O
undoubtedly O
rare O
, O
but O
it O
may O
be O
prevented O
by O
careful O
supervision O
of O
patients O
who O
exhibit O
liver O
function O
abnormalities O
early O
in O
the O
course O
of O
therapy O
. O

In O
eight I-Subject.Population
patients I-Subject
, O
a O
mean I-Effect
decrease I-Effect
in I-Effect
serum I-Effect
Na+ I-Effect
of I-Effect
8.25 I-Effect
+ I-Effect
/ I-Effect
- I-Effect
3.2 I-Effect
mEq I-Effect
/ I-Effect
L I-Effect
was O
observed I-Adverse_event.Trigger
after O
a I-Treatment.Dosage
single I-Treatment.Dosage
200 I-Treatment.Dosage
mg I-Treatment.Dosage
intravenous I-Treatment.Route
dose I-Treatment
of I-Treatment
lorcainide I-Treatment.Drug
. O

Nitrendipine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
gingival I-Effect
hyperplasia I-Effect
. O

Extensive O
immunological O
investigations O
were O
performed O
in O
a I-Subject
patient I-Subject
with I-Subject
definite I-Subject
seronegative I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
hypogammaglobulinemia I-Effect
in O
the O
course O
of O
gold I-Treatment.Drug
therapy I-Treatment
. O

When O
SASP I-Treatment.Drug
was I-Treatment
changed I-Treatment
to I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
( I-Treatment
5 I-Treatment
- I-Treatment
ASA I-Treatment
) I-Treatment
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he I-Subject
developed I-Adverse_event.Trigger
weakness I-Effect
and I-Effect
atrophy I-Effect
in I-Effect
his I-Effect
right I-Effect
arm I-Effect
as I-Effect
well I-Effect
as I-Effect
progressive I-Effect
worsening I-Effect
of I-Effect
the I-Effect
dysesthesia I-Effect
in I-Effect
his I-Effect
legs I-Effect
and I-Effect
gait I-Effect
disturbance I-Effect
. I-Effect

When O
SASP I-Treatment.Drug
was I-Treatment
changed I-Treatment
to I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
( I-Treatment
5 I-Treatment
- I-Treatment
ASA I-Treatment
) I-Treatment
, O
his O
skin I-Treat_Disorder
eruptions I-Treat_Disorder
were O
resolved I-Potential_therapeutic_event.Trigger
, O
however O
, O
he O
developed O
weakness O
and O
atrophy O
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening O
of O
the O
dysesthesia O
in O
his O
legs O
and O
gait O
disturbance O
. O

One O
case O
of O
tacrolimus I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatic I-Effect
VOD I-Effect
developing O
after I-Treatment
lung I-Treatment
transplantation I-Treatment
( I-Treatment
LT I-Treatment
) I-Treatment
has O
been O
recently O
reported O
. O

We O
describe O
a O
case O
of O
an I-Subject
NHL I-Treat_Disorder
patient I-Subject
who O
received O
rituximab I-Treatment.Drug
and O
developed I-Adverse_event.Trigger
symptomatic I-Effect
, I-Effect
biopsy I-Effect
- I-Effect
proven I-Effect
multinodular I-Effect
bronchiolitis I-Effect
obliterans I-Effect
with I-Effect
organizing I-Effect
pneumonia I-Effect
( I-Effect
BOOP I-Effect
) I-Effect
. O

We O
describe O
a O
case O
of O
TdP I-Effect
caused O
by O
a O
drug O
interaction O
in O
a O
76 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
taking I-Adverse_event.Trigger
long I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
term I-Treatment.Combination.Drug
disopyramide I-Treatment.Combination.Drug
after O
she O
was O
given O
clarithromycin I-Treatment.Combination.Drug
concomitantly O
for O
chronic I-Treat_Disorder
bronchitis I-Treat_Disorder
. O

Thus O
, O
clinical O
recognition O
of O
sleep I-Effect
disordered I-Effect
breathing I-Effect
should O
be O
taken O
into O
account O
when O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
patients I-Subject
are O
to O
be O
treated O
with I-Adverse_event.Trigger
infliximab I-Treatment.Drug
. O

We O
present O
a O
case O
of O
a O
sustained I-Effect
monomorphic I-Effect
ventricular I-Effect
tachycardia I-Effect
following I-Adverse_event.Trigger
adenosine I-Treatment.Drug
infusion I-Treatment.Route
. O

Provocation I-Adverse_event.Trigger
of O
non I-Effect
- I-Effect
convulsive I-Effect
status I-Effect
epilepticus I-Effect
by O
tiagabine I-Treatment.Drug
in O
three I-Subject.Population
adolescent I-Subject.Age
patients I-Subject
. O

We O
recommend O
that O
a O
TMA O
in O
association O
with O
quinine O
be O
consistently O
referred O
to O
as O
quinine I-Treatment.Drug
- I-Effect
associated I-Effect
thrombotic I-Effect
microangiopathy I-Effect
( I-Effect
quinine I-Effect
- I-Effect
TMA I-Effect
) I-Effect
to O
better O
distinguish O
this O
entity O
from O
idiopathic O
TTP O
. O

The O
authors O
describe O
a O
case O
of O
oral I-Effect
- I-Effect
facial I-Effect
dyskinesia I-Effect
that O
occurred I-Adverse_event.Trigger
after O
discontinuation I-Treatment
of I-Treatment
amoxapine I-Treatment.Drug
, I-Treatment
and I-Treatment
antidepressant I-Treatment.Drug
which I-Treatment
may I-Treatment
also I-Treatment
have I-Treatment
neuroleptic I-Treatment
effects I-Treatment
. O

A I-Subject
34 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
man I-Subject.Gender
who O
had O
recently O
initiated I-Treatment
efavirenz I-Treatment.Combination.Drug
- I-Treatment
based I-Treatment
antiretroviral I-Treatment.Combination.Drug
therapy I-Treatment
was O
diagnosed O
with O
disseminated I-Sub_Disorder
Histoplasma I-Sub_Disorder
capsulatum I-Sub_Disorder
infection I-Sub_Disorder
. O

Aminoglutethimide I-Treatment.Drug
was I-Treatment
discontinued I-Treatment
until I-Treatment
completion I-Treatment
of I-Treatment
radiotherapy I-Treatment
, O
and I-Potential_therapeutic_event.Trigger
the I-Effect
rash I-Effect
resolved I-Effect
. O

We O
explored I-Adverse_event.Trigger
ophthalmic I-Effect
and I-Effect
neurologic I-Effect
findings I-Effect
in O
two I-Subject.Population
children I-Subject.Age
who O
have O
been O
exposed I-Treatment
prenatally I-Treatment
to I-Treatment
VGB I-Treatment
. O

Two I-Subject.Population
cases I-Subject
are O
described O
of O
chronic I-Treat_Disorder
schizophrenic I-Treat_Disorder
patients O
maintained O
on O
depot I-Treatment.Drug
neuroleptics I-Treatment.Drug
, O
who O
developed I-Adverse_event.Trigger
severe I-Effect
extrapyramidal I-Effect
symptoms I-Effect
following O
a O
period O
of O
heavy I-Treatment
betel I-Treatment.Drug
nut I-Treatment.Drug
consumption I-Treatment
. O

Five O
personal O
observations O
of O
an O
acute I-Effect
amnestic I-Effect
episode I-Effect
in O
younger I-Subject.Age
individuals I-Subject
after I-Adverse_event.Trigger
intake I-Treatment.Route
of I-Treatment
clioquinol I-Treatment.Drug
are O
described O
together O
with O
three O
observations O
from O
the O
medical O
literature O
. O

In O
a I-Subject
patient I-Subject
with I-Subject
severe I-Subject
renovascular I-Treat_Disorder
hypertension I-Treat_Disorder
, O
nonoliguric I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
developed O
after I-Adverse_event.Trigger
she I-Gender
received O
captopril I-Treatment.Drug
treatment O
. O

A I-Subject
30 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
pharmacist I-Subject
suffered I-Adverse_event.Trigger
from O
acute I-Effect
allergic I-Effect
contact I-Effect
dermatitis I-Effect
due O
to O
4 I-Treatment.Drug
- I-Treatment.Drug
chloro I-Treatment.Drug
- I-Treatment.Drug
7 I-Treatment.Drug
- I-Treatment.Drug
nitrobenzofurazan I-Treatment.Drug
( I-Treatment
NBD I-Treatment
- I-Treatment
Cl I-Treatment
) I-Treatment
. O

CONCLUSION O
: O
This O
rare O
case O
of O
PTU I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ANCA I-Effect
- I-Effect
associated I-Effect
vasculitis I-Effect
manifested I-Effect
with I-Effect
ototoxicity I-Effect
in I-Effect
combination I-Effect
with I-Effect
systemic I-Effect
involvement I-Effect
. O

A O
15 I-Time_elapsed
- I-Time_elapsed
year I-Time_elapsed
follow O
- O
up O
of O
phenytoin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
unilateral I-Effect
gingival I-Effect
hyperplasia I-Effect
: O
a O
case O
report O
. O

We O
describe O
two I-Subject.Population
patients I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
factor I-Treat_Disorder
- I-Treat_Disorder
positive I-Treat_Disorder
, I-Treat_Disorder
polyarticular I-Treat_Disorder
- I-Treat_Disorder
onset I-Treat_Disorder
juvenile I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
in O
whom O
accelerated I-Effect
nodulosis I-Effect
developed I-Adverse_event.Trigger
during O
methotrexate I-Treatment.Drug
therapy I-Treatment
. O

The O
clinical O
data O
suggest O
that O
anterior I-Effect
lumbosacral I-Effect
radiculopathy I-Effect
is O
also O
a O
type O
of O
neurologic O
complication O
associated I-Adverse_event.Trigger
with O
intrathecal I-Treatment.Route
methotrexate I-Treatment.Drug
treatment O
. O

At O
admission O
simvastatin I-Treatment.Drug
and I-Treatment
all I-Treatment
antiviral I-Treatment
drugs I-Treatment
were O
discontinued O
because O
toxicity I-Effect
due I-Adverse_event.Trigger
to O
a O
drug O
- O
drug O
interaction O
was O
suspected O
. O

A O
major O
limitation O
in O
the O
use O
of O
amphotericin I-Treatment.Drug
B I-Treatment.Drug
is O
its O
potential O
to O
cause I-Adverse_event.Trigger
nephrotoxicity I-Effect
. O

We O
report O
a O
case O
of O
hyperpigmentation I-Effect
due I-Adverse_event.Trigger
to O
bleomycin I-Treatment.Drug
treatment O
in O
a I-Subject
patient I-Subject
with I-Subject
acquired I-Treat_Disorder
immune I-Treat_Disorder
deficiency I-Treat_Disorder
syndrome I-Treat_Disorder
( I-Subject
AIDS I-Subject
) I-Subject
. O

Azathioprine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myelosuppression I-Effect
due O
to O
thiopurine I-Treat_Disorder
methyltransferase I-Treat_Disorder
deficiency I-Treat_Disorder
in O
a I-Subject
patient I-Subject
with I-Subject
autoimmune I-Treat_Disorder
hepatitis I-Treat_Disorder
. O

Captopril I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
" O
pseudocholangitis I-Effect
' O
. O

A O
case O
of O
toxic I-Effect
hepatitis I-Effect
caused I-Adverse_event.Trigger
by O
combination I-Treatment
therapy I-Treatment
with I-Treatment
methotrexate I-Treatment.Combination.Drug
and I-Treatment
etretinate I-Treatment.Combination.Drug
in O
the O
treatment O
of O
severe I-Treat_Disorder
psoriasis I-Treat_Disorder
is O
presented O
in O
a I-Subject
47 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
. O

Thrombin I-Treatment.Drug
is O
highly O
effective O
for O
stopping O
intractable I-Treat_Disorder
arterial I-Treat_Disorder
hemorrhage I-Treat_Disorder
during O
stereotactic O
brain O
biopsy O
; O
however O
, O
it O
is O
a O
vasospastic O
agent O
and O
may O
have O
been O
responsible I-Adverse_event.Trigger
for O
the O
cerebral I-Effect
infarctions I-Effect
in O
one I-Subject.Population
patient I-Subject
. O

Thrombin I-Treatment.Drug
is O
highly I-Effect
effective I-Effect
for O
stopping I-Potential_therapeutic_event.Trigger
intractable I-Treat_Disorder
arterial I-Treat_Disorder
hemorrhage I-Treat_Disorder
during O
stereotactic O
brain O
biopsy O
; O
however O
, O
it O
is O
a O
vasospastic O
agent O
and O
may O
have O
been O
responsible O
for O
the O
cerebral O
infarctions O
in O
one O
patient O
. O

Carboplatin I-Treatment.Drug
hypersensitivity O
presenting I-Adverse_event.Trigger
as O
coronary I-Effect
vasospasm I-Effect
- O
a O
case O
report O
. O

Severe I-Effect
hypoglycemia I-Effect
from I-Adverse_event.Trigger
Helicobacter I-Treatment.Combination.Drug
pylori I-Treatment.Combination.Drug
triple I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
drug I-Treatment.Combination.Drug
therapy I-Treatment
and I-Treatment
insulin I-Treatment.Combination.Drug
detemir I-Treatment.Combination.Drug
drug I-Treatment.Combination.Drug
interaction I-Treatment
. O

The O
aim O
of O
this O
study O
was O
to O
describe O
the O
occurrence I-Adverse_event.Trigger
of O
acute I-Effect
coronary I-Effect
syndromes I-Effect
in O
3 O
cases O
of O
rituximab I-Treatment.Drug
infusions I-Treatment.Route
. O

Acute I-Treatment
pharmacokinetic I-Treatment
and I-Treatment
pharmacodynamic I-Treatment
interactions I-Treatment
between I-Treatment
phenytoin I-Treatment.Combination.Drug
and I-Treatment
isradipine I-Treatment.Combination.Drug
were O
probably O
responsible I-Adverse_event.Trigger
for O
the I-Effect
lethargy I-Effect
, I-Effect
dysarthria I-Effect
, I-Effect
ataxia I-Effect
, I-Effect
and I-Effect
weakness I-Effect
our O
patient O
developed O
. O

A I-Subject
patient I-Subject
suffering I-Subject
from I-Subject
a I-Subject
rare I-Subject
enzyme I-Treat_Disorder
deficiency I-Treat_Disorder
developed O
a O
malignant I-Effect
neuroleptic I-Effect
syndrome I-Effect
after O
having O
been O
treated I-Adverse_event.Trigger
with O
one I-Treatment.Dosage
single I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
haloperidol I-Treatment.Drug
. O

Captopril I-Treatment.Drug
is O
known O
to O
be O
associated I-Adverse_event.Trigger
with O
dermatologic I-Effect
, I-Effect
hematologic I-Effect
, I-Effect
and I-Effect
pulmonary I-Effect
adverse I-Effect
effects I-Effect
. O

Here O
, O
we O
present O
a O
case O
of O
sirolimus I-Treatment.Drug
- I-Treat_Disorder
associated I-Treat_Disorder
interstitial I-Treat_Disorder
pneumonitis I-Treat_Disorder
in O
a O
cardiac O
transplant O
recipient O
that O
resolved O
completely O
with O
withdrawal O
of O
the O
drug O
and O
treatment O
with O
corticosteroids O
. O

Here O
, O
we O
present O
a I-Subject
case I-Subject
of I-Subject
sirolimus I-Subject
- I-Subject
associated I-Subject
interstitial I-Subject
pneumonitis I-Subject
in I-Subject
a I-Subject
cardiac I-Subject
transplant I-Subject
recipient I-Subject
that O
resolved I-Potential_therapeutic_event.Trigger
completely O
with O
withdrawal I-Treatment
of I-Treatment
the I-Treatment
drug I-Treatment
and I-Treatment
treatment I-Treatment
with I-Treatment
corticosteroids I-Treatment.Drug
. O

Other O
upper I-Effect
tract I-Effect
neoplasms I-Effect
after I-Adverse_event.Trigger
cyclophosphamide I-Treatment.Drug
are O
reviewed O
. O

Four I-Subject.Population
patients I-Subject
receiving I-Adverse_event.Trigger
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
tamoxifen I-Treatment.Drug
for I-Treatment
greater I-Treatment
than I-Treatment
1 I-Treatment.Duration
year I-Treatment.Duration
have O
demonstrated O
similar O
retinal I-Effect
changes I-Effect
. O

Retinal I-Effect
dysfunction I-Effect
and I-Effect
anterior I-Effect
segment I-Effect
deposits I-Effect
in O
a O
patient I-Subject
treated I-Adverse_event.Trigger
with O
rifabutin I-Treatment.Drug
. O

Carbamazepine I-Treatment.Drug
induced I-Adverse_event.Trigger
right I-Effect
bundle I-Effect
branch I-Effect
block I-Effect
in O
a O
Greenlandic I-Subject.Race
patient I-Subject
. O

RESULTS O
: O
Both I-Subject
cases I-Subject
presented O
here O
describe O
corneal I-Effect
ulcers I-Effect
that I-Effect
persisted I-Effect
and O
showed O
signs O
of O
worsening I-Adverse_event.Trigger
during O
weeks I-Treatment
of I-Treatment
frequent I-Treatment.Freq
topical I-Treatment.Route
dosing I-Treatment
with I-Treatment
moxifloxacin I-Treatment.Drug
. O

We O
describe O
a I-Subject
case I-Subject
of O
poisoning I-Effect
with O
3,4 I-Treatment.Drug
- I-Treatment.Drug
methylenedioxymet I-Treatment.Drug
- I-Treatment.Drug
amphetamine I-Treatment.Drug
Ecstasy I-Treatment
that O
presented I-Adverse_event.Trigger
with O
all O
the O
features O
suggestive O
of O
a O
fatal O
outcome O
, O
including O
a O
creatinine I-Effect
phosphokinase I-Effect
level I-Effect
markedly I-Effect
higher I-Effect
than O
any O
previously O
reported O
. O

Ramipril I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cutaneous I-Effect
vasculitis I-Effect
is O
particularly O
rare O
and O
our O
case O
was O
atypical O
because O
the I-Subject
patient I-Subject
had I-Subject
tolerated I-Subject.Sub_Disorder
lisinopril I-Subject.Sub_Disorder
before I-Subject
. O

To O
date O
, O
this O
is O
the O
first O
reported O
case O
of O
what O
appears O
to O
be O
isolated I-Effect
thrombocytopenia I-Effect
associated I-Adverse_event.Trigger
with O
lansoprazole I-Treatment.Drug
. O

A I-Subject
7 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
developed I-Adverse_event.Trigger
diabetes I-Effect
mellitus I-Effect
and I-Effect
exocrine I-Effect
pancreatic I-Effect
insufficiency I-Effect
after O
3.5 I-Treatment.Duration
years I-Treatment.Duration
of I-Treatment
almost I-Treatment
continuous I-Treatment
treatment I-Treatment
with I-Treatment
azathioprine I-Treatment.Combination.Drug
and/or I-Treatment
prednisone I-Treatment.Combination.Drug
for O
idiopathic I-Treat_Disorder
auto I-Treat_Disorder
- I-Treat_Disorder
immune I-Treat_Disorder
haemolytic I-Treat_Disorder
anaemia I-Treat_Disorder
. O

The O
human O
immunodeficiency O
virus O
protease O
inhibitor O
ritonavir O
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P450 O
3A4 O
enzyme O
, O
and O
ritonavir I-Treatment.Combination.Drug
's I-Treatment
concomitant I-Treatment
administration I-Treatment
with I-Treatment
the I-Treatment
substrates I-Treatment.Combination.Drug
of I-Treatment.Combination.Drug
this I-Treatment.Combination.Drug
enzyme I-Treatment.Combination.Drug
may O
lead I-Adverse_event.Trigger
to O
dangerous O
drug I-Effect
interactions I-Effect
. O

There O
remains O
a O
paucity O
of O
information O
pertaining O
to O
alternative O
anticoagulation O
strategies O
for O
use O
during O
cardiopulmonary O
bypass O
concomitant O
with O
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
, O
especially O
in O
children I-Subject.Age
. O

Unintended I-Treatment
exposure I-Treatment
to I-Treatment
acyclovir I-Treatment.Drug
early O
in O
pregnancy O
, O
which O
is O
not O
uncommon O
, O
may O
cause I-Adverse_event.Trigger
excessive I-Effect
maternal I-Effect
and I-Effect
physician I-Effect
anxiety I-Effect
. O

The O
ACE I-Treatment.Drug
inhibitors I-Treatment.Drug
can O
cause I-Adverse_event.Trigger
various O
skin I-Effect
side I-Effect
effects I-Effect
; O
however O
, O
it O
rarely O
causes O
cutaneous O
vasculitis O
. O

Salicylate O
intoxication O
was O
excluded O
, O
and O
theophylline I-Treatment.Drug
was O
finally O
incriminated I-Adverse_event.Trigger
. O

We O
present O
a O
case O
of O
stroke I-Effect
after I-Adverse_event.Trigger
PPA I-Treatment.Drug
ingestion O
that O
occurred O
4 I-Time_elapsed
months I-Time_elapsed
after O
the O
recall O
in O
an I-Subject
8 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
on I-Subject
chronic I-Subject
peritoneal I-Subject
dialysis I-Subject
. O

Cerebral I-Effect
infarcts I-Effect
in O
a O
pediatric I-Subject.Age
patient I-Subject
secondary I-Adverse_event.Trigger
to O
phenylpropanolamine I-Treatment.Drug
, O
a O
recalled O
medication O
. O

To O
our O
knowledge O
, O
our O
report O
is O
one O
of O
the O
first O
on O
shock I-Effect
and I-Effect
angio I-Effect
- I-Effect
oedema I-Effect
from I-Adverse_event.Trigger
irbesartan I-Treatment.Drug
. O

Clinical O
course O
of O
macular I-Effect
edema I-Effect
in O
two I-Subject.Population
cases I-Subject
of O
interferon I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
retinopathy I-Effect
observed O
by O
optical O
coherence O
tomography O
. O

This O
report O
describes O
a I-Subject
13 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
with I-Subject
a I-Subject
right I-Subject.Sub_Disorder
frontal I-Subject.Sub_Disorder
high I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
grade I-Subject.Sub_Disorder
glioma I-Subject.Sub_Disorder
and I-Subject
complex I-Treat_Disorder
partial I-Treat_Disorder
seizures I-Treat_Disorder
who O
developed O
localized I-Effect
purpura I-Effect
after I-Adverse_event.Trigger
23 I-Treatment.Treat_Disorder
months I-Treatment.Treat_Disorder
of I-Treatment
lamotrigine I-Treatment.Drug
monotherapy I-Treatment
. O

Patient I-Subject
1 I-Subject
presented I-Adverse_event.Trigger
bilateral I-Effect
ballism I-Effect
1 O
week O
after O
intravenous I-Treatment.Route
heroin I-Treatment.Drug
injection I-Treatment.Route
. O

He I-Subject.Gender
became O
hyperkalemic I-Effect
on O
rechallenge O
with O
timolol I-Treatment.Drug
and O
normokalemic O
following I-Adverse_event.Trigger
its O
withdrawal O
. O

Ischaemic I-Effect
colitis I-Effect
in O
a I-Subject
patient I-Subject
taking I-Adverse_event.Trigger
meloxicam I-Treatment.Drug
. O

Leflunomide I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
infections I-Effect
in O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Cutaneous I-Effect
sarcoidosis I-Effect
during I-Adverse_event.Trigger
interferon I-Treatment
alfa I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
treatment I-Treatment
of I-Treatment
hepatitis I-Treatment.Treat_Disorder
C I-Treatment.Treat_Disorder
virus I-Treatment.Treat_Disorder
infection I-Treatment.Treat_Disorder
: O
two I-Subject.Population
cases I-Subject
. O

Acute I-Effect
renal I-Effect
failure I-Effect
in O
a I-Subject
child I-Subject.Age
associated I-Adverse_event.Trigger
with O
acyclovir I-Treatment.Drug
. O

Bevacizumab I-Treatment.Drug
is I-Treatment
a I-Treatment
recently I-Treatment
developed I-Treatment
monoclonal I-Treatment
antibody I-Treatment
against O
vascular O
endothelial O
growth O
factor O
receptor O
used O
to O
inhibit I-Potential_therapeutic_event.Trigger
angiogenesis I-Treat_Disorder
. O

Two I-Subject.Population
patients I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
developed I-Adverse_event.Trigger
evidence O
of O
hepatotoxicity I-Effect
while O
receiving O
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
. O

Fatal I-Effect
venous I-Effect
thrombembolism I-Effect
complicating I-Adverse_event.Trigger
imatinib I-Treatment.Drug
therapy O
in O
a I-Subject
patient I-Subject
with I-Subject
metastatic I-Treat_Disorder
gastrointestinal I-Treat_Disorder
stromal I-Treat_Disorder
tumor I-Treat_Disorder
. O

However O
, O
acute I-Effect
cardiomyopathy I-Effect
and I-Effect
pericarditis I-Effect
secondary O
to O
methylphenidate I-Treatment.Drug
use I-Adverse_event.Trigger
has O
been O
rarely O
reported O
. O

Propoxyphene I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
wide I-Effect
QRS I-Effect
complex I-Effect
dysrhythmia I-Effect
responsive O
to O
sodium O
bicarbonate O
-- O
a O
case O
report O
. O

Simvastatin I-Subject.Sub_Disorder
plasma I-Subject.Sub_Disorder
concentration I-Subject.Sub_Disorder
increased I-Subject.Sub_Disorder
30 I-Subject.Sub_Disorder
times I-Subject.Sub_Disorder
in I-Subject
this I-Subject
patient I-Subject
and O
statin I-Treatment.Drug
induced I-Adverse_event.Trigger
muscle I-Effect
toxicity I-Effect
is O
related O
to O
the O
concentration O
of O
the O
statin O
in O
blood O
. O

Poorly I-Effect
controlled I-Effect
hypertension I-Effect
in O
a I-Subject
painter I-Subject
with I-Adverse_event.Trigger
chronic O
lead I-Treatment.Drug
toxicity O
. O

It O
was O
concluded O
that O
ANCA O
is O
closely O
related O
to O
the O
pathogenesis O
of O
crescentic O
glomerulonephritis O
and O
that O
treatment O
with O
PTU I-Treatment.Drug
appeared O
to O
induce I-Adverse_event.Trigger
ANCA I-Effect
. O

Gelatinous I-Effect
transformation I-Effect
of I-Effect
bone I-Effect
marrow I-Effect
following I-Adverse_event.Trigger
chemotherapy I-Treatment.Route
for O
myeloma I-Treat_Disorder
. O

We O
discuss O
a I-Subject
case I-Subject
with O
significant I-Effect
progressive I-Effect
peripheral I-Effect
neurological I-Effect
deterioration I-Effect
following I-Adverse_event.Trigger
administration O
of O
both O
fludarabine I-Treatment.Combination.Drug
and I-Treatment
cytarabine I-Treatment.Combination.Drug
as O
part O
of O
the O
FLA I-Treatment.Drug
( I-Treatment.Drug
fludarabine I-Treatment.Drug
and I-Treatment.Drug
cytarabine I-Treatment.Drug
) I-Treatment.Drug
regime I-Treatment
. O

The O
course O
of O
delirium I-Effect
due I-Adverse_event.Trigger
to O
lithium I-Treatment.Drug
intoxication I-Treatment
. O

Preadmission I-Treatment
warfarin I-Treatment.Drug
use O
was O
not O
associated I-Adverse_event.Trigger
with O
any I-Effect
secondary I-Effect
intracerebral I-Effect
hemorrhage I-Effect
( I-Effect
OR I-Effect
, I-Effect
1.2 I-Effect
; I-Effect
95 I-Effect
% I-Effect
CI I-Effect
, I-Effect
0.7 I-Effect
to I-Effect
2.2 I-Effect
) I-Effect
, I-Effect
symptomatic I-Effect
intracerebral I-Effect
hemorrhage I-Effect
( I-Effect
OR I-Effect
, I-Effect
1.1 I-Effect
; I-Effect
95 I-Effect
% I-Effect
CI I-Effect
, I-Effect
0.5 I-Effect
to I-Effect
2.3 I-Effect
) I-Effect
, I-Effect
or I-Effect
gastrointestinal I-Effect
hemorrhage I-Effect
( I-Effect
OR I-Effect
, I-Effect
1.1 I-Effect
; I-Effect
95 I-Effect
% I-Effect
CI I-Effect
, I-Effect
0.2 I-Effect
to I-Effect
5.6 I-Effect
) I-Effect
. O

In O
this O
case O
of O
a O
possible O
drug O
- O
drug O
interaction O
between O
IFN I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
11 I-Treatment.Combination.Drug
MU I-Treatment
TIW I-Treatment
and O
gemfibrozil I-Treatment.Combination.Drug
600 I-Treatment.Dosage
mg I-Treatment.Dosage
BID I-Treatment
in O
a I-Subject
patient I-Subject
undergoing I-Subject
treatment I-Subject
for I-Subject
IFN I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
hypertriglyceridemia I-Treat_Disorder
, O
the O
Naranjo I-Effect
Adverse I-Effect
Drug I-Effect
Reactions I-Effect
( O
ADR O
) O
Probability I-Adverse_event.Trigger
Scale O
score O
was O
7 O
( O
ie O
, O
ADR O
possibly O
related O
to O
treatment O
) O
. O

Stupor I-Effect
from I-Adverse_event.Trigger
lamotrigine I-Treatment.Drug
toxicity O
. O

Autopsy O
findings O
were O
consistent O
with O
bleomycin I-Treatment.Combination.Drug
and I-Treatment
oxygen I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
damage I-Effect
. O

We O
report O
a O
case O
of O
vitiligo I-Effect
that O
occurred I-Adverse_event.Trigger
during I-Treatment
the I-Treatment.Duration
second I-Treatment.Duration
month I-Treatment.Duration
of I-Treatment
interferon I-Treatment.Drug
alpha I-Treatment.Drug
2a I-Treatment.Drug
therapy I-Treatment
for O
chronic I-Treat_Disorder
active I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

Vardenafil I-Treatment.Drug
is I-Treatment
a I-Treatment
new I-Treatment
oral I-Treatment.Route
phosphodiesterase I-Treatment
inhibitor I-Treatment
used I-Potential_therapeutic_event.Trigger
for I-Potential_therapeutic_event.Trigger
erectile I-Treat_Disorder
dysfunction I-Treat_Disorder
. O

CONCLUSION O
: O
A I-Subject
patient I-Subject
with I-Subject
CHF I-Treat_Disorder
and I-Subject
ESRD I-Subject.Sub_Disorder
developed O
myoclonic I-Effect
muscle I-Effect
spasms I-Effect
after I-Adverse_event.Trigger
receiving O
dobutamine I-Treatment.Drug
by I-Treatment
continuous I-Treatment.Freq
i.v I-Treatment.Route
. O

Nail I-Effect
- I-Effect
changes I-Effect
induced I-Adverse_event.Trigger
by O
penicillamine I-Treatment.Drug
. O

The I-Subject
fourth I-Subject
patient I-Subject
showed O
RLS I-Effect
symptoms I-Effect
that O
were O
initially O
caused I-Adverse_event.Trigger
by O
a O
20 I-Treatment.Dosage
- I-Treatment.Dosage
mg I-Treatment.Dosage
daily I-Treatment.Freq
olanzapine I-Treatment.Drug
dosage I-Treatment
and O
were O
later O
mitigated O
when O
olanzapine O
was O
reduced O
and O
ropinirole O
was O
administered O
. O

Naproxen I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
sudden I-Effect
sensorineural I-Effect
hearing I-Effect
loss I-Effect
. O

Retinoic I-Treatment.Drug
acid I-Treatment.Drug
may O
increase I-Adverse_event.Trigger
the O
risk O
of O
bone I-Effect
marrow I-Effect
transplant I-Effect
nephropathy I-Effect
. O

A O
review O
of O
published O
case O
reports O
showed O
a I-Effect
short I-Effect
time I-Effect
to I-Effect
onset I-Effect
of I-Effect
symptoms I-Effect
following I-Adverse_event.Trigger
the O
introduction I-Treatment
of I-Treatment
linezolid I-Treatment.Drug
, I-Treatment
generally I-Treatment
within I-Treatment.Time_elapsed
1 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
3 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
. O

Intrathecal I-Treatment.Route
chemotherapy I-Treatment.Route
with I-Treatment
methotrexate I-Treatment.Drug
or I-Treatment
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
is O
the O
standard O
approach O
to O
prophylaxis O
and O
treatment I-Potential_therapeutic_event.Trigger
of O
central I-Treat_Disorder
nervous I-Treat_Disorder
system I-Treat_Disorder
leukemia I-Treat_Disorder
in O
children I-Subject.Age
. O

The O
following O
day O
, O
the O
patient I-Subject
developed I-Adverse_event.Trigger
anxiety I-Effect
, I-Effect
panic I-Effect
attacks I-Effect
, I-Effect
tremors I-Effect
, I-Effect
tachycardia I-Effect
, I-Effect
and I-Effect
hypertension I-Effect
that O
persisted O
throughout O
linezolid I-Treatment.Drug
treatment O
. O

Effect O
of O
beta O
- O
blockade O
on O
symptomatic O
dexamethasone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypertrophic I-Effect
obstructive I-Effect
cardiomyopathy I-Effect
in O
premature I-Subject.Sub_Disorder
infants I-Subject.Age
: O
three O
case O
reports O
and O
literature O
review O
. O

Effect I-Potential_therapeutic_event.Trigger
of O
beta I-Treatment.Drug
- I-Treatment.Drug
blockade I-Treatment.Drug
on O
symptomatic I-Treat_Disorder
dexamethasone I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
hypertrophic I-Treat_Disorder
obstructive I-Treat_Disorder
cardiomyopathy I-Treat_Disorder
in O
premature I-Subject.Sub_Disorder
infants I-Subject.Age
: O
three O
case O
reports O
and O
literature O
review O
. O

Although O
transient I-Effect
increases I-Effect
in I-Effect
ectopy I-Effect
after I-Adverse_event.Trigger
bretylium I-Treatment.Drug
therapy O
have O
been O
described O
, O
presumably O
due O
to O
catecholamine O
release O
, O
the O
occurrence O
of O
life I-Effect
- I-Effect
threatening I-Effect
ventricular I-Effect
arrhythmia I-Effect
leading I-Effect
to I-Effect
cardiac I-Effect
arrest I-Effect
has O
not O
previously O
been O
emphasized O
. O

We O
report O
three I-Subject.Population
cases I-Subject
of O
IFN I-Treatment.Drug
beta I-Treatment.Drug
induced I-Adverse_event.Trigger
hepatitis I-Effect
in I-Effect
MS I-Effect
and O
discuss O
the O
pathology O
findings O
and O
possible O
mechanisms O
of O
drug O
- O
induced O
liver O
injury O
. O

RTA I-Effect
is O
one O
type O
of O
nephrotoxicity I-Effect
induced I-Adverse_event.Trigger
by O
FK506 I-Treatment.Drug
, O
and O
it O
is O
reversible O
in O
mild O
cases O
when O
appropriately O
treated O
. O

The O
most O
common O
side O
effects O
associated I-Adverse_event.Trigger
with O
amifostine I-Treatment.Drug
are O
nausea I-Effect
, I-Effect
vomiting I-Effect
, I-Effect
hypotension I-Effect
, I-Effect
hypocalcemia I-Effect
and O
allergic I-Effect
reactions I-Effect
. I-Effect

Nonconvulsive I-Effect
status I-Effect
epilepticus I-Effect
due I-Adverse_event.Trigger
to O
ifosfamide I-Treatment.Drug
. O

Clinical O
experience O
in O
infectious I-Subject.Sub_Disorder
patients I-Subject
has O
shown O
that O
oral I-Treatment.Route
telithromycin I-Treatment.Drug
800 I-Treatment.Dosage
mg I-Treatment.Dosage
once I-Treatment.Freq
daily I-Treatment.Freq
for I-Treatment
5 I-Treatment.Duration
- I-Treatment.Duration
10 I-Treatment.Duration
days I-Treatment.Duration
is O
effective O
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
community I-Treat_Disorder
- I-Treat_Disorder
acquired I-Treat_Disorder
upper I-Treat_Disorder
and I-Treat_Disorder
lower I-Treat_Disorder
respiratory I-Treat_Disorder
tract I-Treat_Disorder
infections I-Treat_Disorder
. O

Five I-Subject.Population
patients I-Subject
receiving O
fluoxetine I-Treatment.Drug
for O
the O
treatment O
of O
obsessive O
compulsive O
disorder O
or O
major O
depression O
developed I-Adverse_event.Trigger
akathisia I-Effect
. O

This O
fourth O
type O
of O
cutaneous O
minocycline I-Treatment.Drug
hyperpigmentation I-Effect
may O
be I-Adverse_event.Trigger
a O
variant O
of O
Type O
I O
, O
but O
based O
on O
clinical O
, O
pathological O
and O
microanalytical O
differences O
, O
appears O
to O
be O
a O
new O
entity O
. O

Phenytoin I-Treatment.Combination.Drug
/ I-Treatment
isradipine I-Treatment.Combination.Drug
interaction I-Treatment
causing I-Adverse_event.Trigger
severe O
neurologic I-Effect
toxicity I-Effect
. O

We O
report O
a O
case O
of O
torsade I-Effect
de I-Effect
pointes I-Effect
following I-Adverse_event.Trigger
a I-Treatment
single I-Treatment.Dosage
oral I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
amiodarone I-Treatment.Drug
( I-Treatment
1400 I-Treatment.Dosage
mg I-Treatment.Dosage
or I-Treatment
30 I-Treatment.Dosage
mg I-Treatment.Dosage
kg I-Treatment.Dosage
- I-Treatment.Dosage
1 I-Treatment.Dosage
) I-Treatment
administered O
after O
short O
intravenous O
loading O
for O
prevention I-Treat_Disorder
of I-Treat_Disorder
paroxysmal I-Treat_Disorder
atrial I-Treat_Disorder
flutter I-Treat_Disorder
. O

Traditionally O
, O
children I-Subject.Age
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
receive I-Potential_therapeutic_event.Trigger
prednisone I-Treatment.Drug
, O
as O
part O
of O
multiagent O
remission O
- O
induction O
chemotherapy O
. O

Propylthiouracil I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
sensorineural I-Effect
hearing I-Effect
loss I-Effect
associated I-Effect
with I-Effect
antineutrophil I-Effect
cytoplasmic I-Effect
antibodies I-Effect
. O

Acute I-Effect
respiratory I-Effect
depression I-Effect
as O
a O
complication I-Adverse_event.Trigger
of O
nebulised I-Treatment
morphine I-Treatment.Drug
. O

We O
report O
on O
a I-Subject
patient I-Subject
with I-Subject
an I-Subject
embryonal I-Treat_Disorder
teratocarcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
testicle I-Treat_Disorder
who O
had I-Adverse_event.Trigger
the O
syndrome I-Effect
of I-Effect
inappropriate I-Effect
secretion I-Effect
of I-Effect
antidiuretic I-Effect
hormone I-Effect
after O
receiving O
a I-Treatment
high I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
vinblastine I-Treatment.Drug
. O

Methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
liver I-Effect
cirrhosis I-Effect
. O

A O
case O
of O
oculogyric I-Effect
crisis I-Effect
induced I-Adverse_event.Trigger
by O
metoclopramide I-Treatment.Drug
is O
described O
in O
this O
paper O
. O

Early I-Effect
- I-Effect
onset I-Effect
acute I-Effect
transverse I-Effect
myelitis I-Effect
following I-Adverse_event.Trigger
hepatitis I-Treatment.Drug
B I-Treatment.Drug
vaccination I-Treatment.Drug
and O
respiratory O
infection O
: O
case I-Subject
report O
. O

The O
pro I-Effect
- I-Effect
arrhythmic I-Effect
effects I-Effect
of I-Adverse_event.Trigger
procainamide I-Treatment.Drug
may O
be O
explained O
on O
the O
basis O
of O
both O
its O
vagolytic O
action O
on O
the O
atrioventricular O
node O
as O
well O
as O
by O
prolongation O
of O
refractoriness O
in O
the O
accessory O
pathway O
. O

We O
present O
the O
management O
of O
agranulocytosis I-Effect
and I-Effect
neutropenic I-Effect
sepsis I-Effect
secondary I-Adverse_event.Trigger
to O
carbimazole I-Treatment.Combination.Drug
with I-Treatment
recombinant I-Treatment.Combination.Drug
human I-Treatment.Combination.Drug
granulocyte I-Treatment.Combination.Drug
colony I-Treatment.Combination.Drug
stimulating I-Treatment.Combination.Drug
factor I-Treatment.Combination.Drug
( I-Treatment
G I-Treatment
- I-Treatment
CSF I-Treatment
) I-Treatment
. O

Cutaneous I-Effect
mycobacterial I-Effect
infection I-Effect
post I-Adverse_event.Trigger
intravesical I-Treatment.Route
BCG I-Treatment
installation I-Treatment
. O

On O
day O
4 O
, O
following I-Adverse_event.Trigger
3 I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
dalteparin I-Treatment.Drug
, O
the I-Subject
patient I-Subject
developed O
acute I-Effect
respiratory I-Effect
distress I-Effect
attributable I-Effect
to I-Effect
a I-Effect
massive I-Effect
right I-Effect
hemothorax I-Effect
confirmed O
by O
computed O
tomography O
pulmonary O
angiography O
( O
CTPA O
) O
and O
intercostal O
drainage O
of O
1500 O
mL O
of O
frank O
blood O
. O

A O
4 O
- O
month O
regimen O
of O
gatifloxacin I-Treatment.Drug
with O
rifampin I-Treatment.Drug
, O
isoniazid I-Treatment.Combination.Drug
, O
and O
pyrazinamide I-Treatment.Combination.Drug
is O
being O
evaluated O
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
tuberculosis I-Treat_Disorder
in O
a O
phase O
3 O
randomized O
controlled O
trial O
( O
OFLOTUB O
) O
. O

We O
postulate O
that O
the O
bolus O
of O
sulprostone I-Treatment.Drug
resulted I-Adverse_event.Trigger
in O
possible O
coronary I-Effect
spasm I-Effect
that I-Effect
resulted I-Effect
in I-Effect
cardiac I-Effect
arrest I-Effect
. O

A O
72 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
a I-Subject
history I-Subject
of I-Subject
thyrotoxicosis I-Subject.Sub_Disorder
presented I-Adverse_event.Trigger
with O
sore I-Effect
throat I-Effect
and I-Effect
fever I-Effect
two I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
starting I-Treatment
carbimazole I-Treatment.Drug
. O

Without O
other O
causes O
for O
the O
hyponatremia I-Effect
, O
she I-Subject.Gender
was O
diagnosed I-Adverse_event.Trigger
with O
the O
syndrome I-Effect
of I-Effect
inappropriate I-Effect
antidiuretic I-Effect
hormone I-Effect
, O
presumably O
caused O
by O
desmopressin I-Treatment.Drug
. O

Fatal I-Effect
peripheral I-Effect
neuropathy I-Effect
following I-Adverse_event.Trigger
FLA I-Treatment.Drug
chemotherapy I-Treatment.Route
. O

Rhabdomyolysis I-Effect
caused I-Adverse_event.Trigger
by O
a O
potential I-Treatment
sitagliptin I-Treatment.Combination.Drug
- I-Treatment
lovastatin I-Treatment.Combination.Drug
interaction I-Treatment
. O

A I-Subject
78 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
a I-Subject
history I-Subject
of I-Subject
congestive I-Subject.Sub_Disorder
heart I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
and I-Subject
coronary I-Subject.Sub_Disorder
artery I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
began O
taking O
amiodarone I-Treatment.Drug
to O
suppress I-Potential_therapeutic_event.Trigger
sustained I-Treat_Disorder
ventricular I-Treat_Disorder
tachycardia I-Treat_Disorder
. O

A I-Subject
patient I-Subject
with O
severe I-Effect
cholestatic I-Effect
jaundice I-Effect
induced I-Adverse_event.Trigger
by O
captopril I-Treatment.Drug
is O
presented O
. O

Three O
distinct O
types O
of O
minocycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cutaneous I-Effect
pigmentation I-Effect
have O
been O
described O
. O

The O
occurrence O
of O
symptoms O
that O
could O
be O
ascribed O
to O
an O
acute I-Effect
coronary I-Effect
syndrome I-Effect
should O
always O
be O
taken O
seriously O
during I-Adverse_event.Trigger
the O
first I-Treatment.Duration
rituximab I-Treatment.Drug
infusion I-Treatment.Route
and O
investigated O
aggressively O
. O

Antithyroid O
treatment O
with O
propylthiouracil I-Treatment.Drug
( I-Treatment
PTU I-Treatment
) I-Treatment
resulted I-Adverse_event.Trigger
in O
elevated I-Effect
hepatic I-Effect
enzymes I-Effect
and O
after O
the O
12th I-Subject
week I-Subject
of I-Subject
pregnancy I-Subject.Sub_Disorder
treatment O
was O
changed O
to O
carbimazole O
( O
CBZ O
) O
. O

Antithyroid I-Treat_Disorder
treatment O
with O
propylthiouracil O
( O
PTU O
) O
resulted O
in O
elevated O
hepatic O
enzymes O
and O
after O
the O
12th I-Subject
week I-Subject
of I-Subject
pregnancy I-Subject.Sub_Disorder
treatment O
was O
changed I-Potential_therapeutic_event.Trigger
to O
carbimazole I-Treatment.Drug
( I-Treatment
CBZ I-Treatment
) I-Treatment
. O

Antineutrophil I-Effect
cytoplasmic I-Effect
antibody I-Effect
- I-Effect
positive I-Effect
crescentic I-Effect
glomerulonephritis I-Effect
associated I-Adverse_event.Trigger
with O
propylthiouracil I-Treatment.Drug
therapy I-Treatment
. O

ADH I-Treat_Disorder
hypersecretion I-Treat_Disorder
in O
relation O
to O
plasma I-Subject.Sub_Disorder
osmolality I-Subject.Sub_Disorder
was O
reversed I-Potential_therapeutic_event.Trigger
by O
mizoribin I-Treatment.Drug
withdrawal I-Treatment
, O
suggesting O
that O
bredinin O
might O
adversely O
induce O
SIADH O
. O

ADH O
hypersecretion O
in O
relation O
to O
plasma O
osmolality O
was O
reversed O
by O
mizoribin O
withdrawal O
, O
suggesting O
that O
bredinin I-Treatment.Drug
might O
adversely I-Effect
induce I-Effect
SIADH I-Effect
. O

Heparin I-Drug
- O
induced O
thrombocytopenia I-Effect
is O
a O
rare O
and O
serious O
complication I-Adverse_event.Trigger
of O
anticoagulation I-Treatment
therapy I-Treatment
. O

Iatrogenic I-Effect
Cushing I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
epidural I-Treatment.Combination.Drug
triamcinolone I-Treatment.Combination.Drug
injections I-Treatment.Route
in O
an I-Subject
HIV I-Treat_Disorder
type I-Treat_Disorder
1 I-Treat_Disorder
- I-Subject
infected I-Subject
patient I-Subject
receiving I-Treatment
therapy I-Treatment
with I-Treatment
ritonavir I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
lopinavir I-Treatment.Combination.Drug
. O

Otolaryngologists O
should O
be O
made O
aware O
of O
a O
newer O
cause O
of O
nasal I-Effect
septal I-Effect
perforations I-Effect
resulting I-Adverse_event.Trigger
from O
the I-Treatment.Drug
more I-Treatment.Drug
recent I-Treatment.Drug
antiangiogenic I-Treatment.Drug
therapy I-Treatment.Drug
used O
to O
treat O
malignancies I-Treat_Disorder
. O

Following O
several O
of O
these O
courses O
of O
therapy O
, O
respiratory I-Effect
distress I-Effect
occurred O
9 I-Time_elapsed
to I-Time_elapsed
12 I-Time_elapsed
days I-Time_elapsed
after I-Adverse_event.Trigger
the I-Treatment
chlorambucil I-Treatment.Drug
was O
given O
. O

Possible O
mechanisms O
for O
damage I-Effect
to I-Effect
the I-Effect
urothelium I-Effect
by I-Adverse_event.Trigger
ketamine I-Treatment.Drug
are O
suggested O
. O

Persistent I-Effect
hypoglycemia I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
diabetes I-Subject.Sub_Disorder
taking I-Adverse_event.Trigger
etanercept I-Treatment.Drug
for O
the O
treatment O
of O
psoriasis I-Treat_Disorder
. O

Cutaneous I-Effect
necrosis I-Effect
after I-Adverse_event.Trigger
injection I-Treatment.Route
of I-Treatment
polyethylene I-Treatment.Drug
glycol I-Treatment.Drug
- I-Treatment.Drug
modified I-Treatment.Drug
interferon I-Treatment.Drug
alfa I-Treatment.Drug
. I-Drug

We O
report O
an O
unusual O
case O
of O
simultaneous I-Effect
transitional I-Effect
cell I-Effect
carcinoma I-Effect
of I-Effect
the I-Effect
renal I-Effect
pelvis I-Effect
and I-Effect
distal I-Effect
ureter I-Effect
without I-Effect
transitional I-Effect
cell I-Effect
carcinoma I-Effect
of I-Effect
the I-Effect
bladder I-Effect
occurring O
after I-Adverse_event.Trigger
chronic I-Treatment.Duration
cyclophosphamide I-Treatment.Drug
therapy I-Treatment
for O
nonHodgkin I-Treat_Disorder
's I-Treat_Disorder
lymphoma I-Treat_Disorder
. O

In O
the O
present O
paper O
, O
we O
describe O
two I-Subject.Population
patients I-Subject
with I-Subject
active I-Treat_Disorder
UC I-Treat_Disorder
who O
developed O
a O
severe I-Effect
systemic I-Effect
CMV I-Effect
infection I-Effect
during O
a O
treatment I-Adverse_event.Trigger
with O
an O
oral I-Treatment.Route
microemulsion I-Treatment
form I-Treatment
of I-Treatment
cyclosporine I-Treatment.Drug
. O

Prior I-Treatment
to I-Treatment
surgery I-Treatment
, O
the I-Subject
patient I-Subject
received I-Potential_therapeutic_event.Trigger
droperidol I-Treatment.Drug
, O
an O
agent O
known O
to O
prolong O
the O
QT O
interval O
. O

OBJECTIVE O
: O
We O
report O
a O
case O
of O
cutaneous I-Effect
KS I-Effect
lesions I-Effect
in O
a I-Subject
patient I-Subject
affected I-Subject
by I-Subject
CML I-Treat_Disorder
treated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
imatinib I-Treatment.Drug
. O

The I-Effect
FK I-Effect
506 I-Effect
dose I-Effect
was I-Effect
constant I-Effect
within I-Effect
21 I-Effect
days I-Effect
after O
discontinuing I-Adverse_event.Trigger
phenytoin I-Treatment.Drug
in O
Patient I-Subject
1 I-Subject.Population
who O
had O
36 I-Time_elapsed
days I-Time_elapsed
of O
phenytoin I-Drug
therapy I-Drug
. O

In O
patients I-Subject
receiving O
antithrombin I-Treatment.Combination.Drug
III I-Treatment.Combination.Drug
and I-Treatment
concomitant I-Treatment.Combination.Drug
heparin I-Treatment.Combination.Drug
, O
a O
significantly O
increased I-Adverse_event.Trigger
bleeding I-Effect
incidence I-Effect
was O
observed O
( O
23.8 O
% O
for O
antithrombin O
III O
group O
vs O
13.5 O
% O
for O
placebo O
group O
; O
P<.001 O
) O
. O

Bone O
marrow O
chromosomes O
were O
studied O
in O
2 I-Subject.Population
patients I-Subject
with I-Subject
polycythaemia I-Treat_Disorder
vera I-Treat_Disorder
( I-Treat_Disorder
PV I-Treat_Disorder
) I-Treat_Disorder
at O
the O
time O
of O
diagnosis O
and O
several O
times O
subsequently O
during O
therapy I-Potential_therapeutic_event.Trigger
with O
chlorambucil I-Treatment.Drug
. O

Procainamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
incessant I-Effect
supraventricular I-Effect
tachycardia I-Effect
in O
the O
Wolff I-Treat_Disorder
- I-Treat_Disorder
Parkinson I-Treat_Disorder
- I-Treat_Disorder
White I-Treat_Disorder
syndrome I-Treat_Disorder
. O

To O
our O
knowledge O
, O
however O
, O
this O
is O
the O
first O
case O
report O
of O
a O
possible O
sitagliptin I-Treatment.Combination.Drug
- I-Treatment
lovastatin I-Treatment.Combination.Drug
interaction I-Treatment
that O
may O
have O
caused I-Adverse_event.Trigger
rhabdomyolysis I-Effect
. O

A I-Subject
drug I-Subject.Sub_Disorder
addict I-Subject.Sub_Disorder
with O
staphylococcal I-Treat_Disorder
endocarditis I-Treat_Disorder
treated O
with O
methicillin I-Treatment.Drug
, O
who O
developed I-Adverse_event.Trigger
massive I-Effect
proteinuria I-Effect
and I-Effect
acute I-Effect
nephritic I-Effect
syndrome I-Effect
is O
described O
. O

Although O
inhibition O
of O
the O
angiotensin O
- O
converting O
enzyme O
is O
considered O
to O
be O
efficient O
treatment I-Potential_therapeutic_event.Trigger
for O
hypertension I-Treat_Disorder
associated I-Treat_Disorder
with I-Treat_Disorder
chronic I-Treat_Disorder
renal I-Treat_Disorder
failure I-Treat_Disorder
, O
care O
should O
be O
taken O
when O
captopril I-Treatment.Drug
is O
administered O
initially O
to O
a I-Subject
patient I-Subject
with I-Subject
decreased I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
function I-Subject.Sub_Disorder
, O
under O
the O
conditions O
of O
sodium O
and O
water O
depletion O
. O

Two I-Subject.Population
patients I-Subject
with O
extrapyramidal I-Effect
side I-Effect
effects I-Effect
after I-Adverse_event.Trigger
the O
use O
of O
fluphenazine I-Treatment.Drug
decanoate I-Treatment.Drug
were O
evaluated O
by O
means O
of O
IBZM O
- O
SPECT O
. O

The O
clinical O
course O
suggests O
that O
the O
interstitial I-Effect
pneumonitis I-Effect
was O
induced I-Adverse_event.Trigger
by O
hydroxyurea I-Treatment.Drug
. O

Disulfiram I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatitis I-Effect
. O

The O
majority O
of O
radiation I-Effect
recall I-Effect
reactions I-Effect
attributed I-Adverse_event.Trigger
to O
gemcitabine I-Treatment.Drug
are O
reported O
to O
affect O
internal O
tissue O
or O
organs O
. O

The O
known O
side O
effects O
of I-Adverse_event.Trigger
sibutramine I-Treatment.Dosage
, O
ie O
, O
hypertension I-Effect
and I-Effect
tachycardia I-Effect
, O
depend O
on O
its O
adrenergic O
and O
serotoninergic O
effects O
. O

Because O
at O
the O
end O
of O
the O
first O
month O
the O
patient O
's O
platelet O
counts O
were O
normal O
and O
the O
thrombocytopenia O
developed O
after O
the O
co O
- O
medication O
with O
conventional O
drugs O
, O
it O
was O
suspected O
that O
the O
thrombocytopenia I-Effect
might O
not O
be O
attributed I-Adverse_event.Trigger
to O
the O
use O
of O
FHP I-Treatment.Drug
. O

Two I-Subject.Population
cases I-Subject
of I-Subject
childhood I-Subject.Age
- I-Subject
onset I-Subject
schizophrenia I-Treat_Disorder
associated O
with O
clozapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
akathisia I-Effect
responsive I-Effect
to O
beta O
- O
blocker O
treatment O
are O
described O
. O

Two I-Subject.Population
cases I-Subject
of I-Subject
childhood I-Subject.Age
- I-Subject
onset I-Subject
schizophrenia I-Subject
associated I-Potential_therapeutic_event.Trigger
with O
clozapine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
akathisia I-Treat_Disorder
responsive I-Treat_Disorder
to O
beta I-Treatment.Drug
- I-Treatment.Drug
blocker I-Treatment.Drug
treatment I-Treatment
are O
described O
. O

Syndrome I-Effect
of I-Effect
inappropriate I-Effect
secretion I-Effect
of I-Effect
ADH I-Effect
( I-Effect
SIADH I-Effect
) I-Effect
following I-Adverse_event.Trigger
cisplatin I-Treatment.Drug
administration O
in O
a I-Subject
pulmonary I-Treat_Disorder
adenocarcinoma I-Treat_Disorder
patient I-Subject
with I-Subject
a I-Subject
malignant I-Subject.Sub_Disorder
pleural I-Subject.Sub_Disorder
effusion I-Subject.Sub_Disorder
. O

He O
had O
an O
immediate I-Time_elapsed
hypersensitivity I-Effect
reaction I-Effect
during I-Adverse_event.Trigger
the O
initiation O
of O
the O
MTX I-Treatment.Drug
infusion I-Treatment.Route
with I-Effect
diffuse I-Effect
urticaria I-Effect
, I-Effect
facial I-Effect
swelling I-Effect
, I-Effect
cough I-Effect
, I-Effect
and I-Effect
chest I-Effect
tightness I-Effect
. O

CONCLUSIONS O
: O
We O
present O
a O
case O
of O
a I-Subject
patient I-Subject
with O
CML O
who O
developed I-Adverse_event.Trigger
KS I-Effect
12 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after O
starting O
treatment O
with O
imatinib I-Treatment.Drug
400 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
. O

Grade I-Effect
3 I-Effect
hepatotoxicity I-Effect
( O
AST O
and O
ALT O
> O
5 O
to O
20 O
upper O
limit O
normal O
) O
or O
higher O
has O
been O
observed I-Adverse_event.Trigger
in O
as O
many O
as O
1.4 I-Subject.Population
% I-Subject.Population
of I-Subject
MS I-Treat_Disorder
patients I-Subject
on O
IFN I-Treatment.Drug
beta I-Treatment.Drug
. O

The O
second O
patient O
was O
a I-Subject
girl I-Subject.Gender
of I-Subject
6 I-Subject.Age
, O
already O
on I-Potential_therapeutic_event.Trigger
risperidone I-Treatment.Drug
for O
ADHD I-Treat_Disorder
and O
borderline I-Treat_Disorder
intellectual I-Treat_Disorder
functioning I-Treat_Disorder
when O
referred O
. O

To O
report O
a I-Subject
young I-Subject.Age
man I-Subject.Gender
on O
phenytoin I-Treatment.Combination.Drug
who O
developed I-Adverse_event.Trigger
acute I-Effect
neurologic I-Effect
symptoms I-Effect
after O
isradipine I-Treatment.Combination.Drug
was O
introduced O
to O
his O
treatment O
regimen O
and O
discuss O
the O
possible O
causes O
of O
this O
drug O
interaction O
. O

Reversible O
sirolimus I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
pneumonitis I-Effect
after O
heart O
transplantation O
. O

We O
report O
a I-Subject
girl I-Subject.Gender
with O
the O
Rett I-Effect
syndrome I-Effect
who O
had O
acute I-Effect
encephalopathy I-Effect
probably O
induced I-Adverse_event.Trigger
by O
calcium I-Treatment.Drug
hopantenate I-Treatment.Drug
( I-Treatment
HOPA I-Treatment
) I-Treatment
. O

Only O
after O
three O
subsequent O
episodes O
of O
severe O
, O
symptomatic I-Effect
thrombocytopenia I-Effect
over I-Time_elapsed
the I-Time_elapsed
next I-Time_elapsed
four I-Time_elapsed
weeks I-Time_elapsed
did O
he O
say O
, O
upon O
repeat O
questioning O
, O
that O
he I-Subject.Gender
had O
continued I-Treatment
to I-Treatment
take I-Treatment
quinine I-Treatment.Drug
for O
night I-Treat_Disorder
leg I-Treat_Disorder
cramps I-Treat_Disorder
. O

An O
episode O
of O
subacute I-Effect
encephalopathy I-Effect
after I-Adverse_event.Trigger
the O
infusion O
of O
a I-Treatment
moderate I-Treatment
dose I-Treatment
of I-Treatment
methotrexate I-Treatment.Drug
( I-Treatment
1500 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
) I-Treatment
( I-Treatment
MTX I-Treatment
) I-Treatment
is O
reported O
in O
a I-Subject
young I-Subject.Age
adult I-Subject.Age
with I-Subject
metastastic I-Treat_Disorder
gastric I-Treat_Disorder
cancer I-Treat_Disorder
. O

Rhabdomyolysis I-Effect
in O
a O
hepatitis I-Treat_Disorder
C I-Treat_Disorder
virus I-Treat_Disorder
infected I-Subject
patient I-Subject
treated I-Adverse_event.Trigger
with O
telaprevir I-Treatment.Combination.Drug
and I-Treatment
simvastatin I-Treatment.Combination.Drug
. O

Four I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
intravenous I-Treatment.Route
Zoledronic I-Treatment.Drug
acid I-Treatment.Drug
, O
the O
patient I-Subject
presented O
to O
emergency O
room O
with O
complaints I-Adverse_event.Trigger
of O
carpopedal I-Effect
spasm I-Effect
and I-Effect
bronchospasm I-Effect
. O

Ulcerating I-Effect
enteritis I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
flucytosine I-Treatment.Drug
therapy I-Treatment
. O

OBJECTIVES O
: O
To O
describe O
clinical O
and O
pathologic O
findings O
in O
patients I-Subject
noted O
to O
develop I-Adverse_event.Trigger
lower I-Effect
gastrointestinal I-Effect
symptoms I-Effect
when O
exposed O
to O
rofecoxib I-Treatment.Drug
. O

Our O
findings O
suggest O
that O
significant I-Effect
progression I-Effect
of I-Effect
marrow I-Effect
reticulin I-Effect
fibrosis I-Effect
during I-Adverse_event.Trigger
imatinib I-Treatment.Drug
therapy O
can O
be O
an O
indicator O
for O
a O
return O
or O
progression O
of O
CML O
and O
, O
in O
some O
patients O
with O
CML O
, O
imatinib O
may O
promote O
cytogenetic O
clonal O
evolution O
, O
resulting O
in O
a O
poor O
response O
to O
treatment O
. O

Metabolic I-Effect
acidosis I-Effect
induced I-Adverse_event.Trigger
by O
cetrimide I-Treatment.Combination.Drug
- I-Treatment
chlorhexidine I-Treatment.Combination.Drug
solution I-Treatment.Route
in O
hydatid I-Treat_Disorder
cyst I-Treat_Disorder
surgery O
. O

Reversal O
of O
gold I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
neutropenia I-Effect
with O
granulocyte I-Treatment
colony I-Treatment
- I-Treatment
stimulating I-Treatment
factor I-Treatment
( I-Treatment
G I-Treatment
- I-Treatment
CSF I-Treatment
) I-Treatment
. O

Methyldopa I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
liver I-Effect
injury I-Effect
. O

After O
infliximab I-Treatment.Drug
treatment O
, O
additional O
sleep O
studies O
revealed O
an O
increase I-Effect
in I-Effect
the I-Effect
number I-Effect
of I-Effect
apneic I-Effect
events I-Effect
and I-Effect
SaO2 I-Effect
dips I-Effect
suggesting O
that O
TNFalpha O
plays O
an O
important O
role O
in O
the O
pathophysiology I-Treat_Disorder
of I-Treat_Disorder
sleep I-Treat_Disorder
apnea I-Treat_Disorder
. O

One I-Subject.Population
patient I-Subject
developed I-Adverse_event.Trigger
severe I-Effect
hyponatremia I-Effect
with I-Effect
serum I-Effect
Na+ I-Effect
of I-Effect
108 I-Effect
mEq I-Effect
/ I-Effect
L I-Effect
when O
hydrochlorothiazide I-Treatment.Drug
was O
given O
to O
control O
hypertension I-Treat_Disorder
. O

Thyroid I-Effect
dysfunction I-Effect
has O
been O
reported I-Adverse_event.Trigger
in O
patients I-Subject
with I-Subject
malignant I-Treat_Disorder
disease I-Treat_Disorder
treated O
with O
recombinant I-Treatment.Drug
alpha I-Treatment.Drug
interferon I-Treatment.Drug
. O

The O
authors O
also O
determined O
that O
their O
case O
of O
myositis I-Effect
developing I-Effect
in I-Effect
the I-Effect
rectus I-Effect
abdominus I-Effect
muscle I-Effect
of O
a I-Subject
patient I-Subject
with I-Subject
pancreatic I-Treat_Disorder
adenocarcinoma I-Treat_Disorder
was O
the O
manifestation O
of O
radiation O
recall O
, O
thereby O
bringing O
the O
number O
of O
patients O
who O
developed I-Adverse_event.Trigger
radiation I-Effect
recall I-Effect
to O
gemcitabine I-Treatment.Drug
and O
were O
discussed O
in O
the O
current O
study O
to O
13 O
. O

Even O
after O
a O
strict O
warning O
, O
he O
took O
another O
quinine I-Treatment.Drug
tablet I-Treatment.Route
that O
evening O
, O
which O
triggered I-Adverse_event.Trigger
his O
fifth O
episode O
of O
severe I-Effect
thrombocytopenia I-Effect
, O
and O
confirmed O
the O
etiology O
of O
quinine O
- O
induced O
thrombocytopenia O
. O

Case I-Subject
1 I-Subject.Population
presented O
after I-Adverse_event.Trigger
25 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
of I-Treatment
myelosuppressive I-Treatment.Drug
therapy I-Treatment
a I-Effect
deletion I-Effect
of I-Effect
chromosome I-Effect
no I-Effect
. I-Effect
12 I-Effect
, I-Effect
del I-Effect
( I-Effect
12 I-Effect
) I-Effect
( I-Effect
p11 I-Effect
) I-Effect
, I-Effect
in I-Effect
60 I-Effect
% I-Effect
of I-Effect
the I-Effect
diploid I-Effect
cells I-Effect
. O

Diabetes I-Effect
Mellitus I-Effect
was O
observed O
in O
a I-Subject
patient I-Subject
given I-Adverse_event.Trigger
carbamazepine I-Treatment.Drug
. O

Anxiety I-Treat_Disorder
is O
common O
in O
patients I-Subject
with I-Subject
schizophrenia I-Subject.Sub_Disorder
and O
pregabalin I-Treatment.Drug
has I-Treatment
been I-Treatment
suggested I-Treatment
as I-Treatment
an I-Treatment
off I-Treatment
- I-Treatment
label I-Treatment
add I-Treatment
- I-Treatment
on I-Treatment
treatment I-Treatment
. O

Large I-Effect
cerebral I-Effect
infarction I-Effect
during I-Adverse_event.Trigger
praziquantel I-Treatment.Drug
therapy O
in O
neurocysticercosis I-Treat_Disorder
. O

We O
report O
a I-Subject
13 I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject
who O
developed I-Adverse_event.Trigger
life O
- O
threatening O
anaphylaxis I-Effect
early O
in O
the O
course O
of O
Increlex I-Treatment.Drug
therapy O
. O

Drug O
induced O
liver I-Effect
injury I-Effect
secondary I-Adverse_event.Trigger
to O
interferon I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
( I-Treatment
IFN I-Treatment
- I-Treatment
beta I-Treatment
) I-Treatment
in O
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
. O

CONCLUSION O
: O
Lipoid I-Effect
pneumonia I-Effect
as O
a O
result I-Adverse_event.Trigger
of O
mineral I-Treatment.Drug
oil I-Treatment.Drug
aspiration I-Treatment
still O
occurs O
in O
the O
pediatric I-Subject.Age
population O
. O

The O
results O
from O
the O
present O
study O
suggest O
that O
tissue I-Treatment.Combination.Drug
plasminogen I-Treatment.Combination.Drug
activator I-Treatment.Combination.Drug
treatment I-Treatment
appears I-Potential_therapeutic_event.Trigger
to O
be O
safe O
in O
patients I-Subject
with I-Subject
acute I-Treat_Disorder
ischemic I-Treat_Disorder
stroke I-Treat_Disorder
taking I-Treatment
warfarin I-Treatment.Combination.Drug
with I-Treatment
an I-Treatment
international I-Treatment
normalized I-Treatment
ratio I-Treatment
< I-Treatment
1.7 I-Treatment
and O
may I-Effect
reduce I-Effect
the I-Effect
risk I-Effect
of I-Effect
poor I-Effect
functional I-Effect
outcome I-Effect
. O

Because O
of O
chronic I-Treat_Disorder
asthma I-Treat_Disorder
, O
she I-Subject
had O
been O
receiving I-Potential_therapeutic_event.Trigger
a I-Treatment
leukotriene I-Treatment
receptor I-Treatment
antagonist I-Treatment
( I-Treatment
montelukast I-Treatment.Drug
) I-Treatment
for I-Treatment
5 I-Treatment.Time_elapsed
years I-Treatment.Time_elapsed
before O
the O
current O
presentation O
; O
1 O
week O
before O
onset O
she O
had O
had O
1 O
week O
of O
treatment O
with O
two O
dietary O
supplements O
for O
weight O
control O
; O
one O
of O
these O
included O
Garcinia O
Cambogia O
, O
a O
possible O
cause O
of O
two O
recent O
cases O
of O
hepatitis O
in O
the O
USA O
; O
in O
addition O
, O
both O
formulas O
contained O
a O
citrus O
derivative O
that O
interferes O
cytochrome O
functions O
. O

Because O
of O
chronic O
asthma O
, O
she O
had O
been O
receiving O
a O
leukotriene O
receptor O
antagonist O
( O
montelukast O
) O
for O
5 O
years O
before O
the O
current O
presentation O
; O
1 O
week O
before O
onset O
she O
had O
had O
1 O
week O
of O
treatment O
with O
two O
dietary O
supplements O
for O
weight O
control O
; O
one O
of O
these O
included O
Garcinia I-Treatment.Drug
Cambogia I-Treatment.Drug
, O
a O
possible O
cause I-Adverse_event.Trigger
of O
two I-Subject.Population
recent I-Subject
cases I-Subject
of O
hepatitis I-Effect
in O
the O
USA O
; O
in O
addition O
, O
both O
formulas O
contained O
a O
citrus O
derivative O
that O
interferes O
cytochrome O
functions O
. O

An O
episode O
of O
leukoencephalopathy I-Effect
is O
reported O
in O
a O
13 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
who I-Subject
, O
after I-Adverse_event.Trigger
standard I-Treatment
radiotherapy I-Treatment.Drug
for I-Treatment
a I-Treatment
posterior I-Treatment
fossa I-Treatment
medulloblastoma I-Treatment
, I-Treatment
received I-Treatment
8 I-Treatment
treatments I-Treatment
with I-Treatment
a I-Treatment
protocol I-Treatment
containing I-Treatment
a I-Treatment
4 I-Treatment
- I-Treatment
hour I-Treatment
infusion I-Treatment.Route
of I-Treatment
500 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
methotrexate I-Treatment.Drug
and I-Treatment
12 I-Treatment.Dosage
mg I-Treatment.Dosage
intrathecal I-Treatment.Drug
methotrexate I-Treatment.Drug
. O

BACKGROUND O
: O
Accutane I-Treatment.Drug
a O
teratogenic O
prescription O
drug O
licensed O
to O
treat I-Potential_therapeutic_event.Trigger
severe I-Treat_Disorder
, I-Treat_Disorder
recalcitrant I-Treat_Disorder
nodular I-Treat_Disorder
acne I-Treat_Disorder
. O

OBJECTIVE O
: O
To O
report O
the O
safe I-Potential_therapeutic_event.Trigger
use O
of O
fluorouracil I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
breast I-Treat_Disorder
cancer I-Treat_Disorder
who I-Subject
had I-Subject
allergic I-Subject.Sub_Disorder
reactions I-Subject.Sub_Disorder
to I-Subject.Sub_Disorder
capecitabine I-Subject.Sub_Disorder
. O

Esophageal I-Effect
candidiasis I-Effect
following I-Adverse_event.Trigger
omeprazole I-Treatment.Drug
therapy O
: O
a O
report O
of O
two I-Subject.Population
cases I-Subject
. O

We O
describe O
a I-Subject
10 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
with I-Subject
ulcerative I-Treat_Disorder
colitis I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
acute I-Effect
pancreatitis I-Effect
while O
on O
long I-Treatment.Freq
- I-Treatment.Freq
term I-Treatment.Freq
treatment I-Treatment.Freq
with I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
. O

The O
mechanism O
of O
niacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
coagulopathy I-Effect
is O
theorized O
to O
be O
related O
to O
diminished O
coagulation O
factors O
, O
and O
limited O
data O
suggest O
that O
this O
may O
be O
more O
pronounced O
with O
extended I-Drug
- I-Drug
release I-Drug
niacin I-Drug
. O

OBJECTIVE O
: O
To O
report O
2 O
cases O
of O
nonconvulsive I-Effect
status I-Effect
epilepticus I-Effect
( I-Effect
NCSE I-Effect
) I-Effect
following I-Adverse_event.Trigger
infusion I-Treatment.Route
of I-Treatment
ifosfamide I-Treatment.Drug
. O

We O
conclude O
that O
the O
observed O
toxicity I-Effect
with I-Effect
jaundice I-Effect
was O
probably O
caused I-Adverse_event.Trigger
by O
an O
interaction O
of O
this O
popular O
Chinese O
formula O
and O
temozolomide I-Treatment.Drug
. O

Pigmentary I-Effect
disorders I-Effect
are O
recognized O
adverse I-Adverse_event.Trigger
effects O
of O
the O
semi I-Treatment
- I-Treatment
synthetic I-Treatment
tetracycline I-Treatment
derivative I-Treatment
antibiotic I-Treatment
, I-Treatment
minocycline I-Treatment.Drug
. O

Pregabalin I-Treatment.Drug
is I-Treatment
an I-Treatment
antiepileptic I-Treatment
drug I-Treatment
with I-Treatment
anti I-Treatment
- I-Treatment
anxiety I-Treatment
properties I-Treatment
and O
is O
approved O
for O
treatment I-Potential_therapeutic_event.Trigger
of O
generalized I-Treat_Disorder
anxiety I-Treat_Disorder
disorder I-Treat_Disorder
. O

We O
report O
a O
case O
of O
chronic I-Treatment.Duration
use I-Treatment
of I-Treatment
HCQ I-Treatment.Drug
associated I-Adverse_event.Trigger
with O
torsade I-Effect
de I-Effect
pointes I-Effect
. O

PURPOSE O
: O
The O
occurrence O
of O
myoclonus I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
continuous I-Treatment
i.v I-Treatment
. I-Treatment
infusion I-Treatment.Route
of I-Treatment
dobutamine I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
end I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
stage I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
( I-Subject.Sub_Disorder
ESRD I-Subject.Sub_Disorder
) I-Subject.Sub_Disorder
is O
described O
. O

The O
case O
concerns O
the O
sudden I-Effect
death I-Effect
of O
a I-Subject
29 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Population
during I-Adverse_event.Trigger
clozapine I-Treatment.Drug
therapy O
started O
2 I-Time_elapsed
weeks I-Time_elapsed
before I-Time_elapsed
. O

In O
this O
paper O
, O
we O
report O
a O
case O
of O
3 I-Subject.Age
years I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
who O
developed I-Adverse_event.Trigger
acute I-Effect
onset I-Effect
tetraparesia I-Effect
following O
a I-Sub_Disorder
viral I-Sub_Disorder
respiratory I-Sub_Disorder
infecction I-Sub_Disorder
and O
hepatitis I-Treatment.Drug
B I-Treatment.Drug
vaccination I-Treatment.Drug
. O

Treatment O
of O
ELP I-Treat_Disorder
in O
children O
is O
generally O
supportive O
, O
with O
the O
symptoms I-Effect
and I-Effect
roentgenographic I-Effect
abnormalities I-Effect
resolving I-Effect
within O
months O
after I-Potential_therapeutic_event.Trigger
stopping I-Treatment
the I-Treatment
use I-Treatment
of I-Treatment
mineral I-Treatment.Drug
oil I-Treatment.Drug
. O

PET O
scintigraphy O
of O
etoposide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
. O

We O
report O
a I-Subject
patient I-Subject
who O
experienced I-Effect
LABD I-Effect
shortly I-Effect
after I-Adverse_event.Trigger
starting I-Treatment.Route
carbamazepine I-Treatment.Drug
therapy I-Treatment
. O

Fulminant I-Treatment
metoclopramide I-Treatment.Drug
induced I-Adverse_event.Trigger
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
rapidly O
responsive O
to O
intravenous O
dantrolene O
. O

Can O
ketamine I-Treatment.Drug
prescribed O
for O
pain I-Treat_Disorder
cause I-Adverse_event.Trigger
damage I-Effect
to I-Effect
the I-Effect
urinary I-Effect
tract I-Effect
? O

Sixteen O
hours O
after O
the O
first O
administration O
of O
IFN O
, O
IFN I-Treatment.Drug
was O
suspended I-Adverse_event.Trigger
by O
the O
symptoms O
of O
congestive I-Effect
heart I-Effect
failure I-Effect
( I-Effect
CHF I-Effect
) I-Effect
. O

We O
believe O
this O
is O
the O
first O
report O
of O
myocardial I-Effect
infarction I-Effect
due O
to O
coronary I-Effect
spasm I-Effect
, O
demonstrated O
by O
angiography O
associated I-Adverse_event.Trigger
with O
L I-Treatment.Drug
- I-Treatment.Drug
thyroxine I-Treatment.Drug
therapy O
. O

A O
58 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
( I-Treat_Disorder
RA I-Treat_Disorder
) I-Treat_Disorder
developed I-Adverse_event.Trigger
fever I-Effect
, I-Effect
skin I-Effect
eruptions I-Effect
, I-Effect
leukocytopenia I-Effect
, I-Effect
and I-Effect
thrombocytopenia I-Effect
, O
3 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
treatment I-Treatment
with I-Treatment
sulfasalazine I-Treatment.Drug
. O

Gold I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
aplastic I-Effect
anemia I-Effect
. O

One I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
large I-Effect
intramural I-Effect
esophageal I-Effect
hematoma I-Effect
as O
a I-Treatment
complication I-Treatment
of I-Treatment
heparin I-Treatment.Drug
therapy I-Treatment
. O

Mammary I-Effect
gigantism I-Effect
is O
a O
rare O
complication I-Adverse_event.Trigger
of I-Adverse_event.Trigger
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
treatment I-Treatment
. O

Cyclobenzaprine I-Treatment.Drug
shares O
anticholinergic I-Effect
effects I-Effect
, I-Effect
tachycardia I-Effect
, I-Effect
and I-Effect
dysrhythmic I-Effect
potential I-Adverse_event.Trigger
with I-Treatment
the I-Treatment
tricyclic I-Treatment.Drug
antidepressants I-Treatment.Drug
( I-Treatment
TCAs I-Treatment
) I-Treatment
. O

The O
autopsy O
findings O
and O
a O
detailed O
medical O
history O
supported O
the O
conclusion O
that O
clozapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypersensitivity I-Effect
myocarditis I-Effect
was O
the O
most O
likely O
cause O
of O
death I-Effect
. O

PURPOSE O
: O
To O
present O
a O
case O
of O
respiratory I-Effect
depression I-Effect
following I-Adverse_event.Trigger
the O
administration O
of O
nebulised I-Treatment.Route
morphine I-Treatment.Drug
. O

METHODS O
: O
A I-Subject
55 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
became I-Adverse_event.Trigger
stuporous I-Effect
after O
overdose I-Treatment.Dosage
with I-Treatment
lamotrigine I-Treatment.Combination.Drug
( I-Treatment
LTG I-Treatment
) I-Treatment
and I-Treatment
valproic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
( I-Treatment
VPA I-Treatment
) I-Treatment
tablets I-Treatment.Route
. O

Recrudescence I-Effect
of I-Effect
imported I-Effect
falciparum I-Effect
malaria I-Effect
after I-Adverse_event.Trigger
quinine I-Treatment.Combination.Drug
therapy O
: O
potential O
drug O
interaction O
with O
phenytoin I-Treatment.Combination.Drug
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
of O
the O
possible O
association I-Adverse_event.Trigger
of O
thrombocytopenia I-Effect
with O
lansoprazole I-Treatment.Drug
and O
discontinue O
the O
drug O
if O
thrombocytopenia O
becomes O
apparent O
. O

One I-Subject.Population
of I-Subject
the I-Subject
subjects I-Subject
who O
was O
using O
extemporaneous I-Treatment
topical I-Treatment.Route
minoxidil I-Treatment.Drug
had I-Adverse_event.Trigger
hypertension I-Effect
and I-Effect
arteriosclerotic I-Effect
disease I-Effect
and O
the O
other O
died O
of O
a O
myocardial O
infarction O
. O

One O
of O
the O
subjects O
who O
was O
using O
extemporaneous I-Treatment
topical I-Treatment.Route
minoxidil I-Treatment.Drug
had O
hypertension O
and O
arteriosclerotic O
disease O
and O
the I-Subject
other I-Subject
died I-Effect
of I-Effect
a I-Effect
myocardial I-Effect
infarction I-Effect
. O

CONCLUSION O
: O
Long O
- O
term O
treatment O
with O
rifabutin I-Treatment.Drug
may O
have I-Adverse_event.Trigger
a O
reversible O
and O
previously O
undescribed O
side I-Effect
- I-Effect
effect I-Effect
on I-Effect
retinal I-Effect
function I-Effect
. O

Toxic I-Effect
hepatitis I-Effect
due I-Adverse_event.Trigger
to O
combination O
therapy O
with O
methotrexate I-Treatment.Combination.Drug
and I-Treatment
etretinate I-Treatment.Combination.Drug
in O
psoriasis I-Treat_Disorder
. O

To O
report O
the O
results O
of O
therapeutic O
drug O
monitoring O
of O
lopinavir I-Treatment.Combination.Drug
/ I-Treatment
ritonavir I-Treatment.Combination.Drug
and I-Treatment
itraconazole I-Treatment.Combination.Drug
concentrations I-Treatment
in O
an I-Subject
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
male I-Subject.Gender
who O
was O
treated I-Potential_therapeutic_event.Trigger
for O
histoplasmosis I-Treat_Disorder
. O

Ulcer I-Treat_Disorder
became I-Effect
worse I-Effect
after I-Adverse_event.Trigger
tobramycin I-Treatment.Combination.Drug
and I-Treatment
gentamycin I-Treatment.Combination.Drug
treatment O
for O
2 O
days O
. O

Thalidomide O
has O
proven O
activity O
in O
refractory I-Treat_Disorder
multiple I-Treat_Disorder
myeloma I-Treat_Disorder
( I-Treat_Disorder
MM I-Treat_Disorder
) I-Treat_Disorder
, O
and O
although O
single I-Treatment
- I-Treatment
agent I-Treatment
thalidomide I-Treatment.Combination.Drug
has O
minimal O
prothrombogenic O
activity O
, O
its O
combination I-Treatment
with I-Treatment
cytotoxic I-Treatment.Combination.Drug
chemotherapy I-Treatment.Route
is O
associated I-Adverse_event.Trigger
with O
a O
significantly I-Effect
increased I-Effect
risk I-Effect
of I-Effect
DVT I-Effect
. O

These O
cases O
indicate O
that O
sulpiride I-Treatment.Drug
can O
cause I-Adverse_event.Trigger
tardive I-Effect
dyskinesia I-Effect
and O
that O
this O
drug O
should O
be O
administered O
with O
caution O
. O

Well I-Effect
- I-Effect
differentiated I-Effect
endometrial I-Effect
adenocarcinoma I-Effect
of I-Effect
the I-Effect
secretory I-Effect
type I-Effect
( I-Effect
FIGO I-Effect
Grade I-Effect
1 I-Effect
) I-Effect
with I-Effect
minimal I-Effect
myometrial I-Effect
invasion I-Effect
occurred I-Adverse_event.Trigger
in O
a I-Subject
postmenopausal I-Subject.Sub_Disorder
patient I-Subject
on O
tamoxifen I-Treatment.Drug
therapy I-Treatment
5 I-Treatment
years I-Treatment
after I-Treatment
mastectomy I-Treatment
for I-Treatment
breast I-Treatment.Treat_Disorder
carcinoma I-Treatment.Treat_Disorder
. I-Treatment

Secondary I-Effect
hematologic I-Effect
neoplasm I-Effect
after I-Adverse_event.Trigger
intravesical I-Treatment.Drug
chemotherapy I-Treatment.Route
for O
superficial O
bladder I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

Ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
renal I-Effect
insufficiency I-Effect
in O
cystic I-Treat_Disorder
fibrosis I-Treat_Disorder
. O

While O
the I-Treatment
introduction I-Treatment
of I-Treatment
carmustine I-Treatment.Drug
wafers I-Treatment.Drug
( I-Treatment
Gliadel I-Treatment
wafers I-Treatment
) I-Treatment
into I-Treatment
the I-Treatment
tumor I-Treatment
resection I-Treatment
cavity I-Treatment
has O
been O
shown O
to O
be O
a O
beneficial O
therapy O
for O
malignant I-Treat_Disorder
glioma I-Treat_Disorder
, O
it O
is O
recognized O
that O
clinically O
significant I-Effect
cerebral I-Effect
edema I-Effect
is O
a O
potential O
adverse I-Adverse_event.Trigger
effect O
. O

Didanosine I-Treatment.Drug
also O
has O
a O
potential O
for O
inducing I-Adverse_event.Trigger
seizures I-Effect
. O

Obsessive I-Effect
- I-Effect
compulsive I-Effect
symptoms I-Effect
suddenly O
emerged I-Adverse_event.Trigger
10 O
days O
after O
starting O
risperidone I-Treatment.Drug
and O
resolved O
within O
3 O
days O
of O
discontinuation O
. O

Refractory I-Effect
hypoglycemia I-Effect
from I-Adverse_event.Trigger
ciprofloxacin I-Treatment.Combination.Drug
and I-Treatment
glyburide I-Treatment.Combination.Drug
interaction I-Treatment
. O

Anaphylactic I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
recombinant I-Treatment.Drug
insulin I-Treatment.Drug
- I-Treatment.Drug
like I-Treatment.Drug
growth I-Treatment.Drug
factor I-Treatment.Drug
- I-Treatment.Drug
I. I-Treatment.Drug

Subtherapeutic I-Treatment
warfarin I-Treatment.Combination.Drug
is O
not O
associated I-Adverse_event.Trigger
with O
increased I-Effect
hemorrhage I-Effect
rates I-Effect
in O
ischemic I-Treat_Disorder
strokes I-Treat_Disorder
treated I-Treatment
with I-Treatment
tissue I-Treatment.Combination.Drug
plasminogen I-Treatment.Combination.Drug
activator I-Treatment.Combination.Drug
. O

Pediatric I-Subject.Age
heparin I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
thrombocytopenia I-Treat_Disorder
: O
management I-Potential_therapeutic_event.Trigger
with O
Danaparoid I-Treatment.Drug
( I-Treatment
orgaran I-Treatment
) I-Treatment
. O

Pediatric I-Subject.Age
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
: O
management O
with O
Danaparoid O
( O
orgaran O
) O
. O

Teicoplanin I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
agranulocytosis I-Effect
that O
followed I-Treatment
vancomycin I-Treatment.Combination.Drug
- O
induced O
agranulocytosis O
suggests O
a O
possible O
cross O
- O
reactivity O
between O
the O
2 O
drugs O
. O

A I-Subject
55 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
developed I-Adverse_event.Trigger
symptoms O
suggestive O
of O
hepatitis I-Effect
12 I-Time_elapsed
weeks I-Time_elapsed
after O
first O
receiving O
methyldopa I-Treatment.Drug
for O
hypertension I-Treat_Disorder
. O

Cyclophosphamide I-Treatment.Drug
can O
rarely O
cause I-Adverse_event.Trigger
interstitial I-Effect
pneumonitis I-Effect
and I-Effect
fibrosis I-Effect
. O

Flucytosine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
diarrhea I-Effect
has O
been O
previously O
described O
in O
6% I-Subject.Population
- I-Subject.Population
10 I-Subject.Population
% I-Subject.Population
of I-Subject
patients I-Subject
receiving O
the O
drug O
. O

IV I-Treatment.Route
propranolol I-Treatment.Drug
was O
used O
as O
the O
initial O
treatment O
for O
his I-Subject.Gender
hyperadrenergic I-Treat_Disorder
state I-Treat_Disorder
, O
resulting I-Adverse_event.Trigger
in O
a O
decrease I-Effect
in I-Effect
heart I-Effect
rate I-Effect
but I-Effect
a I-Effect
paroxsymal I-Effect
increase I-Effect
in I-Effect
blood I-Effect
pressure I-Effect
. O

We O
believe O
that O
this O
is O
the O
first O
report O
of O
secretory I-Effect
carcinoma I-Effect
of I-Effect
the I-Effect
endometrium I-Effect
associated I-Adverse_event.Trigger
with O
tamoxifen I-Treatment.Drug
use O
. O

Herpes I-Effect
simplex I-Effect
esophagitis I-Effect
in O
a O
renal I-Treat_Disorder
transplant I-Treat_Disorder
patient I-Subject
treated I-Adverse_event.Trigger
with O
cyclosporine I-Treatment.Drug
A O
: O
a O
case O
report O
. O

This O
clinical O
course O
suggests O
that O
the O
sensorimotor I-Effect
polyneuropathy I-Effect
may O
have O
been O
caused I-Adverse_event.Trigger
by O
5 I-Treatment.Drug
- I-Treatment.Drug
ASA I-Treatment.Drug
. O

Spontaneous I-Effect
nasal I-Effect
septal I-Effect
perforation I-Effect
with I-Adverse_event.Trigger
antiangiogenic I-Treatment
bevacizumab I-Treatment.Drug
therapy I-Treatment
. O

There O
are O
a O
few O
case O
reports O
on O
hair I-Effect
loss I-Effect
associated I-Adverse_event.Trigger
with O
tricyclic I-Treatment.Combination.Drug
antidepressants I-Treatment.Combination.Drug
and I-Treatment
serotonin I-Treatment.Combination.Drug
selective I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
( O
SSRIs O
) O
, O
but O
none O
deal O
specifically O
with O
paroxetine O
. O

There O
have O
been O
more I-Effect
than I-Effect
20 I-Effect
observations I-Effect
of I-Effect
the I-Effect
appearance I-Effect
or I-Effect
aggravation I-Effect
of I-Effect
this I-Effect
granulomatosis I-Effect
with I-Adverse_event.Trigger
interferon I-Treatment.Drug
alfa I-Treatment.Drug
and I-Treatment
more I-Treatment
recently I-Treatment
with I-Treatment
the I-Treatment
combination I-Treatment
of I-Treatment
interferon I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
plus I-Treatment
ribavirin I-Treatment.Combination.Drug
. O

CONCLUSION O
: O
A I-Subject
37 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
African I-Subject.Race
- I-Subject.Race
American I-Subject.Race
man I-Subject.Gender
with I-Subject
G6PD I-Subject.Sub_Disorder
deficiency I-Subject.Sub_Disorder
developed I-Adverse_event.Trigger
hemolytic I-Effect
anemia I-Effect
, I-Effect
hepatitis I-Effect
, I-Effect
orthostatic I-Effect
hypotension I-Effect
, I-Effect
and I-Effect
aseptic I-Effect
meningitis I-Effect
simultaneously O
after O
using O
trimethoprim I-Treatment.Drug
- I-Treatment.Drug
sulfamethoxazole I-Treatment.Drug
. O

All I-Treatment.Drug
- I-Treatment.Drug
trans I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
focal I-Effect
myositis I-Effect
, I-Effect
synovitis I-Effect
, I-Effect
and I-Effect
mononeuritis I-Effect
. O

Oxygen I-Treatment.Combination.Drug
potentiation I-Treatment
of I-Treatment
bleomycin I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
is O
discussed O
. O

CONCLUSIONS O
: O
LTG I-Treatment.Drug
overdose I-Treatment.Dosage
may O
result I-Adverse_event.Trigger
in O
a O
severe O
but O
reversible I-Effect
encephalopathy I-Effect
, O
a O
previously O
undescribed O
phenomenon O
. O

In O
this O
report O
, O
we O
describe O
a O
case O
of O
rhabdomyolysis I-Effect
and I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
secondary I-Adverse_event.Trigger
to O
the O
interaction I-Treatment
between I-Treatment
danazol I-Treatment.Combination.Drug
and I-Treatment
simvastatin I-Treatment.Combination.Drug
. O

Infectious I-Effect
toxicity I-Effect
of O
dexamethasone I-Treatment.Drug
during I-Adverse_event.Trigger
all I-Treatment
remission I-Treatment
- I-Treatment
induction I-Treatment
chemotherapy I-Treatment.Route
: O
report O
of O
two I-Subject.Population
cases I-Subject
and O
literature O
review O
. O

A I-Subject
56 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
male I-Subject.Gender
had O
been O
receiving I-Potential_therapeutic_event.Trigger
chronic I-Treatment
warfarin I-Treatment.Drug
therapy I-Treatment
for I-Treatment
11 I-Treatment
years I-Treatment
after I-Treatment
mechanical I-Treatment
heart I-Treatment
valve I-Treatment
replacement I-Treatment
. O

Isoniazid I-Treatment.Drug
associated I-Adverse_event.Trigger
, O
painful I-Effect
, I-Effect
bilateral I-Effect
gynaecomastia I-Effect
. O

Electrocardiographic O
findings O
and O
laboratory O
data O
indicated O
a O
diagnosis O
of O
acute I-Effect
myocardial I-Effect
infarction I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
the I-Treatment
L I-Treatment.Drug
- I-Treatment.Drug
thyroxine I-Treatment.Drug
therapy I-Treatment
. I-Treatment

Combining I-Treatment
methylephedrine I-Treatment.Combination.Drug
and I-Treatment
Chinese I-Treatment.Combination.Drug
herbal I-Treatment.Combination.Drug
drugs I-Treatment.Combination.Drug
might O
carry I-Adverse_event.Trigger
a O
risk I-Effect
of I-Effect
stroke I-Effect
. O

Coadministration I-Treatment
of I-Treatment
200 I-Treatment.Dosage
mg I-Treatment.Dosage
bid I-Treatment
voriconazole I-Treatment.Combination.Drug
with I-Treatment
400 I-Treatment.Dosage
mg I-Treatment.Dosage
( I-Treatment
or I-Treatment
higher I-Treatment
) I-Treatment
qd I-Treatment
efavirenz I-Treatment.Combination.Drug
is O
contraindicated I-Adverse_event.Trigger
due O
to O
the O
clinically I-Effect
significant I-Effect
effect I-Effect
of O
efavirenz I-Treatment.Drug
on I-Treatment
voriconazole I-Treatment.Drug
pharmacokinetics O
. O

An O
interaction I-Treatment
between I-Treatment
niacin I-Treatment.Combination.Drug
and I-Treatment
warfarin I-Treatment.Combination.Drug
likely O
elevated I-Effect
the I-Effect
INR I-Effect
in O
this I-Subject
patient I-Subject
because O
of O
synergistic O
coagulopathy O
and O
pharmacokinetic O
effects O
of O
niacin O
. O

We O
present O
two I-Subject.Population
cases I-Subject
in I-Subject
which I-Subject
both I-Subject
patients I-Subject
suffered I-Subject
with I-Subject
CLS I-Effect
, O
which O
we O
believe O
was O
caused O
following O
administration I-Adverse_event.Trigger
of O
granulocyte I-Treatment.Drug
colony I-Treatment.Drug
- I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
, O
to O
our O
knowledge O
not O
described O
in O
the O
intensive O
care O
patient O
previously O
. O

Capecitabine I-Effect
was I-Effect
discontinued I-Effect
and I-Effect
the I-Effect
allergic I-Effect
reactions I-Effect
resolved I-Effect
after O
the O
woman I-Subject.Gender
took I-Potential_therapeutic_event.Trigger
diphenhydramine I-Treatment.Drug
for I-Treatment
1 I-Treatment.Time_elapsed
week I-Treatment.Time_elapsed
. O

Intravenous I-Treatment.Route
fluconazole I-Treatment.Combination.Drug
400 I-Treatment.Dosage
mg I-Treatment.Dosage
, I-Treatment.Dosage
followed I-Treatment.Dosage
by I-Treatment.Dosage
100 I-Treatment.Dosage
mg I-Treatment.Dosage
every I-Treatment.Dosage
24 I-Treatment.Dosage
hours I-Treatment.Dosage
according O
to O
impaired O
renal O
function O
, O
was O
immediately O
started O
; O
to O
avoid I-Potential_therapeutic_event.Trigger
further O
nephrotoxicity I-Treat_Disorder
, O
immunosuppressant I-Treatment
therapy I-Treatment
was I-Treatment
switched I-Treatment
from I-Treatment
cyclosporine I-Treatment.Combination.Drug
plus I-Treatment
mycophenolate I-Treatment.Combination.Drug
mofetil I-Treatment.Combination.Drug
to I-Treatment
oral I-Treatment.Route
everolimus I-Treatment.Combination.Drug
0.75 I-Treatment.Dosage
mg I-Treatment.Dosage
every I-Treatment.Dosage
12 I-Treatment.Dosage
hours I-Treatment.Dosage
. O

We O
report O
3 I-Subject.Population
patients I-Subject
with O
severe I-Effect
hepatocellular I-Effect
damage I-Effect
due I-Adverse_event.Trigger
to O
CPA I-Treatment.Drug
therapy O
, O
2 O
with O
fatal O
fulminant O
hepatitis O
. O

We O
report O
3 O
patients O
with O
severe O
hepatocellular O
damage O
due I-Adverse_event.Trigger
to O
CPA I-Treatment.Drug
therapy O
, O
2 I-Subject.Population
with O
fatal I-Effect
fulminant I-Effect
hepatitis I-Effect
. O

Soon O
after O
introduction O
of O
insulin I-Treatment.Drug
therapy O
, O
she I-Subject.Gender
developed I-Adverse_event.Trigger
severe O
anasarca I-Effect
, I-Effect
including I-Effect
marked I-Effect
peripheral I-Effect
oedema I-Effect
, I-Effect
ascites I-Effect
and I-Effect
pleural I-Effect
effusion I-Effect
. O

We O
describe O
a I-Subject
continuous I-Subject.Sub_Disorder
ambulatory I-Subject.Sub_Disorder
peritoneal I-Subject.Sub_Disorder
dialysis I-Subject.Sub_Disorder
( I-Subject.Sub_Disorder
CAPD I-Subject.Sub_Disorder
) I-Subject.Sub_Disorder
patient I-Subject
that O
developed O
vancomycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
agranulocytosis I-Effect
during O
treatment O
for O
methicillin I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
Staphylococcus I-Treat_Disorder
aureus I-Treat_Disorder
( I-Treat_Disorder
MRSA) I-Treat_Disorder
- I-Treat_Disorder
associated I-Treat_Disorder
external I-Treat_Disorder
cuff I-Treat_Disorder
infection I-Treat_Disorder
and I-Treat_Disorder
pneumonia I-Treat_Disorder
. O

In I-Subject
both I-Subject.Population
cases I-Subject
, O
we O
believe O
that O
serotonin I-Effect
syndrome I-Effect
was O
produced I-Adverse_event.Trigger
by O
a I-Treatment
combination I-Treatment
of I-Treatment
an I-Treatment
antidepressant I-Treatment.Combination.Drug
and I-Treatment
an I-Treatment
atypical I-Treatment.Combination.Drug
antipsychotic I-Treatment.Combination.Drug
. O

Cyclosporin I-Treatment.Drug
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
included O
hirsutism I-Effect
, I-Effect
hypertension I-Effect
, I-Effect
increased I-Effect
blood I-Effect
levels I-Effect
of I-Effect
urea I-Effect
and I-Effect
creatinine I-Effect
, I-Effect
and I-Effect
abnormalities I-Effect
in I-Effect
liver I-Effect
function I-Effect
tests I-Effect
. I-Effect

She O
displayed I-Adverse_event.Trigger
severe O
hyperactivity I-Effect
, I-Effect
agitation I-Effect
and I-Effect
irritability I-Effect
upon O
switching I-Treatment
to I-Treatment
methylphenidate I-Treatment.Drug
medication O
. O

To O
date O
, O
only O
three I-Subject.Population
cases I-Subject
of O
seizures I-Effect
associated I-Adverse_event.Trigger
with O
amphotericin I-Treatment.Drug
B I-Treatment.Drug
have O
been O
reported O
in O
the O
literature O
, O
but O
healthcare O
providers O
should O
be O
aware O
of O
the O
potential O
for O
this O
rare O
adverse O
effect O
. O

Heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
complicated I-Effect
with I-Effect
massive I-Effect
thrombosis I-Effect
of I-Effect
the I-Effect
inferior I-Effect
vena I-Effect
cava I-Effect
after I-Effect
filter I-Effect
placement I-Effect
. O

Pharmacokinetics O
of O
methadone I-Treatment.Combination.Drug
in O
human I-Treat_Disorder
- I-Treat_Disorder
immunodeficiency I-Treat_Disorder
- I-Treat_Disorder
virus I-Treat_Disorder
- I-Subject
infected I-Subject
patients I-Subject
receiving I-Potential_therapeutic_event.Trigger
nevirapine I-Treatment.Combination.Drug
once I-Treatment.Freq
daily I-Treatment.Freq
. O

Three I-Subject.Population
patients I-Subject
receiving O
gold I-Treatment.Drug
salt I-Treatment.Drug
treatment O
for O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
developed I-Adverse_event.Trigger
severe I-Effect
aplastic I-Effect
anemia I-Effect
. O

A O
case O
of O
anaphylactoid I-Effect
reaction I-Adverse_event.Trigger
due O
solely O
to O
the O
use O
of O
Gelofusine I-Treatment.Drug
in O
a O
patient I-Subject
with I-Subject
non I-Treat_Disorder
- I-Treat_Disorder
haemorrhagic I-Treat_Disorder
hypovolaemia I-Treat_Disorder
is O
presented O
, O
with O
a O
discussion O
on O
the O
management O
and O
the O
use O
of O
allergy O
identification O
jewellery O
. O

Nonoliguric I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
after I-Adverse_event.Trigger
captopril I-Treatment.Drug
therapy O
. O

We O
report O
a I-Subject
patient I-Subject
with I-Subject
type I-Treat_Disorder
2 I-Treat_Disorder
diabetes I-Treat_Disorder
mellitus I-Treat_Disorder
who O
, O
while O
treated I-Adverse_event.Trigger
with O
the I-Treatment
antitumor I-Treatment
necrosis I-Treatment
factor I-Treatment
- I-Treatment
alpha I-Treatment
blocking I-Treatment
agent I-Treatment
etanercept I-Treatment.Combination.Drug
for O
severe I-Treat_Disorder
plaque I-Treat_Disorder
psoriasis I-Treat_Disorder
, O
experienced O
persistent I-Effect
hypoglycemia I-Effect
requiring O
the O
lowering O
and O
eventual O
elimination O
of O
his O
previous I-Treatment
insulin I-Treatment.Combination.Drug
regimen I-Treatment
. O

We O
report O
the O
first O
case O
of O
doxycycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypoglycemia I-Effect
in O
a I-Subject
young I-Subject.Age
nondiabetic I-Subject.Sub_Disorder
man I-Subject.Gender
. O

The O
time O
course O
of O
events O
suggested O
that O
amphotericin I-Treatment.Drug
B I-Treatment.Drug
was O
the O
cause I-Adverse_event.Trigger
of O
the O
seizures I-Effect
in O
this O
AIDS I-Subject.Sub_Disorder
patient I-Subject
. O

Focal I-Effect
glomerulonephritis I-Effect
and I-Effect
interstitial I-Effect
nephritis I-Effect
in O
methicillin I-Treatment.Drug
- O
treated I-Adverse_event.Trigger
, O
heroin I-Treat_Disorder
- I-Treat_Disorder
related I-Treat_Disorder
infective I-Treat_Disorder
endocarditis I-Treat_Disorder
. O

Focal O
glomerulonephritis O
and O
interstitial O
nephritis O
in O
methicillin O
- O
treated O
, O
heroin I-Treatment.Drug
- O
related I-Adverse_event.Trigger
infective I-Effect
endocarditis I-Effect
. O

Allergic I-Effect
contact I-Effect
dermatitis I-Effect
from I-Adverse_event.Trigger
4 I-Treatment.Drug
- I-Treatment.Drug
chloro I-Treatment.Drug
- I-Treatment.Drug
7 I-Treatment.Drug
- I-Treatment.Drug
nitrobenzofurazan I-Treatment.Drug
. O

We O
describe O
a I-Subject
5 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
showed O
recovery I-Effect
of I-Effect
vincristine I-Effect
induced I-Effect
cranial I-Effect
polyneuropathy I-Effect
with I-Potential_therapeutic_event.Trigger
pyridoxine I-Treatment.Combination.Drug
and I-Treatment
pyridostigmine I-Treatment.Combination.Drug
treatment I-Treatment
. O

Lipoid I-Effect
pneumonia I-Effect
: O
a O
silent O
complication O
of I-Adverse_event.Trigger
mineral I-Treatment.Drug
oil I-Treatment.Drug
aspiration I-Treatment
. O

Elevated I-Treat_Disorder
serum I-Treat_Disorder
triglycerides I-Treat_Disorder
with I-Treat_Disorder
clozapine I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
with O
risperidone I-Treatment.Drug
in O
four I-Subject.Population
patients I-Subject
. O

Elevated I-Effect
serum I-Effect
triglycerides I-Effect
with I-Adverse_event.Trigger
clozapine I-Treatment.Drug
resolved O
with O
risperidone O
in O
four O
patients O
. O

Seizures I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
fluoxetine I-Treatment.Drug
therapy I-Treatment
. O

Sustained I-Effect
monomorphic I-Effect
ventricular I-Effect
tachycardia I-Effect
after I-Adverse_event.Trigger
adenosine I-Treatment.Drug
infusion I-Treatment.Route
. I-Treatment

A I-Subject
9 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
developed I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
following O
intravenous I-Treatment.Drug
acyclovir I-Treatment.Drug
( O
30 I-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
per I-Freq
day I-Freq
) O
administered O
for O
6 I-Duration
days I-Duration
to O
treat O
herpetic I-Treat_Disorder
encephalitis I-Treat_Disorder
. O

We O
report O
a I-Subject
4 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
who O
presented O
with O
acute I-Effect
bilateral I-Effect
blindness I-Effect
, I-Effect
a I-Effect
focal I-Effect
seizure I-Effect
and I-Effect
hypertension I-Effect
10 I-Time_elapsed
days I-Time_elapsed
after I-Adverse_event.Trigger
commencing O
oxybutynin I-Treatment.Drug
to O
treat O
enuresis I-Treat_Disorder
. O

Severe I-Effect
arrhythmia I-Effect
as O
a O
result I-Adverse_event.Trigger
of O
the O
interaction I-Treatment
of I-Treatment
cetirizine I-Treatment.Combination.Drug
and I-Treatment
pilsicainide I-Treatment.Combination.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
renal I-Subject.Sub_Disorder
insufficiency I-Subject.Sub_Disorder
: O
first O
case O
presentation O
showing O
competition O
for O
excretion O
via O
renal O
multidrug O
resistance O
protein O
1 O
and O
organic O
cation O
transporter O
2 O
. O

Reported O
are O
three I-Subject.Population
children I-Subject.Age
who O
developed I-Adverse_event.Trigger
progressive O
paraparesis I-Effect
after O
intrathecal I-Treatment.Route
methotrexate I-Treatment.Drug
administration O
followed O
by O
complete O
or O
partial O
recovery O
. O

We O
observed O
ventricular I-Effect
fibrillation I-Effect
in O
2 I-Subject.Population
patients I-Subject
who I-Subject
presented I-Subject
to I-Subject
the I-Subject
emergency I-Subject
department I-Subject
with I-Subject
pre I-Treat_Disorder
- I-Treat_Disorder
excited I-Treat_Disorder
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
and O
were O
given I-Adverse_event.Trigger
12 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
adenosine I-Treatment.Drug
. O

During O
administration O
of O
chemotherapy I-Treatment.Route
, O
the O
patient I-Subject
progressively O
developed I-Adverse_event.Trigger
a I-Effect
complex I-Effect
association I-Effect
of I-Effect
Beau I-Effect
's I-Effect
lines I-Effect
, I-Effect
transverse I-Effect
melanonychia I-Effect
, I-Effect
Muehrcke I-Effect
's I-Effect
lines I-Effect
, I-Effect
and I-Effect
diffuse I-Effect
hyperpigmentation I-Effect
of I-Effect
the I-Effect
skin I-Effect
. O

Distinct I-Effect
patterns I-Effect
of I-Effect
chromonychia I-Effect
, I-Effect
Beau I-Effect
's I-Effect
lines I-Effect
, I-Effect
and I-Effect
melanoderma I-Effect
seen I-Adverse_event.Trigger
with O
vincristine I-Treatment.Drug
, I-Treatment
adriamycin I-Treatment.Drug
, I-Treatment
dexamethasone I-Treatment.Drug
therapy O
for O
multiple I-Treat_Disorder
myeloma I-Treat_Disorder
. O

Theophylline I-Treatment.Drug
intoxication I-Effect
mimicking O
diabetic O
ketoacidosis O
in I-Adverse_event.Trigger
a I-Subject
child I-Subject.Age
. O

We O
describe O
a I-Subject
patient I-Subject
who O
, O
after O
receiving O
his O
first O
dose O
of O
pregabalin I-Treatment.Drug
to O
relieve O
neuropathic I-Treat_Disorder
pain I-Treat_Disorder
, O
presented I-Adverse_event.Trigger
with O
a O
negative I-Effect
myoclonus I-Effect
. O

CONCLUSIONS O
: O
The O
use O
of O
fluorouracil I-Treatment.Drug
treatment I-Treatment
with I-Treatment
careful I-Treatment
monitoring I-Treatment
can I-Potential_therapeutic_event.Trigger
be I-Potential_therapeutic_event.Trigger
considered I-Potential_therapeutic_event.Trigger
in O
a I-Subject
patient I-Subject
with I-Subject
mild I-Subject
allergic I-Subject.Sub_Disorder
reactions I-Subject.Sub_Disorder
to I-Subject.Sub_Disorder
capecitabine I-Subject.Sub_Disorder
. O

Symptomatic I-Effect
hypocalcaemia I-Effect
and I-Effect
renal I-Effect
impairment I-Effect
associated I-Adverse_event.Trigger
with O
bisphosphonate I-Treatment.Drug
treatment I-Treatment
in O
patients I-Subject
with I-Subject
multiple I-Treat_Disorder
myeloma I-Treat_Disorder
. O

Although O
this O
G I-Treatment.Drug
- I-Treatment.Drug
CSF I-Treatment.Drug
- O
driven I-Adverse_event.Trigger
leucocytosis I-Effect
was O
alarming O
it O
did O
not O
appear O
to O
have O
adversely O
affected O
the O
patient O
's O
prognosis O
. O

A I-Subject
case I-Subject
of O
pyridoxine I-Treatment.Drug
- O
dependent I-Adverse_event.Trigger
seizures I-Effect
is O
reported O
. O

A I-Subject
case I-Subject
of I-Subject
a I-Subject
53 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who O
developed O
acute I-Effect
pneumonitis I-Effect
after I-Adverse_event.Trigger
bleomycin I-Treatment.Combination.Drug
and I-Treatment
moderate I-Treatment.Dosage
oxygen I-Treatment.Combination.Drug
administration O
is O
presented O
. O

Renal I-Effect
tubular I-Effect
acidosis I-Effect
secondary I-Adverse_event.Trigger
to O
FK506 I-Treatment.Drug
in O
living O
donor O
liver O
transplantation O
: O
a I-Subject
case I-Subject
report O
. O

Retinopathy I-Effect
in O
hepatitis I-Treat_Disorder
C I-Treat_Disorder
patients I-Subject
due I-Adverse_event.Trigger
to O
combination O
therapy O
with O
pegylated I-Treatment.Combination.Drug
interferon I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
. O

After O
excluding O
other O
causes O
of O
long O
QT O
syndrome O
, O
the O
HCQ I-Treatment.Drug
was O
suspected I-Adverse_event.Trigger
as O
the O
cause O
of O
her I-Subject.Gender
ventricular I-Effect
tachycardia I-Effect
. O

Phantom I-Effect
limb I-Effect
pain I-Effect
as O
a O
manifestation I-Adverse_event.Trigger
of O
paclitaxel I-Treatment.Drug
neurotoxicity O
. O

A O
case O
of I-Adverse_event.Trigger
allopurinol I-Treatment.Drug
hypersensitivity I-Effect
, O
possibly O
the O
first O
in O
a I-Subject
black I-Subject.Race
African I-Subject.Race
, O
is O
reported O
. O

Ramipril O
was O
stopped O
and O
he I-Subject.Gender
required O
a I-Treatment.Dosage
course I-Treatment.Dosage
of I-Treatment
steroids I-Treatment.Drug
after O
which O
the I-Effect
rash I-Treat_Disorder
improved I-Effect
slowly I-Effect
. O

Late O
development O
of O
diabetes I-Effect
mellitus I-Effect
after I-Adverse_event.Trigger
interferon I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
and O
ribavirin I-Treatment.Combination.Drug
therapy O
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
: O
a O
case O
report O
. O

Second I-Effect
cancers I-Effect
including I-Effect
various I-Effect
types I-Effect
of I-Effect
hematological I-Effect
malignancy I-Effect
have O
been O
reported I-Adverse_event.Trigger
in O
patients I-Subject
with I-Subject
hairy I-Treat_Disorder
cell I-Treat_Disorder
leukemia I-Treat_Disorder
treated O
with O
chemotherapy I-Treatment.Route
or I-Treatment
interferon I-Treatment.Drug
alfa I-Treatment.Drug
. O

A I-Subject
patient I-Subject
with I-Subject
a I-Subject.Sub_Disorder
large I-Subject.Sub_Disorder
hydatid I-Subject.Sub_Disorder
cyst I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
the I-Subject.Sub_Disorder
left I-Subject.Sub_Disorder
lobe I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
the I-Subject.Sub_Disorder
liver I-Subject.Sub_Disorder
developed I-Adverse_event.Trigger
metabolic I-Effect
acidosis I-Effect
following O
rather I-Treatment.Dosage
liberal I-Treatment.Dosage
use I-Treatment.Dosage
of I-Treatment
cetrimide I-Treatment.Drug
- I-Treatment.Drug
chlorhexidine I-Treatment.Drug
solution I-Treatment
as I-Treatment
a I-Treatment.Route
scolicidal I-Treatment.Route
agent I-Treatment.Route
. O

INTERVENTIONS O
AND O
RESULTS O
: O
Cardiac I-Effect
complications I-Effect
were O
observed O
in O
five I-Subject.Population
pediatric I-Subject.Age
patients I-Subject
who O
received I-Adverse_event.Trigger
between I-Treatment
4.6 I-Treatment.Dosage
and I-Treatment.Dosage
40.8 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
kg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
of I-Treatment
amphotericin I-Treatment.Drug
B. I-Treatment.Drug

In O
this O
case O
report O
, O
we O
have O
described O
a I-Subject
patient I-Subject
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
subfulminant I-Effect
hepatitis I-Effect
B I-Effect
after O
the O
fourth I-Treatment.Time_elapsed
infusion I-Treatment.Route
of I-Treatment
infliximab I-Treatment.Drug
due O
to O
an O
unrecognized O
HBs O
- O
antigen O
carrier O
state O
. O

We O
analyzed O
the O
incidence I-Adverse_event.Trigger
of O
DVT I-Effect
in O
232 I-Subject.Population
MM I-Treat_Disorder
patients I-Subject
who O
received O
a O
combination O
of O
chemotherapy I-Treatment.Combination.Drug
and O
thalidomide I-Treatment.Combination.Drug
on O
2 O
protocols O
that O
differed O
only O
by O
the O
inclusion O
of O
doxorubicin O
in O
one O
. O

Valvular I-Effect
heart I-Effect
disease I-Effect
in O
a I-Subject
patient I-Subject
taking I-Adverse_event.Trigger
benfluorex I-Treatment
. O

The I-Subject
fifth I-Subject
patient I-Subject
exhibited O
paraesthesia I-Effect
and I-Effect
agitation I-Effect
caused I-Adverse_event.Trigger
by O
olanzapine I-Treatment.Drug
that O
was O
misdiagnosed O
as O
psychotic O
agitation O
. O

Hydrocortisone O
may O
decrease O
the O
incidence I-Effect
of I-Effect
mortality I-Effect
associated O
with O
cardiac I-Treat_Disorder
arrhythmias I-Treat_Disorder
in I-Subject
children I-Subject.Age
receiving I-Adverse_event.Trigger
amphotericin I-Treatment.Drug
B I-Treatment.Drug
overdoses I-Treatment.Dosage
. O

Hydrocortisone I-Treatment.Drug
may O
decrease I-Potential_therapeutic_event.Trigger
the O
incidence I-Treat_Disorder
of I-Treat_Disorder
mortality I-Treat_Disorder
associated O
with O
cardiac I-Subject
arrhythmias I-Subject
in I-Subject
children I-Subject.Age
receiving O
amphotericin O
B O
overdoses O
. O

A O
review O
of O
the O
literature O
found O
11 I-Subject.Population
children I-Subject.Age
and I-Subject
2 I-Subject.Population
adults I-Subject.Age
in O
whom O
intranasal I-Treatment.Route
desmopressin I-Treatment.Drug
was O
associated I-Adverse_event.Trigger
with O
hyponatremia I-Effect
, O
all O
of O
whom O
experienced O
seizures I-Effect
or I-Effect
altered I-Effect
mental I-Effect
status I-Effect
. O

Hepatotoxicity I-Effect
associated I-Adverse_event.Trigger
with O
use O
of O
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
in O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Accelerated I-Effect
nodulosis I-Effect
during I-Adverse_event.Trigger
methotrexate I-Treatment.Drug
therapy O
for O
juvenile I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Amiodarone I-Treatment
is O
a O
Class O
III O
antiarrhythmic O
with O
an I-Effect
adverse I-Effect
- I-Effect
effect I-Effect
profile I-Effect
involving I-Effect
many I-Effect
different I-Effect
organ I-Effect
systems I-Effect
. O

Nail I-Effect
and I-Effect
skin I-Effect
alterations I-Effect
associated I-Adverse_event.Trigger
with O
the O
use O
of O
chemotherapy I-Treatment.Route
have O
been O
described O
in O
the O
last O
decade O
involving O
various O
combinations O
of O
two O
different O
types O
of O
nail O
changes O
. O

This O
report O
describes O
a O
case O
of O
flucytosine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
ulcerating I-Effect
enteritis I-Effect
in I-Effect
which I-Effect
the I-Effect
small I-Effect
bowel I-Effect
x I-Effect
- I-Effect
ray I-Effect
demonstrated I-Effect
severe I-Effect
luminal I-Effect
narrowing I-Effect
, I-Effect
ulceration I-Effect
, I-Effect
and I-Effect
marked I-Effect
separation I-Effect
of I-Effect
loops I-Effect
of I-Effect
bowel I-Effect
. O

Chromosome I-Effect
abnormalities I-Effect
after I-Adverse_event.Trigger
chlorambucil I-Treatment.Drug
therapy I-Treatment
of O
polycythaemia I-Treat_Disorder
vera I-Treat_Disorder
. O

With O
the O
use O
of O
optical O
coherence O
tomography O
( O
OCT O
) O
, O
two O
patients O
with O
IFN I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
retinopathy I-Effect
who O
had O
developed O
macular I-Effect
edema I-Effect
and I-Effect
reduced I-Effect
visual I-Effect
acuity I-Effect
during O
the O
clinical O
course O
of O
IFN O
therapy O
were O
observed O
. O

Atrial I-Effect
fibrillation I-Effect
after I-Adverse_event.Trigger
vardenafil I-Treatment.Drug
therapy I-Treatment
. O

In O
phase O
III O
clinical O
trials O
, O
the O
telithromycin I-Treatment.Drug
800 I-Treatment.Dosage
mg I-Treatment.Dosage
once I-Treatment.Freq
- I-Treatment.Freq
daily I-Treatment.Freq
dose I-Treatment
has O
been O
shown O
to O
provide I-Potential_therapeutic_event.Trigger
close O
to O
the O
maximum O
antimicrobial O
activity O
against O
S. I-Treat_Disorder
pneumoniae I-Treat_Disorder
, O
Haemophilus I-Treat_Disorder
influenzae I-Treat_Disorder
and O
Staphylococcus I-Treat_Disorder
aureus I-Treat_Disorder
in O
patients I-Subject
with I-Subject
community I-Subject
- I-Subject
acquired I-Subject
pneumonia I-Treat_Disorder
. O

We O
suggest O
that O
meloxicam I-Treatment.Drug
might O
have I-Adverse_event.Trigger
intestinal I-Effect
toxic I-Effect
effects I-Effect
when O
taken O
in O
high I-Dosage
doses I-Dosage
, O
because O
of O
reduced O
COX O
- O
2 O
selectivity O
. O

Atrial I-Effect
fibrillation I-Effect
following I-Adverse_event.Trigger
methylprednisolone I-Treatment.Drug
pulse I-Treatment
therapy I-Treatment
. O

Subglottic I-Effect
stenosis I-Effect
in I-Effect
Wegener I-Treat_Disorder
's I-Treat_Disorder
granulomatosis I-Treat_Disorder
: O
development O
during I-Adverse_event.Trigger
cyclophosphamide I-Treatment.Drug
treatment I-Treatment
with I-Treatment
response I-Treatment
to I-Treatment
carbon I-Treatment
dioxide I-Treatment
laser I-Treatment
therapy I-Treatment
. O

Pregabalin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cortical I-Effect
negative I-Effect
myoclonus I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
neuropathic I-Treat_Disorder
pain I-Treat_Disorder
. O

We O
conclude O
that O
quinine I-Treatment.Drug
does O
not O
improve O
the O
survival O
of O
adult O
patients O
with O
de I-Treat_Disorder
novo I-Treat_Disorder
AML I-Treat_Disorder
, O
even O
though O
it O
improves I-Effect
CR I-Effect
rate I-Effect
in O
a I-Subject.Population
small I-Subject.Population
subgroup I-Subject.Population
of I-Subject
patients I-Subject
defined I-Subject
by I-Subject
rhodamine I-Subject.Sub_Disorder
123 I-Subject.Sub_Disorder
efflux I-Subject.Sub_Disorder
. O

We O
conclude O
that O
quinine I-Treatment.Drug
does O
not O
improve I-Potential_therapeutic_event.Trigger
the O
survival O
of O
adult I-Subject.Age
patients I-Subject
with O
de I-Treat_Disorder
novo I-Treat_Disorder
AML I-Treat_Disorder
, O
even O
though O
it O
improves O
CR O
rate O
in O
a O
small O
subgroup O
of O
patients O
defined O
by O
rhodamine O
123 O
efflux O
. O

The O
mechanism O
of O
RTA I-Effect
induced I-Adverse_event.Trigger
by O
FK506 I-Treatment.Drug
has O
not O
yet O
been O
clearly O
elucidated O
. O

The O
risk I-Adverse_event.Trigger
of O
new I-Effect
- I-Effect
onset I-Effect
diabetic I-Effect
ketoacidosis I-Effect
in O
patients I-Subject
with I-Subject
diabetic I-Subject.Sub_Disorder
risk I-Subject.Sub_Disorder
factors I-Subject.Sub_Disorder
who O
are O
taking O
perospirone I-Treatment.Drug
hydrochloride I-Treatment.Drug
or I-Treatment
other I-Treatment
atypical I-Treatment
antipsychotics I-Treatment
should O
be O
kept O
in O
mind O
. O

Severe I-Effect
symptomatic I-Effect
hyponatremia I-Effect
during I-Adverse_event.Trigger
sibutramine I-Treatment.Drug
therapy O
: O
a O
case O
report O
. O

Zoledronic I-Treatment.Drug
acid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
severe I-Effect
hypocalcaemia I-Effect
in O
a O
prostate I-Treat_Disorder
cancer I-Treat_Disorder
patient I-Subject
with I-Subject
extensive I-Treat_Disorder
osteoblastic I-Treat_Disorder
bone I-Treat_Disorder
metastases I-Treat_Disorder
. O

MM I-Treat_Disorder
patients I-Subject
treated O
with O
thalidomide I-Treatment.Combination.Drug
and I-Treatment
doxorubicin I-Treatment.Combination.Drug
have I-Adverse_event.Trigger
a I-Effect
high I-Effect
risk I-Effect
of I-Effect
developing I-Effect
DVT I-Effect
. O

These O
two O
cases O
highlight O
the O
importance O
of O
considering O
lopinavir I-Treatment.Combination.Drug
/ I-Treatment
ritonavir I-Treatment.Combination.Drug
induced I-Adverse_event.Trigger
arrhythmias I-Effect
when O
dealing O
with O
HIV I-Treat_Disorder
- I-Subject
positive I-Subject
individuals I-Subject
. O

Atrial I-Effect
fibrillation I-Effect
occurring O
in O
a I-Subject
patient I-Subject
taking I-Adverse_event.Trigger
etanercept I-Treatment.Combination.Drug
plus I-Treatment
methotrexate I-Treatment.Combination.Drug
for I-Treatment
rheumatoid I-Treatment.Treat_Disorder
arthritis I-Treatment.Treat_Disorder
. O

We O
describe O
a I-Subject
52 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
diagnosed O
with O
stage I-Treat_Disorder
III I-Treat_Disorder
multiple I-Treat_Disorder
myeloma I-Treat_Disorder
, O
who O
was O
treated I-Potential_therapeutic_event.Trigger
with O
5 I-Treatment.Duration
- I-Treatment.Duration
monthly I-Treatment.Duration
cycles I-Treatment
of I-Treatment
VAD I-Treatment
( I-Treatment
vincristine I-Treatment.Combination.Drug
, I-Treatment
adriamycin I-Treatment.Combination.Drug
and I-Treatment
dexamathasone I-Treatment.Combination.Drug
) I-Treatment
. O

We O
review O
the O
literature O
on O
previously O
reported O
cases O
of O
cutaneous I-Effect
necrosis I-Effect
after I-Adverse_event.Trigger
injection I-Route
of O
standard I-Treatment.Drug
interferon I-Treatment.Drug
alfa I-Treatment.Drug
or O
pegylated I-Treatment.Drug
interferon I-Treatment.Drug
alfa I-Treatment.Drug
- I-Treatment.Drug
2b I-Treatment.Drug
and O
discuss O
the O
different O
pathophysiologic O
mechanisms O
that O
might O
be O
involved O
. O

Our O
cohort O
included O
1739 I-Subject.Population
patients I-Subject
with O
acute O
ischemic O
stroke O
treated I-Potential_therapeutic_event.Trigger
with O
intravenous I-Treatment.Route
tissue I-Treatment.Drug
plasminogen I-Treatment.Drug
activator I-Treatment.Drug
of O
whom O
125 O
( O
7.2 O
% O
) O
were O
receiving O
warfarin O
before O
admission O
and O
had O
an O
international O
normalized O
ratio O
< O
1.7 O
. O

Our O
cohort O
included O
1739 O
patients O
with O
acute I-Treat_Disorder
ischemic I-Treat_Disorder
stroke I-Treat_Disorder
treated O
with O
intravenous O
tissue O
plasminogen O
activator O
of O
whom O
125 I-Subject
( I-Subject
7.2 I-Subject
% I-Subject
) I-Subject
were O
receiving I-Potential_therapeutic_event.Trigger
warfarin I-Treatment.Drug
before I-Treatment
admission I-Treatment
and O
had O
an O
international O
normalized O
ratio O
< O
1.7 O
. O

Used I-Treatment
injudiciously I-Treatment
, I-Treatment
naloxone I-Treatment.Drug
can O
lead I-Adverse_event.Trigger
to O
withdrawal I-Effect
syndrome I-Effect
, I-Effect
return I-Effect
of I-Effect
severe I-Effect
pain I-Effect
, I-Effect
and I-Effect
other I-Effect
adverse I-Effect
effects I-Effect
. O

When O
vague I-Effect
symptoms I-Effect
develop O
during I-Adverse_event.Trigger
desmopressin I-Treatment.Drug
therapy O
, O
hyponatremia I-Effect
must O
be O
considered O
as O
part O
of O
the O
differential O
diagnosis O
. O

Intravesical I-Treatment.Route
chemotherapy I-Treatment.Drug
may O
be O
associated I-Adverse_event.Trigger
with O
a O
risk O
of O
secondary I-Effect
malignancy I-Effect
. O

In O
all O
the O
cases O
described O
here O
, O
it O
is O
only O
with O
the O
discontinuation O
of O
methylphenidate O
that O
the O
adverse O
reactions O
resolved O
and O
readministration O
of O
methylphenidate I-Treatment.Drug
in O
two I-Subject.Population
patients I-Subject
did O
not O
produce I-Adverse_event.Trigger
any O
adverse I-Effect
effect I-Effect
after I-Effect
a I-Effect
drug I-Effect
- I-Effect
free I-Effect
interval I-Effect
. O

In O
all O
the O
cases O
described O
here O
, O
it O
is O
only O
with O
the O
discontinuation I-Treatment
of I-Treatment
methylphenidate I-Treatment.Drug
that O
the O
adverse I-Effect
reactions I-Effect
resolved I-Adverse_event.Trigger
and O
readministration O
of O
methylphenidate O
in O
two O
patients O
did O
not O
produce O
any O
adverse O
effect O
after O
a O
drug O
- O
free O
interval O
. O

Discontinuation O
of O
methicillin I-Treatment.Drug
therapy O
and O
appropriate O
antibiotic I-Drug
treatment O
of O
endocarditis I-Treat_Disorder
led O
to O
clinical O
improvement O
, O
emphasizing O
the O
need O
to O
promptly O
discontinue O
potential O
nephrotoxic I-Drug
agents I-Drug
when O
abnormalities I-Effect
in I-Effect
renal I-Effect
function I-Effect
appear I-Adverse_event.Trigger
. O

CONCLUSIONS O
: O
This O
study O
confirmed O
that O
in O
most I-Subject
patients I-Subject
MTX I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
liver I-Effect
cirrhosis I-Effect
is I-Effect
not I-Effect
aggressive I-Effect
. O

We O
report O
the O
case O
of O
severe I-Effect
liver I-Effect
toxicity I-Effect
with I-Effect
jaundice I-Effect
during O
radiochemotherapy O
with O
temozolomide I-Treatment.Combination.Drug
likely O
due I-Adverse_event.Trigger
to O
interaction O
with O
a I-Treatment
popular I-Treatment
Chinese I-Treatment.Combination.Drug
herbal I-Treatment.Combination.Drug
formula I-Treatment.Combination.Drug
after O
surgery O
for O
glioblastoma I-Treat_Disorder
. O

He I-Subject.Gender
was O
started O
on O
oral I-Treatment.Route
lansoprazole I-Treatment.Drug
60 I-Treatment.Dosage
mg I-Treatment.Dosage
twice I-Treatment.Freq
daily I-Treatment.Freq
and O
, O
on I-Adverse_event.Trigger
hospital O
day I-Duration
2 I-Duration
, O
his O
platelet I-Effect
count I-Effect
decreased I-Effect
to O
102 O
x O
10(3)/mm(3 O
) O
; O
on O
hospital O
day O
3 O
, O
the O
platelet O
count O
was O
36 O
x O
10(3)/mm(3 O
) O
. O

She I-Subject.Age
received O
an O
accidental O
450 I-Treatment.Dosage
- I-Treatment.Dosage
mg I-Treatment.Dosage
bolus I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
morphine I-Treatment.Drug
intrathecally O
and O
developed I-Adverse_event.Trigger
hypertension I-Effect
, I-Effect
status I-Effect
epilepticus I-Effect
, I-Effect
intracerebral I-Effect
hemorrhage I-Effect
, I-Effect
and I-Effect
respiratory I-Effect
failure I-Effect
. O

We O
describe O
six I-Subject.Population
patients I-Subject
who O
developed I-Adverse_event.Trigger
tardive I-Effect
dyskinesia I-Effect
after O
treatment O
with O
sulpiride I-Treatment.Drug
for O
depression I-Treat_Disorder
or O
gastrointestinal I-Treat_Disorder
symptoms I-Treat_Disorder
. O

A I-Subject
38 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
female I-Subject.Gender
with O
cystic O
fibrosis O
treated O
with O
venlafaxine O
300 O
mg O
/ O
day O
for O
one O
year O
was O
prescribed O
linezolid I-Treatment.Drug
600 I-Treatment.Dosage
mg I-Treatment.Dosage
intravenously I-Treatment.Route
every I-Treatment.Freq
12 I-Treatment.Freq
hours I-Treatment.Freq
for O
treatment I-Potential_therapeutic_event.Trigger
of O
methicillin I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
Staphylococcus I-Treat_Disorder
aureus I-Treat_Disorder
( I-Treat_Disorder
MRSA I-Treat_Disorder
) I-Treat_Disorder
pulmonary I-Treat_Disorder
infection I-Treat_Disorder
. O

A I-Subject
38 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
female I-Subject.Gender
with O
cystic I-Treat_Disorder
fibrosis I-Treat_Disorder
treated I-Potential_therapeutic_event.Trigger
with O
venlafaxine I-Treatment.Drug
300 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
for I-Treatment
one I-Treatment.Duration
year I-Treatment.Duration
was O
prescribed O
linezolid O
600 O
mg O
intravenously O
every O
12 O
hours O
for O
treatment O
of O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
pulmonary O
infection O
. O

Hepatotoxicity I-Effect
of I-Adverse_event.Trigger
hycanthone I-Treatment.Drug
in O
patients I-Subject
with I-Subject
metastatic I-Treat_Disorder
breast I-Treat_Disorder
cancer I-Treat_Disorder
. O

The O
authors O
report O
five O
additional O
cases O
of O
capecitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
multifocal I-Effect
leukoencephalopathy I-Effect
. O

Chlormadinone I-Treatment.Combination.Drug
acetate I-Treatment.Combination.Drug
withdrawal O
syndrome O
under I-Potential_therapeutic_event.Trigger
combined O
androgen I-Treatment.Combination.Drug
blockade I-Treatment.Combination.Drug
for O
advanced I-Treat_Disorder
prostate I-Treat_Disorder
cancer I-Treat_Disorder
. O

Restless I-Effect
legs I-Effect
syndrome I-Effect
and O
periodic I-Effect
limb I-Effect
movements I-Effect
during I-Effect
sleep I-Effect
probably O
associated I-Adverse_event.Trigger
with O
olanzapine I-Treatment.Drug
. O

Evaluation O
of O
the O
literature O
provides O
substantial O
evidence O
for O
the O
use O
of O
hydrocortisone I-Treatment.Drug
in O
prevention I-Potential_therapeutic_event.Trigger
of O
cardiac I-Treat_Disorder
arrhythmias I-Treat_Disorder
. O

We O
report O
a I-Subject
case I-Subject
of I-Subject
RTA I-Effect
secondary I-Adverse_event.Trigger
to O
FK506 I-Treatment.Drug
administration I-Treatment
in I-Treatment
liver I-Treatment
transplantation I-Treatment
. O

Myoclonus I-Effect
associated I-Adverse_event.Trigger
with O
continuous I-Treatment
dobutamine I-Treatment.Drug
infusion I-Treatment.Route
in O
a I-Subject
patient I-Subject
with I-Subject
end I-Treat_Disorder
- I-Treat_Disorder
stage I-Treat_Disorder
renal I-Treat_Disorder
disease I-Treat_Disorder
. O

Amphotericin I-Effect
B I-Effect
nephrotoxicity I-Effect
in I-Effect
humans I-Effect
decreased I-Effect
by O
salt I-Treatment.Drug
repletion I-Treatment
. O

Only O
a O
few O
reports O
of O
overt I-Effect
jaundice I-Effect
are O
associated I-Adverse_event.Trigger
with O
streptokinase I-Treatment.Drug
. O

Possible O
heart I-Effect
failure I-Effect
exacerbation I-Effect
associated I-Adverse_event.Trigger
with O
rosiglitazone I-Treatment.Drug
: O
case O
report O
and O
literature O
review O
. O

We O
report O
the I-Subject
first I-Subject
case I-Subject
of O
polymorphic I-Effect
ventricular I-Effect
tachycardia I-Effect
with I-Effect
normal I-Effect
QT I-Effect
interval I-Effect
associated I-Adverse_event.Trigger
with O
the O
oral I-Treatment.Route
use I-Treatment
of I-Treatment
levofloxacin I-Treatment.Drug
in O
the O
absence O
of O
other O
etiologies O
known O
to O
cause O
these O
arrhythmias I-Effect
. O

Reversible I-Effect
leukopenia I-Effect
was O
documented I-Adverse_event.Trigger
in O
an I-Subject
81 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
treated O
with O
adjunctive I-Treatment
ibopamine I-Treatment.Drug
100 I-Treatment.Dosage
mg I-Treatment.Dosage
t.i.d I-Treatment
. I-Treatment
for O
chronic I-Treat_Disorder
congestive I-Treat_Disorder
heart I-Treat_Disorder
failure I-Treat_Disorder
. O

We O
conjectured O
that O
the O
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of O
insulin I-Treatment.Drug
, O
such O
as O
anti I-Effect
- I-Effect
natriuresis I-Effect
and I-Effect
increased I-Effect
vascular I-Effect
permeability I-Effect
, O
might O
be O
pronounced O
in O
the O
presence O
of O
the O
hepatic O
dysfunction O
that O
accompanies O
insulin O
insensitivity O
, O
hyperinsulinaemia O
and O
hypoalbuminaemia O
. O

Acute I-Effect
myelogenous I-Effect
leukemia I-Effect
in I-Adverse_event.Trigger
patients I-Subject
receiving I-Treatment
chlorambucil I-Treatment.Drug
as I-Treatment
long I-Treatment
- I-Treatment
term I-Treatment
adjuvant I-Treatment
chemotherapy I-Treatment.Route
for O
stage I-Treat_Disorder
II I-Treat_Disorder
breast I-Treat_Disorder
cancer I-Treat_Disorder
. I-Treat_Disorder

We O
report O
a O
case O
of O
generalized I-Effect
cutaneous I-Effect
sclerosis I-Effect
associated I-Effect
with I-Effect
muscle I-Effect
and I-Effect
oesophageal I-Effect
involvement I-Effect
in O
a O
patient O
exposed I-Adverse_event.Trigger
to I-Adverse_event.Trigger
herbicides I-Treatment
containing I-Treatment
bromocil I-Treatment.Combination.Drug
, I-Treatment
diuron I-Treatment.Combination.Drug
and I-Treatment
aminotriazole I-Treatment.Combination.Drug
. O

Only O
3 O
cases O
of O
imatinib I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
tumor I-Effect
lysis I-Effect
syndrome I-Effect
have O
been O
reported O
. O

A I-Subject
61 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
who I-Subject
had I-Subject
been I-Subject
treated I-Subject
with I-Subject
lisinopril I-Subject
in I-Subject
the I-Subject
past I-Subject
without I-Subject
any I-Subject
problems I-Subject
was O
commenced I-Potential_therapeutic_event.Trigger
on O
ramipril I-Treatment.Drug
for O
left I-Treat_Disorder
ventricular I-Treat_Disorder
dysfunction I-Treat_Disorder
. O

However O
, O
repeated I-Treatment
intracameral I-Treatment.Route
tPA I-Treatment.Drug
injections I-Treatment.Route
may O
cause I-Adverse_event.Trigger
unwanted I-Effect
complications I-Effect
such I-Effect
as I-Effect
vitreous I-Effect
hemorrhage I-Effect
. O

In O
this O
article O
, O
we O
present O
the O
case O
of O
a I-Subject
vitiligo I-Subject.Sub_Disorder
patient I-Subject
who O
was O
admitted O
to O
our O
facility O
with O
an O
intense I-Effect
burn I-Effect
after I-Adverse_event.Trigger
the O
topical I-Treatment.Route
use I-Treatment
of I-Treatment
8 I-Treatment.Drug
- I-Treatment.Drug
methoxypsoralen I-Treatment.Drug
solution I-Treatment
as I-Treatment
a I-Treatment
suntanning I-Treatment
agent I-Treatment
. O

The O
frequency O
and O
relationship O
of O
granulocytopenia I-Effect
caused I-Adverse_event.Trigger
by O
sustained O
- O
release O
procainamide I-Treatment.Drug
in O
patients I-Subject
with I-Subject
tachyarrhythmias I-Treat_Disorder
are O
briefly O
discussed O
, O
and O
prior O
reported O
cases O
are O
reviewed O
. O

Cicatricial I-Effect
entropion I-Effect
associated I-Adverse_event.Trigger
with O
chronic I-Treatment
dipivefrin I-Treatment.Drug
application I-Treatment
. O

Nine I-Subject.Population
delirious I-Subject.Sub_Disorder
patients I-Subject
suffering I-Adverse_event.Trigger
from I-Adverse_event.Trigger
lithium I-Treatment.Drug
intoxication I-Effect
were O
examined O
with O
the O
Mini O
- O
Mental O
State O
Exam O
( O
MMS O
) O
to O
describe O
the O
clinical O
course O
of O
the O
disorder O
. O

Cryptococcus I-Effect
neoformans I-Effect
fatal I-Effect
sepsis I-Effect
in I-Adverse_event.Trigger
a I-Subject
chronic I-Treat_Disorder
lymphocytic I-Treat_Disorder
leukemia I-Treat_Disorder
patient I-Subject
treated O
with O
alemtuzumab I-Treatment.Drug
: O
case O
report O
and O
review O
of O
the O
literature O
. O

Cholestyramine I-Treatment.Drug
induced I-Adverse_event.Trigger
hyperchloremic I-Effect
metabolic I-Effect
acidosis I-Effect
. I-Effect

Methadone O
is O
recommended O
as O
being O
free O
of O
some O
of O
the O
neuropsychological I-Effect
side I-Effect
effects I-Effect
noticed I-Adverse_event.Trigger
with O
morphine I-Treatment.Drug
, O
which O
are O
attributed O
to O
active O
metabolites O
. O

This O
is O
the O
first O
reported O
case O
of O
BOOP I-Effect
associated I-Adverse_event.Trigger
with O
single I-Treatment
- I-Treatment
agent I-Treatment
rituximab I-Treatment.Drug
, O
and O
along O
with O
two O
other O
patients O
we O
describe O
, O
as O
well O
as O
two O
prior O
reports O
of O
BOOP O
in O
NHL O
patients O
receiving O
rituximab O
- O
based O
combinations O
, O
strengthens O
the O
possibility O
of O
a O
causal O
relationship O
. O

The O
treatment O
for O
acidosis I-Effect
and I-Effect
hyperkalaemia I-Effect
should O
be O
started O
as O
soon O
as O
RTA I-Effect
is O
diagnosed O
, O
and O
the O
dosage O
of I-Adverse_event.Trigger
FK506 I-Treatment.Drug
should O
also O
be O
reduced O
if O
possible O
. O

A I-Subject
62 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
treated I-Treatment
with I-Treatment
pranlukast I-Treatment.Drug
for I-Treatment
2 I-Treatment.Duration
months I-Treatment.Duration
developed I-Adverse_event.Trigger
interstitial I-Effect
pneumonitis I-Effect
with I-Effect
a I-Effect
high I-Effect
fever I-Effect
. O

Neurotoxicity I-Effect
of O
valacyclovir I-Treatment.Drug
in I-Treatment
peritoneal I-Treatment
dialysis I-Treatment
: O
a O
pharmacokinetic O
study O
. O

He I-Subject.Gender
had O
been O
taking I-Adverse_event.Trigger
trimethoprim I-Treatment.Combination.Drug
- I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
for I-Treatment
approximately I-Treatment
eight I-Treatment.Duration
days I-Treatment.Duration
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches I-Effect
, I-Effect
dizziness I-Effect
, I-Effect
difficulty I-Effect
with I-Effect
speech I-Effect
, I-Effect
weakness I-Effect
, I-Effect
and I-Effect
itching I-Effect
on I-Effect
the I-Effect
trunk I-Effect
of I-Effect
his I-Effect
body I-Effect
and I-Effect
legs I-Effect
, O
where O
a O
maculopapular I-Effect
rash I-Effect
was O
noted O
. O

We O
present I-Adverse_event.Trigger
an I-Subject
AIDS I-Treat_Disorder
patient I-Subject
with O
severe I-Effect
and I-Effect
prolonged I-Effect
lactic I-Effect
acidosis I-Effect
on O
stavudine I-Treatment.Combination.Drug
and I-Treatment
lamivudine I-Treatment.Combination.Drug
. O

Sudden I-Effect
cardiac I-Effect
death I-Effect
due I-Effect
to I-Effect
hypersensitivity I-Effect
myocarditis I-Effect
during I-Adverse_event.Trigger
clozapine I-Treatment.Drug
treatment O
. O

It O
also O
highlights O
a O
current O
major O
etiologic O
question O
, O
that O
is O
, O
whether O
and O
to O
what O
degree O
lead I-Treatment.Drug
exposure I-Treatment.Route
contributes I-Adverse_event.Trigger
to O
the O
development O
of O
hypertension I-Effect
, O
and O
raises O
the O
issue O
of O
whether O
lead O
- O
induced O
hypertension O
constitutes O
a O
subset O
of O
hypertension O
that O
is O
especially O
amenable O
to O
therapy O
with O
dietary O
calcium O
. O

We O
report O
an O
allogeneic I-Subject.Sub_Disorder
bone I-Subject.Sub_Disorder
marrow I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
recipient I-Subject
who O
developed O
CMV I-Treat_Disorder
infection I-Treat_Disorder
refractory I-Potential_therapeutic_event.Trigger
to O
sequential I-Treatment
therapy I-Treatment
with I-Treatment
ganciclovir I-Treatment.Combination.Drug
, I-Treatment
foscarnet I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
cidofovir I-Treatment.Combination.Drug
. O

Acute I-Effect
interstitial I-Effect
pneumonia I-Effect
induced I-Adverse_event.Trigger
by O
ONO I-Treatment.Drug
- I-Treatment.Drug
1078 I-Treatment.Drug
( I-Treatment
pranlukast I-Treatment
) I-Treatment
, O
a O
leukotriene O
receptor O
antagonist O
. O

CONCLUSION O
: O
Significant O
ocular O
complications O
such O
as O
an O
irreversible I-Effect
decrease I-Effect
of I-Effect
visual I-Effect
acuity I-Effect
may O
develop O
in O
patients I-Subject
treated I-Adverse_event.Trigger
with O
pegylated I-Treatment.Drug
interferon I-Treatment.Drug
. O

CONCLUSIONS O
: O
This O
case O
report O
showed O
that O
the O
clinical I-Effect
appearance I-Effect
of I-Effect
Hashimoto I-Effect
's I-Effect
disease I-Effect
after I-Adverse_event.Trigger
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
therapy O
for O
chronic I-Treat_Disorder
C I-Treat_Disorder
hepatitis I-Treat_Disorder
in O
our I-Subject
patient I-Subject
was O
associated O
with O
a I-Sub_Disorder
specific I-Sub_Disorder
genetic I-Sub_Disorder
predisposition I-Sub_Disorder
( I-Sub_Disorder
DR5 I-Sub_Disorder
) I-Sub_Disorder
for I-Sub_Disorder
this I-Sub_Disorder
pathology I-Sub_Disorder
. O

We O
present O
here O
a I-Subject
female I-Subject.Gender
patient I-Subject
who O
developed I-Adverse_event.Trigger
acute I-Effect
bilateral I-Effect
parotitis I-Effect
within I-Time_elapsed
minutes I-Time_elapsed
of O
i.v I-Treatment
. I-Treatment
enalaprilat I-Treatment.Drug
injection I-Treatment.Route
and O
recovered O
within O
24 O
hours O
of O
stopping O
the O
drug O
and O
with O
symptomatic O
treatment O
. O

We O
describe O
2 I-Subject.Population
patients I-Subject
with I-Subject
prior I-Subject.Sub_Disorder
amputation I-Subject.Sub_Disorder
who O
experienced O
phantom I-Effect
limb I-Effect
pain I-Effect
( I-Effect
PLP I-Effect
) I-Effect
after I-Adverse_event.Trigger
receiving O
paclitaxel I-Treatment.Drug
therapy I-Treatment
. O

There O
is O
evidence O
that O
the O
angiotensin I-Treatment
II I-Treatment
receptor I-Treatment
antagonist I-Treatment
, I-Treatment
losartan I-Treatment.Drug
, O
increases I-Effect
urate I-Effect
excretion I-Effect
by O
reducing I-Effect
reabsorption I-Effect
of I-Effect
urate I-Effect
in I-Effect
the I-Effect
renal I-Effect
proximal I-Effect
tubule I-Effect
. I-Effect

Although O
no O
coagulation O
study O
was O
done O
and O
the O
Meckel O
's O
diverticulum O
is O
normally O
associated O
with O
bleeding O
, O
the O
particular O
intensity O
of O
the O
following O
hemorrhage I-Effect
may O
have O
been O
favored I-Adverse_event.Trigger
by O
metformin I-Treatment.Drug
. O

We O
describe O
2 O
patients O
with O
severe O
erosive O
rheumatoid O
arthritis O
and O
rheumatoid O
vasculitis O
, O
respectively O
, O
in O
whom O
infliximab I-Treatment.Drug
therapy I-Treatment
was O
associated I-Adverse_event.Trigger
with O
peripheral I-Effect
neuropathy I-Effect
due O
to O
necrotizing I-Treat_Disorder
vasculitis I-Treat_Disorder
in O
one O
patient O
and O
to O
progression O
of O
preexisting I-Subject.Sub_Disorder
mononeuritis I-Subject.Sub_Disorder
multiplex I-Subject.Sub_Disorder
in I-Subject
the I-Subject
other I-Subject
. O

We O
describe O
2 O
patients O
with O
severe O
erosive O
rheumatoid O
arthritis O
and O
rheumatoid O
vasculitis O
, O
respectively O
, O
in O
whom O
infliximab I-Treatment.Drug
therapy I-Treatment
was O
associated I-Adverse_event.Trigger
with O
peripheral I-Effect
neuropathy I-Effect
due O
to O
necrotizing I-Treat_Disorder
vasculitis I-Treat_Disorder
in O
one I-Subject
patient I-Subject
and O
to O
progression O
of O
preexisting O
mononeuritis O
multiplex O
in O
the O
other O
. O

Upper I-Effect
tract I-Effect
urothelial I-Effect
malignancy I-Effect
after I-Adverse_event.Trigger
cyclophosphamide I-Treatment.Drug
therapy I-Treatment
: O
a O
case O
report O
and O
literature O
review O
. O

BACKGROUND O
: O
Methotrexate I-Treatment.Drug
( I-Treatment
MTX I-Treatment
) I-Treatment
may O
induce I-Adverse_event.Trigger
liver I-Effect
damage I-Effect
, I-Effect
which I-Effect
in I-Effect
some I-Effect
psoriatics I-Treat_Disorder
will I-Effect
lead I-Effect
to I-Effect
fibrosis I-Effect
or I-Effect
cirrhosis I-Effect
. O

The O
infection I-Effect
proceeded I-Effect
even O
after I-Adverse_event.Trigger
treatment O
with O
fluconazole I-Treatment.Drug
. O

We O
report O
the O
case O
of O
intoxication I-Effect
of O
a I-Subject
41 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
suffering O
from O
major I-Treat_Disorder
depression I-Treat_Disorder
with I-Adverse_event.Trigger
mirtazapine I-Treatment.Drug
complicated O
by O
severe O
hypothermia I-Effect
. O

The O
bilateral O
ptosis O
markedly O
improved I-Potential_therapeutic_event.Trigger
after O
7 I-Time_elapsed
days I-Time_elapsed
of O
pyridoxine I-Treatment.Combination.Drug
and I-Treatment
pyridostigmine I-Treatment.Combination.Drug
treatment I-Treatment
and O
completely O
resolved O
after O
two O
weeks O
. O

PURPOSE O
: O
The O
case O
of O
a I-Subject
patient I-Subject
who O
developed I-Adverse_event.Trigger
aseptic I-Effect
meningitis I-Effect
, I-Effect
hemolytic I-Effect
anemia I-Effect
, I-Effect
hepatitis I-Effect
, I-Effect
and I-Effect
orthostatic I-Effect
hypotension I-Effect
simultaneously O
during O
treatment O
with O
trimethoprim I-Treatment.Drug
- I-Treatment.Drug
sulfamethoxazole I-Treatment.Drug
is O
described O
. O

Seizures I-Effect
and I-Effect
extrapyramidal I-Effect
symptoms I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
Tourette I-Treat_Disorder
's I-Treat_Disorder
syndrome I-Treat_Disorder
, I-Subject
Asperger I-Treat_Disorder
's I-Treat_Disorder
syndrome I-Treat_Disorder
, I-Subject
and I-Subject
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
treated I-Adverse_event.Trigger
with O
interferon I-Treatment.Combination.Drug
beta I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
1a I-Treatment.Combination.Drug
and I-Treatment
clomipramine I-Treatment.Combination.Drug
. O

Psychotic I-Effect
disorder I-Effect
associated I-Adverse_event.Trigger
with O
isoniazid I-Treatment.Drug
. O

The I-Treatment
azathioprine I-Treatment.Drug
dose I-Treatment
was I-Treatment
low I-Treatment
( I-Treatment
1 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
kg I-Treatment.Dosage
) I-Treatment
and O
pancytopenia I-Effect
occurred I-Adverse_event.Trigger
after O
56 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
therapy I-Treatment
. O

Findings O
on O
discontinuation O
and O
rechallenge O
supported O
the O
assumption O
that O
the O
hair I-Effect
loss I-Effect
was O
a O
side I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
the O
paroxetine I-Treatment.Drug
. I-Treatment

The O
successful O
development O
and O
implementation O
of O
this O
protocol O
will O
have O
impact O
on O
patients I-Subject
who O
have I-Adverse_event.Trigger
anaphylactic I-Effect
reactions I-Effect
to O
MTX I-Treatment.Drug
but O
require O
this O
medication O
for O
specific O
diseases O
. O

Clomiphene I-Treatment.Drug
is O
a O
first O
line O
treatment I-Potential_therapeutic_event.Trigger
for O
anovulation I-Treat_Disorder
, O
a O
common O
cause O
of O
infertility O
. O

A I-Subject
new I-Subject
case I-Subject
of O
Creutzfeldt I-Effect
- I-Effect
Jakob I-Effect
disease I-Effect
associated I-Adverse_event.Trigger
with O
human I-Treatment.Drug
growth I-Treatment.Drug
hormone I-Treatment.Drug
therapy O
in O
New O
Zealand O
. O

This O
case O
study O
is O
the O
second O
report O
of O
localized I-Effect
purpura I-Effect
after O
prolonged I-Duration
lamotrigine O
treatment O
suggesting O
this O
may O
be O
an O
atypical O
lamotrigine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
drug I-Effect
reaction I-Effect
. O

Extrapyramidal I-Effect
symptoms I-Effect
are O
well O
- O
documented O
complications I-Adverse_event.Trigger
of O
therapy O
with O
haloperidol I-Treatment.Drug
, O
even O
when O
small I-Treatment.Dosage
doses I-Treatment.Dosage
are O
used O
. O

Although O
cetirizine I-Treatment.Drug
has O
less O
potential O
for O
causing I-Adverse_event.Trigger
arrhythmias I-Effect
than O
other O
histamine O
1 O
blockers O
, O
such O
an O
interaction O
should O
be O
considered O
, O
especially O
in O
patients I-Subject
with I-Subject
renal I-Subject.Sub_Disorder
insufficiency I-Subject.Sub_Disorder
who O
are O
receiving O
pilsicainide O
. O

Bronchiolitis I-Effect
obliterans I-Effect
with I-Effect
organizing I-Effect
pneumonia I-Effect
after I-Adverse_event.Trigger
rituximab I-Treatment.Drug
therapy I-Treatment
for O
non I-Treat_Disorder
- I-Treat_Disorder
Hodgkin I-Treat_Disorder
's I-Treat_Disorder
lymphoma I-Treat_Disorder
. O

The O
case O
demonstrates O
that O
hypersensitivity I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
pranlukast I-Treatment.Drug
and O
resultant O
ATIN O
is O
possible O
, O
and O
that O
periodic O
urine O
testing O
in O
patients O
receiving O
pranlukast I-Drug
should O
be O
considered O
. O

Successful O
desensitization O
to O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
after I-Adverse_event.Trigger
systemic I-Effect
anaphylaxis I-Effect
. I-Effect

Successful I-Effect
desensitization I-Effect
to I-Potential_therapeutic_event.Trigger
high I-Treatment
- I-Treatment
dose I-Treatment
methotrexate I-Treatment
after O
systemic I-Treat_Disorder
anaphylaxis I-Treat_Disorder
. O

The O
patient O
's O
clinical O
presentation O
, O
histologic O
features O
on O
liver O
biopsy O
and O
favorable O
course O
after O
stopping O
the O
drug O
suggest O
that O
barbiturates I-Treatment.Drug
can O
be O
added O
to O
the O
list O
of O
agents O
which O
can O
cause I-Adverse_event.Trigger
submassive I-Effect
hepatic I-Effect
necrosis I-Effect
. O

Although O
there O
have O
been O
numerous O
reports O
of O
effusions O
, O
none O
have O
provided O
complete O
pleural O
fluid O
analysis O
; O
therefore O
, O
we O
report O
2 I-Subject.Population
patients I-Subject
with O
dasatinib I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pleural I-Effect
effusion I-Effect
with O
complete O
pleural O
fluid O
analysis O
. O

Morphea I-Effect
after I-Adverse_event.Trigger
bromocriptine I-Treatment.Drug
therapy I-Treatment
. O

PURPOSE O
: O
To O
describe O
the O
clinical O
and O
electrophysiological O
findings O
in O
a I-Subject
young I-Subject.Age
boy I-Subject.Gender
with O
decreased I-Effect
vision I-Effect
possibly O
due I-Adverse_event.Trigger
to O
retinal I-Effect
damage I-Effect
by O
rifabutin I-Treatment.Drug
. O

We O
reported O
a I-Subject
case I-Subject
of O
disulfiram I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatitis I-Effect
with O
unique O
clinical O
features O
and O
compared O
our O
case O
with O
others O
in O
the O
literature O
. O

We O
report O
a O
patient I-Subject
receiving O
chronic I-Treatment.Duration
lithium I-Treatment.Drug
therapy I-Treatment
who O
presented I-Adverse_event.Trigger
with O
a O
transient I-Effect
CDI I-Effect
occurring O
in O
the O
setting O
of O
underlying I-Sub_Disorder
chronic I-Sub_Disorder
NDI I-Sub_Disorder
. O

Here O
we O
report O
a I-Subject
patient I-Subject
with I-Subject
newly I-Subject
diagnosed I-Subject
acute I-Treat_Disorder
promyelocytic I-Treat_Disorder
leukemia I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
acute I-Effect
focal I-Effect
myositis I-Effect
, I-Effect
synovitis I-Effect
, I-Effect
and I-Effect
possible I-Effect
vasculitis I-Effect
, O
after O
receiving O
all I-Treatment.Drug
- I-Treatment.Drug
trans I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
therapy O
. O

We O
report O
a O
case O
of O
methotrexate I-Effect
toxicity I-Effect
potentially O
induced I-Adverse_event.Trigger
by O
a O
drug O
interaction O
between O
methotrexate I-Treatment.Combination.Drug
and I-Treatment
omeprazole I-Treatment.Combination.Drug
in O
a I-Subject
25 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
osteosarcoma I-Subject.Sub_Disorder
. O

Increasing I-Treatment
the I-Treatment
olanzapine I-Treatment.Drug
dosage I-Treatment
severely O
aggravated I-Adverse_event.Trigger
the O
symptoms I-Effect
of I-Effect
RLS I-Effect
. O

We O
report O
a I-Subject
case I-Subject
of I-Subject
48 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
seizure I-Treat_Disorder
disorder I-Treat_Disorder
on O
divalproex I-Treatment.Drug
sodium I-Treatment.Drug
( I-Treatment
Depakote I-Treatment
) I-Treatment
who O
presented I-Adverse_event.Trigger
with O
dyspnea I-Effect
. O

To O
report O
a O
probable O
interaction I-Treatment
between I-Treatment
warfarin I-Treatment.Combination.Drug
and I-Treatment
marijuana I-Treatment.Combination.Drug
smoking I-Treatment.Route
, O
resulting I-Adverse_event.Trigger
in O
increased I-Effect
international I-Effect
normalized I-Effect
ratio I-Effect
( I-Effect
INR I-Effect
) I-Effect
values I-Effect
and I-Effect
bleeding I-Effect
complications I-Effect
. O

Transient I-Effect
cardiac I-Effect
arrhythmias I-Effect
related I-Adverse_event.Trigger
to O
lopinavir I-Treatment.Combination.Drug
/ I-Treatment
ritonavir I-Treatment.Combination.Drug
in O
two I-Subject.Population
patients I-Subject
with I-Subject
HIV I-Treat_Disorder
infection I-Treat_Disorder
. O

Interestingly O
, O
the O
use O
of O
carboplatin O
( O
CBDCA O
) O
and O
VDS O
in O
the O
subsequent O
treatment O
course O
was O
well O
tolerated O
indicating O
that O
the O
SIADH I-Effect
was O
most O
likely O
to O
have O
been O
induced I-Adverse_event.Trigger
by O
administration O
of O
CDDP I-Treatment.Drug
. O

Although O
heparin I-Treatment.Drug
- I-Treatment
dependent I-Treatment
antibodies I-Treatment
( I-Treatment
HDAs I-Treatment
) I-Treatment
typically O
manifest I-Adverse_event.Trigger
with O
thrombocytopenia I-Effect
as O
in O
heparin O
- O
induced O
thrombocytopenia O
( O
HIT O
) O
, O
they O
may O
also O
manifest O
with O
preserved O
platelet O
counts O
. O

A O
69 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
female I-Subject.Gender
whose O
anticoagulation I-Treatment
treatment I-Treatment
had I-Treatment
been I-Treatment
stable I-Treatment
for I-Treatment
18 I-Treatment
months I-Treatment
with I-Treatment
warfarin I-Treatment.Combination.Drug
2.5 I-Treatment.Dosage
mg I-Treatment.Dosage
daily I-Treatment.Freq
( I-Treatment
17.5 I-Treatment
mg I-Treatment
/ I-Treatment
wk I-Treatment
) I-Treatment
presented O
to O
an O
anticoagulation O
clinic O
with O
a O
critically O
elevated I-Effect
INR I-Effect
of I-Effect
greater I-Effect
than I-Effect
12.3 I-Effect
after I-Adverse_event.Trigger
a O
dose I-Treatment
increase I-Treatment
in I-Treatment
extended I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
release I-Treatment.Combination.Drug
niacin I-Treatment.Combination.Drug
( I-Treatment
Niaspan I-Treatment
) I-Treatment
from I-Treatment
500 I-Treatment
mg I-Treatment
to I-Treatment
1000 I-Treatment.Dosage
mg I-Treatment.Dosage
daily I-Treatment.Freq
the I-Treatment
previous I-Treatment
week I-Treatment
. O

The O
most O
serious O
dental O
side I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
bisphosphonate I-Treatment.Drug
treatment I-Treatment
( I-Treatment
particularly I-Treatment
when I-Treatment
it I-Treatment
is I-Treatment
administered I-Treatment
intravenously I-Treatment.Route
) I-Treatment
is O
, O
paradoxically O
, O
osteonecrosis I-Effect
of I-Effect
the I-Effect
mandible I-Effect
or I-Effect
the I-Effect
maxilla I-Effect
represented I-Effect
by I-Effect
exposed I-Effect
nonhealing I-Effect
bone I-Effect
. O

Pericardial I-Effect
hemorrhage I-Effect
due I-Adverse_event.Trigger
to O
acetylsalicylic I-Treatment.Drug
acid I-Treatment.Drug
in O
a O
patient O
with O
essential O
thrombocythemia O
. O

These I-Subject
cases I-Subject
and O
a O
review O
of O
the O
literature O
suggested O
that O
hepatotoxicity I-Effect
, O
though O
rare O
, O
should O
be O
added O
to O
the O
list O
of O
adverse I-Adverse_event.Trigger
reactions O
to O
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
. O

After I-Time_elapsed
four I-Time_elapsed
months I-Time_elapsed
, O
while O
receiving I-Treatment
RH I-Treatment.Drug
, O
he O
developed I-Adverse_event.Trigger
painful I-Effect
bilateral I-Effect
gynaecomastia I-Effect
. O

The O
plasma O
concentrations O
of O
both O
drugs O
were O
significantly O
increased O
during O
the O
coadministration O
, O
and O
the O
cetirizine O
concentration O
decreased O
on O
cessation O
of O
pilsicainide I-Treatment.Combination.Drug
despite O
the O
fact O
that O
treatment O
with O
cetirizine I-Treatment.Combination.Drug
was O
continued O
, O
which O
suggested O
that O
the O
fainting I-Effect
was O
induced I-Adverse_event.Trigger
by O
the O
pharmacokinetic O
drug O
interaction O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
multiple I-Effect
episodes I-Effect
of I-Effect
seizure I-Effect
activity I-Effect
in O
an I-Subject
AIDS I-Treat_Disorder
patent I-Subject
following I-Adverse_event.Trigger
amphotericin I-Treatment.Drug
B I-Treatment.Drug
infusion I-Treatment.Route
. O

The O
vomiting I-Effect
occurred O
on O
switching I-Adverse_event.Trigger
to O
different I-Treatment
pancreatic I-Treatment
enzymes I-Treatment
preparations I-Treatment
, I-Treatment
ie I-Treatment
, I-Treatment
Creon I-Treatment.Drug
10 I-Treatment.Drug
, I-Treatment
Viokase I-Treatment.Drug
, I-Treatment
and I-Treatment
Pancrease I-Treatment.Drug
MT I-Treatment.Drug
16 I-Treatment.Drug
. O

Although O
tardive I-Effect
dyskinesia I-Effect
is O
a O
known O
adverse O
reaction O
of O
sustained O
treatment O
with O
traditional O
neuroleptic O
agents O
, O
it O
was O
only O
rarely O
reported O
in O
association I-Adverse_event.Trigger
with O
sulpiride I-Treatment.Drug
, O
a O
selective O
D2 O
- O
receptor O
antagonist O
. O

This O
report O
highlights O
a O
case O
of O
drug O
- O
induced I-Adverse_event.Trigger
dysphagia I-Effect
in O
a I-Subject
patient I-Subject
receiving O
haloperidol I-Treatment.Drug
for O
obsessive I-Treat_Disorder
nocturnal I-Treat_Disorder
thoughts I-Treat_Disorder
and I-Treat_Disorder
auditory I-Treat_Disorder
disturbances I-Treat_Disorder
. O

In O
addition O
to O
disease O
refractoriness O
, O
rare O
instances O
of O
disease I-Effect
progression I-Effect
from I-Effect
chronic I-Effect
phase I-Effect
to I-Effect
blast I-Effect
crisis I-Effect
during I-Adverse_event.Trigger
imatinib I-Treatment.Drug
therapy I-Treatment
have O
recently O
been O
anecdotally O
reported O
. O

We O
report O
a I-Subject
typical I-Subject
case I-Subject
of O
transient I-Effect
serotonin I-Effect
syndrome I-Effect
secondary I-Adverse_event.Trigger
to O
tramadol I-Treatment.Combination.Drug
- I-Treatment
Citalopram I-Treatment.Combination.Drug
combination I-Treatment
. O

Although O
use O
of O
the O
Naranjo O
adverse O
reaction O
probability O
scale O
indicated O
a O
probable O
relationship I-Adverse_event.Trigger
( O
score O
of O
6 O
) O
between O
the I-Subject
patient I-Subject
's O
development O
of O
methotrexate I-Treatment.Combination.Drug
toxicity I-Effect
and I-Treatment
omeprazole I-Treatment.Combination.Drug
use I-Treatment
, O
we O
believe O
this O
was O
a O
drug O
- O
drug O
interaction O
case O
consistent O
with O
previous O
reports O
in O
the O
literature O
. O

Systemic I-Treatment.Drug
cyclosporin I-Treatment.Drug
( I-Treatment
10 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
kg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
) I-Treatment
resulted I-Potential_therapeutic_event.Trigger
in O
resolution I-Effect
of I-Effect
the I-Effect
corneal I-Effect
ulceration I-Effect
within O
two O
weeks O
of O
beginning O
treatment O
, O
and O
the O
patient I-Subject
has O
remained O
in O
remission O
after O
15 O
months O
of O
therapy O
. O

We O
report O
a I-Subject
59 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
myeloid I-Treat_Disorder
leukemia I-Treat_Disorder
, O
who O
developed I-Adverse_event.Trigger
severe O
interstitial I-Effect
lung I-Effect
fibrosis I-Effect
after O
short I-Treatment.Time_elapsed
term I-Treatment.Time_elapsed
and I-Treatment
sequential I-Treatment
treatment I-Treatment
with I-Treatment
melphalan I-Treatment.Combination.Drug
and I-Treatment
busulfan I-Treatment.Combination.Drug
. O

Does O
the O
use I-Adverse_event.Trigger
of O
insulin I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
liver I-Treat_Disorder
dysfunction I-Treat_Disorder
increase I-Effect
water I-Effect
retention I-Effect
in I-Effect
the I-Effect
body I-Effect
, I-Effect
i.e. I-Effect
cause I-Effect
insulin I-Effect
oedema I-Effect
? I-Effect

Sustained I-Effect
hypothyroidism I-Effect
induced I-Adverse_event.Trigger
by O
recombinant I-Treatment.Drug
alpha I-Treatment.Drug
interferon I-Treatment.Drug
in O
patients I-Subject
with I-Subject
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

Withdrawal I-Treatment
of I-Treatment
Depakote I-Treatment.Drug
resulted I-Adverse_event.Trigger
in O
resolution I-Effect
of I-Effect
the I-Effect
effusion I-Effect
. O

Adenosine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ventricular I-Effect
fibrillation I-Effect
. O

Evaluation O
of O
initial O
and O
steady O
- O
state O
gatifloxacin I-Treatment.Drug
pharmacokinetics O
and O
dose O
in I-Potential_therapeutic_event.Trigger
pulmonary I-Treat_Disorder
tuberculosis I-Treat_Disorder
patients I-Subject
by O
using O
monte O
carlo O
simulations O
. O

We O
report O
two I-Subject.Population
patients I-Subject
with I-Subject
acne I-Treat_Disorder
vulgaris I-Treat_Disorder
with O
a O
fourth I-Effect
type I-Effect
of I-Effect
minocycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cutaneous I-Effect
pigmentation I-Effect
. O

Budesonide I-Treatment.Drug
is O
a O
synthetic O
glucocorticosteroid O
that O
is O
commonly O
used I-Potential_therapeutic_event.Trigger
in I-Potential_therapeutic_event.Trigger
topical O
treatment O
of O
asthma I-Treat_Disorder
and I-Treat_Disorder
rhinitis I-Treat_Disorder
. I-Treat_Disorder

Cyclosporin I-Treatment.Drug
therapy I-Potential_therapeutic_event.Trigger
in O
Mooren I-Treat_Disorder
's I-Treat_Disorder
ulcer I-Treat_Disorder
. O

She I-Subject.Gender
developed I-Adverse_event.Trigger
neurotoxicity I-Effect
with O
an O
adjustment I-Treatment.Dosage
dosage I-Treatment.Dosage
of I-Treatment
valacyclovir I-Treatment.Drug
for O
a O
cutaneous I-Treat_Disorder
zoster I-Treat_Disorder
infection I-Treat_Disorder
. O

Nine I-Subject
eyes I-Subject
from I-Subject
6 I-Subject.Population
patients I-Subject
, I-Subject
74 I-Subject.Age
years I-Subject.Age
to I-Subject.Age
90 I-Subject.Age
years I-Subject.Age
of I-Subject
age I-Subject
, O
referred O
by O
ophthalmologists O
for O
repair O
of O
cicatricial I-Effect
entropion I-Effect
after I-Adverse_event.Trigger
at I-Treatment
least I-Treatment
2 I-Treatment.Duration
years I-Treatment.Duration
of I-Treatment
twice I-Treatment.Freq
- I-Treatment.Freq
a I-Treatment.Freq
- I-Treatment.Freq
day I-Treatment.Freq
application I-Treatment
of I-Treatment
dipivefrin I-Treatment.Drug
. O

We O
report O
5 O
patients O
( O
3 I-Subject
patients I-Subject
with I-Subject
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
treated O
with O
pegylated I-Treatment.Combination.Drug
interferon I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2b I-Treatment.Combination.Drug
in I-Treatment
association I-Treatment
with I-Treatment
oral I-Treatment.Route
ribavirin I-Treatment.Combination.Drug
and O
two O
patients O
with O
chronic O
myelocytic O
leukemia O
) O
who O
developed I-Adverse_event.Trigger
local I-Effect
cutaneous I-Effect
reactions I-Effect
at I-Effect
sites I-Effect
of I-Effect
injection I-Effect
after O
the O
administration O
of O
weekly O
subcutaneous O
injections O
of O
pegylated O
interferon O
alfa O
- O
2b O
at O
different O
doses O
. O

We O
report O
5 O
patients O
( O
3 O
patients O
with O
chronic O
hepatitis O
C O
treated O
with O
pegylated O
interferon O
alfa O
- O
2b O
in O
association O
with O
oral O
ribavirin O
and O
two I-Subject
patients I-Subject
with I-Subject
chronic I-Treat_Disorder
myelocytic I-Treat_Disorder
leukemia I-Treat_Disorder
) O
who O
developed I-Adverse_event.Trigger
local I-Effect
cutaneous I-Effect
reactions I-Effect
at I-Effect
sites I-Effect
of I-Effect
injection I-Effect
after O
the O
administration I-Treatment
of I-Treatment
weekly I-Treatment.Freq
subcutaneous I-Treatment.Route
injections I-Treatment.Route
of I-Treatment
pegylated I-Treatment.Drug
interferon I-Treatment.Drug
alfa I-Treatment.Drug
- I-Treatment.Drug
2b I-Treatment.Drug
at I-Treatment
different I-Treatment.Dosage
doses I-Treatment.Dosage
. O

Artemether I-Treatment.Drug
- I-Treatment.Drug
lumefantrine I-Treatment.Drug
( I-Treatment
AL I-Treatment
) I-Treatment
is O
first I-Potential_therapeutic_event.Trigger
- I-Potential_therapeutic_event.Trigger
line I-Potential_therapeutic_event.Trigger
treatment I-Potential_therapeutic_event.Trigger
for O
uncomplicated I-Treat_Disorder
malaria I-Treat_Disorder
in O
many O
African O
countries O
. O

Functional O
regulation O
of O
certain O
neuroreceptors O
during O
risperidone I-Treatment.Drug
treatment O
may O
lead I-Adverse_event.Trigger
to O
altered I-Effect
behavioural I-Effect
responses I-Effect
upon O
switching I-Treatment
to I-Treatment
methylphenidate I-Treatment.Drug
. O

Transient I-Effect
leucopenia I-Effect
and I-Effect
thrombocytopenia I-Effect
associated I-Adverse_event.Trigger
with O
sodium I-Treatment.Drug
nitroprusside I-Treatment.Drug
infusion I-Treatment.Route
. O

This O
unusual I-Effect
pattern I-Effect
of I-Effect
low I-Effect
- I-Effect
grade I-Effect
endometrial I-Effect
carcinoma I-Effect
adds I-Effect
to I-Effect
the I-Effect
spectrum I-Effect
of I-Effect
uterine I-Effect
neoplasia I-Effect
associated I-Adverse_event.Trigger
with O
tamoxifen I-Treatment.Drug
therapy O
. O

Inappropriate I-Effect
antidiuretic I-Effect
hormone I-Effect
secretion I-Effect
after I-Adverse_event.Trigger
high I-Treatment.Dosage
dose I-Treatment.Dosage
vinblastine I-Treatment.Drug
. O

Osteomyelitis I-Effect
occurring O
during O
infliximab I-Treatment.Drug
treatment I-Adverse_event.Trigger
of O
severe I-Treat_Disorder
psoriasis I-Treat_Disorder
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
transitional I-Treat_Disorder
cell I-Treat_Disorder
carcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
renal I-Treat_Disorder
pelvis I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
respiratory I-Effect
dysfunction I-Effect
and I-Effect
an I-Effect
abnormal I-Effect
chest I-Effect
x I-Effect
- I-Effect
ray I-Effect
with I-Effect
diffuse I-Effect
interstitial I-Effect
opacities I-Effect
while O
on O
chemotherapy I-Treatment.Route
with I-Treatment
piritrexim I-Treatment.Drug
, I-Treatment
a I-Treatment
methotrexate I-Treatment
analog I-Treatment
. O

Amiodarone I-Treatment.Drug
induced I-Adverse_event.Trigger
torsades I-Effect
de I-Effect
pointe I-Effect
. O

A I-Subject
patient I-Subject
with I-Subject
Wegener I-Treat_Disorder
's I-Treat_Disorder
granulomatosis I-Treat_Disorder
rapidly O
developed I-Adverse_event.Trigger
a O
circumferential I-Effect
subglottic I-Effect
stenosis I-Effect
while O
on O
a O
cyclophosphamide I-Treatment.Drug
regimen I-Treatment
that O
had O
caused O
resolution I-Effect
of I-Effect
systemic I-Effect
symptoms I-Effect
and I-Effect
pulmonary I-Effect
infiltrates I-Effect
. O

A I-Subject
case I-Subject
is O
presented O
which O
illustrates O
a O
probably O
fatal I-Effect
interaction I-Effect
between I-Adverse_event.Trigger
minoxidil I-Treatment.Drug
and O
a O
coagulation I-Sub_Disorder
disorder I-Sub_Disorder
. O

Methadone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myoclonus I-Effect
in O
advanced I-Treat_Disorder
cancer I-Treat_Disorder
. O

Life I-Effect
- I-Effect
threatening I-Effect
anaphylactoid I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
amifostine I-Treatment.Combination.Drug
used I-Treatment
with I-Treatment
concurrent I-Treatment
chemoradiotherapy I-Treatment.Combination.Drug
for O
nasopharyngeal I-Treat_Disorder
cancer I-Treat_Disorder
in O
a I-Subject
patient I-Subject
with I-Subject
dermatomyositis I-Subject.Sub_Disorder
: O
a O
case O
report O
with O
literature O
review O
. O

We O
conclude O
that O
while O
thrombocytopenia I-Effect
and I-Effect
schistocytosis I-Effect
can O
be O
seen O
in O
quinine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
TTP I-Effect
/ I-Effect
HUS I-Effect
, O
the O
pathophysiology O
seems O
to O
be O
distinct O
from O
that O
seen O
in O
most O
cases O
of O
idiopathic O
TTP O
( O
i.e. O
, O
severely O
decreased O
ADAMTS13 O
with O
an O
inhibitor O
) O
. O

CONCLUSIONS O
: O
Spontaneous I-Effect
hemothorax I-Effect
is O
a O
rare O
phenomenon O
in O
conjunction O
with O
LMWH I-Treatment.Drug
but O
should O
be O
considered I-Adverse_event.Trigger
in O
cases O
of O
acute I-Effect
respiratory I-Effect
distress I-Effect
following O
commencement O
of O
LMWH O
. O

CONCLUSION O
: O
These I-Subject
cases I-Subject
suggest O
that O
moxifloxacin I-Treatment.Drug
may O
interfere I-Effect
with I-Effect
the I-Effect
healing I-Effect
of I-Effect
corneal I-Effect
ulcers I-Effect
. O

Reinstitution O
of O
penicillamine I-Drug
treatment O
caused O
a O
recurrence O
thus O
proving O
a O
causal I-Adverse_event.Trigger
relationship I-Adverse_event.Trigger
between O
penicillamine I-Treatment.Drug
and O
the O
described O
nail I-Effect
- I-Effect
changes I-Effect
. O

A I-Subject
34 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
lady I-Subject.Gender
developed I-Adverse_event.Trigger
a I-Effect
constellation I-Effect
of I-Effect
dermatitis I-Effect
, I-Effect
fever I-Effect
, I-Effect
lymphadenopathy I-Effect
and I-Effect
hepatitis I-Effect
, O
beginning O
on O
the O
17th I-Duration
day I-Duration
of O
a I-Treatment
course I-Treatment
of I-Treatment
oral I-Treatment.Route
sulphasalazine I-Treatment.Drug
for O
sero I-Treat_Disorder
- I-Treat_Disorder
negative I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

He O
had O
been O
commenced O
on O
a I-Treatment
course I-Treatment
of I-Treatment
fusidic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
at I-Treatment
discharge I-Treatment
in I-Treatment
addition I-Treatment
to I-Treatment
his I-Treatment
ongoing I-Treatment
statin I-Treatment.Combination.Drug
prescription I-Treatment
and O
presented I-Adverse_event.Trigger
4 I-Time_elapsed
weeks I-Time_elapsed
later I-Time_elapsed
with O
symptoms I-Effect
consistent I-Effect
with I-Effect
rhabdomyolysis I-Effect
. O

1 O
. O
Artelinic I-Treatment.Drug
acid I-Treatment.Drug
( I-Treatment
AL I-Treatment
) I-Treatment
, I-Treatment
a I-Treatment
water I-Treatment
- I-Treatment
soluble I-Treatment
artemisinin I-Treatment
analogue I-Treatment
for O
treatment I-Potential_therapeutic_event.Trigger
of O
multidrug I-Treat_Disorder
resistant I-Treat_Disorder
malaria I-Treat_Disorder
, O
is O
metabolized O
to O
the O
active O
metabolite O
dihydroqinghaosu O
( O
DQHS O
) O
solely O
by O
CYP3A4/5 O
. O

Inhaled I-Treatment.Route
tobramycin I-Treatment.Drug
solution O
- O
associated I-Adverse_event.Trigger
recurrent I-Effect
eosinophilia I-Effect
and I-Effect
severe I-Effect
persistent I-Effect
bronchospasm I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
cystic I-Treat_Disorder
fibrosis I-Treat_Disorder
: O
a O
case O
report O
. O

The O
occurrence O
of O
BMTN I-Effect
in O
two I-Subject.Population
children I-Subject.Age
treated I-Potential_therapeutic_event.Trigger
with O
RA I-Treatment.Drug
in O
our O
unit O
is O
unlikely O
to O
be O
coincidental O
. O

Comeoscleral I-Effect
perforation I-Effect
after I-Adverse_event.Trigger
pterygium I-Treatment
excision I-Treatment
and I-Treatment
intraoperative I-Treatment
mitomycin I-Treatment.Drug
C. I-Treatment.Drug

Capecitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
multifocal I-Effect
leukoencephalopathy I-Effect
: O
a O
report O
of O
five I-Subject.Population
cases I-Subject
. O

Vigabatrin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
visual I-Effect
field I-Effect
defects I-Effect
are O
at O
present O
the O
most O
important O
safety O
issue O
in O
the O
use O
of O
the O
drug O
. O

Serotonin I-Effect
syndrome I-Effect
in O
elderly I-Subject.Age
patients I-Subject
treated O
for O
psychotic I-Treat_Disorder
depression I-Treat_Disorder
with I-Adverse_event.Trigger
atypical I-Treatment.Combination.Drug
antipsychotics I-Treatment.Combination.Drug
and O
antidepressants I-Treatment.Combination.Drug
: O
two O
case O
reports O
. O

We O
report O
two O
new O
cases O
of O
sarcoidosis I-Effect
in I-Adverse_event.Trigger
two I-Subject.Population
patients I-Subject
with I-Subject
hepatitis I-Treat_Disorder
C I-Treat_Disorder
virus I-Treat_Disorder
infection I-Treat_Disorder
treated O
with O
interferon I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
. O

A I-Subject
57 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed O
morphea I-Effect
while O
taking I-Adverse_event.Trigger
bromocriptine I-Treatment.Drug
. O

Potential O
mechanisms O
regarding O
the O
pathophysiology O
of O
lithium I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
CDI I-Effect
are O
discussed O
. O

Acute I-Effect
coronary I-Effect
syndromes I-Effect
complicating I-Adverse_event.Trigger
the I-Treatment
first I-Treatment
infusion I-Treatment.Route
of I-Treatment
rituximab I-Treatment.Drug
. O

Spontaneous I-Effect
hemothorax I-Effect
following I-Effect
anticoagulation I-Effect
with I-Adverse_event.Trigger
low I-Treatment.Drug
- I-Treatment.Drug
molecular I-Treatment.Drug
- I-Treatment.Drug
weight I-Treatment.Drug
heparin I-Treatment.Drug
. O

There O
were O
no I-Effect
incremental I-Effect
increases I-Effect
in I-Effect
myelosuppression I-Effect
, I-Effect
peripheral I-Effect
neuropathy I-Effect
, I-Effect
or I-Effect
renal I-Effect
, I-Effect
hepatic I-Effect
, I-Effect
or I-Effect
cardiac I-Effect
toxicity I-Effect
and I-Effect
no I-Effect
deaths I-Effect
related I-Potential_therapeutic_event.Trigger
to O
tirapazamine I-Treatment.Drug
. O

A O
phase O
III O
trial O
, O
Cisplatin O
and O
Tirapazamine O
in O
Subjects O
with O
Advanced O
Previously O
Untreated O
Non O
- O
Small O
- O
Cell O
Lung O
Tumors O
( O
CATAPULT O
I O
) O
, O
was O
designed O
to O
determine O
the O
efficacy O
and O
safety O
of O
tirapazamine I-Treatment.Combination.Drug
plus I-Treatment
cisplatin I-Treatment.Combination.Drug
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
non I-Treat_Disorder
- I-Treat_Disorder
small I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lung I-Treat_Disorder
cancer I-Treat_Disorder
( I-Treat_Disorder
NSCLC I-Treat_Disorder
) I-Treat_Disorder
. O

Combination I-Treatment
antimicrobial I-Treatment
regimens I-Treatment
( I-Treatment
e.g. I-Treatment
, I-Treatment
linezolid I-Treatment.Combination.Drug
with I-Treatment
rifampin I-Treatment.Combination.Drug
) I-Treatment
aimed I-Potential_therapeutic_event.Trigger
at O
improving I-Effect
bacterial I-Effect
eradication I-Effect
and I-Effect
preventing I-Effect
resistance I-Effect
are O
often O
used O
; O
however O
, O
most O
data O
supporting O
this O
treatment O
strategy O
are O
not O
from O
randomized O
controlled O
trials O
. O

Clinicians O
treating O
elderly I-Subject.Age
patients I-Subject
with O
a I-Treatment
combination I-Treatment
of I-Treatment
serotonergic I-Treatment.Combination.Drug
antidepressants I-Treatment.Combination.Drug
and I-Treatment
atypical I-Treatment.Combination.Drug
antipsychotics I-Treatment.Combination.Drug
for I-Treatment
psychotic I-Treatment.Treat_Disorder
depression I-Treatment.Treat_Disorder
should O
be I-Adverse_event.Trigger
aware I-Adverse_event.Trigger
of O
the O
potential O
for O
serotonin I-Effect
syndrome I-Effect
. O

Enalaprilat I-Treatment.Drug
induced I-Adverse_event.Trigger
acute I-Effect
parotitis I-Effect
. O

We O
believe O
the O
most O
likely O
cause O
was O
hepatic O
inhibition O
of O
the O
CYP3A4 O
hepatic O
isoenzyme O
by O
fusidic I-Treatment.Drug
acid I-Treatment.Drug
resulting I-Adverse_event.Trigger
in O
an I-Effect
acute I-Effect
severe I-Effect
rise I-Effect
in I-Effect
plasma I-Effect
simvastatin I-Effect
level I-Effect
and I-Effect
extensive I-Effect
myocellular I-Effect
damage I-Effect
. O

The O
authors O
describe O
pericardial I-Effect
hemorrhage I-Effect
, O
which O
is O
related I-Adverse_event.Trigger
to O
the O
use O
of O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
acetylsalicylic I-Treatment.Drug
acid I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
essential I-Treat_Disorder
thrombocythemia I-Treat_Disorder
. O

This O
complex I-Effect
pattern I-Effect
of I-Effect
nail I-Effect
and I-Effect
skin I-Effect
changes I-Effect
is O
accounted O
by O
synergy I-Adverse_event.Trigger
or I-Adverse_event.Trigger
an I-Adverse_event.Trigger
additive I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
chemotherapy I-Treatment.Drug
agents I-Treatment.Drug
on O
cellular O
proliferation O
of O
nail O
compartments O
. O

Akathisia I-Effect
is O
a O
relatively O
rare O
side O
effect O
with I-Adverse_event.Trigger
the O
newer O
atypical O
antipsychotic O
agents O
, O
particularly O
clozapine I-Treatment.Drug
, O
and O
is O
easily O
misdiagnosed O
in O
children I-Subject
. O

In O
this O
case O
, O
discontinuing I-Treatment
piroxicam I-Treatment.Drug
, I-Treatment
a I-Treatment
nonsteroidal I-Treatment
anti I-Treatment
- I-Treatment
inflammatory I-Treatment
drug I-Treatment
, I-Treatment
and I-Treatment
starting I-Treatment
a I-Treatment
palliative I-Treatment
treatment I-Treatment
plan O
helped O
resolve I-Potential_therapeutic_event.Trigger
a I-Subject
patient I-Subject
's I-Subject
ulcers I-Treat_Disorder
. O

Eosinophilia I-Effect
has O
been O
encountered I-Adverse_event.Trigger
from O
0.2 O
to O
61.7 O
% O
in O
clozapine I-Treatment.Drug
- O
treated O
patients I-Subject
, O
mostly O
with O
a O
transient O
course O
and O
spontaneous O
remission O
. O

We O
presented O
a I-Subject
patient I-Subject
with I-Subject
status I-Treat_Disorder
asthmaticus I-Treat_Disorder
treated O
with O
a O
combination O
of O
theophylline I-Treatment.Combination.Drug
and I-Treatment
prednisone I-Treatment.Combination.Drug
who O
developed I-Adverse_event.Trigger
a O
perforated I-Effect
gastric I-Effect
ulcer I-Effect
. O

We O
speculate O
on O
a O
causal O
relationship I-Adverse_event.Trigger
between O
the O
assumption O
of O
the O
additives O
and O
the I-Effect
fatal I-Effect
hepatitis I-Effect
and O
envisage O
a O
synergy O
between O
the O
additives O
and O
montelukast I-Treatment.Drug
, O
which O
per O
se O
has O
well O
been O
studied O
as O
a O
hepatotoxic O
drug O
. O

Fatal I-Effect
liver I-Effect
failure I-Effect
following I-Adverse_event.Trigger
food I-Treatment.Combination.Drug
supplements I-Treatment.Combination.Drug
during I-Treatment
chronic I-Treatment
treatment I-Treatment
with I-Treatment
montelukast I-Treatment.Combination.Drug
. O

The O
nodules I-Treat_Disorder
regressed O
after O
withdrawal O
of O
methotrexate O
therapy O
in O
one I-Subject.Population
patient I-Subject
and O
were O
arrested I-Effect
with I-Potential_therapeutic_event.Trigger
the I-Treatment
addition I-Treatment
of I-Treatment
hydroxychloroquine I-Treatment.Drug
in O
the I-Subject
other I-Subject
. O

The O
nodules I-Treat_Disorder
regressed I-Effect
after I-Potential_therapeutic_event.Trigger
withdrawal I-Treatment
of I-Treatment
methotrexate I-Treatment.Drug
therapy I-Treatment
in O
one I-Subject.Population
patient I-Subject
and O
were O
arrested O
with O
the O
addition O
of O
hydroxychloroquine O
in O
the O
other O
. O

Treatment I-Potential_therapeutic_event.Trigger
of O
carbimazole I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
agranulocytosis I-Treat_Disorder
and I-Treat_Disorder
sepsis I-Treat_Disorder
with O
granulocyte I-Treatment.Drug
colony I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
. O

A O
study O
following O
large I-Subject
patient I-Subject
groups I-Subject
on O
theophylline I-Treatment.Drug
and I-Treatment
a I-Treatment
combination I-Treatment
of I-Treatment
theophylline I-Treatment.Combination.Drug
and I-Treatment
steroids I-Treatment.Combination.Drug
might O
clarify O
the O
risk I-Adverse_event.Trigger
of O
ulcer I-Effect
formation O
in O
patients O
being O
treated O
with O
these O
medications O
for O
asthma I-Treat_Disorder
. O

The I-Treatment
combination I-Treatment
of I-Treatment
cyclobenzaprine I-Treatment.Combination.Drug
and I-Treatment
fluoxetine I-Treatment.Combination.Drug
resulted I-Adverse_event.Trigger
in O
significant I-Effect
QT I-Effect
prolongation I-Effect
in O
our I-Subject
patient I-Subject
that O
progressed I-Effect
to I-Effect
torsade I-Effect
de I-Effect
pointes I-Effect
after O
preoperative I-Treatment.Time_elapsed
droperidol I-Treatment.Combination.Drug
administration I-Treatment
. O

INTRODUCTION O
- O
The O
aim O
of O
this O
case O
report O
is O
to O
present O
a O
15 O
- O
year O
follow O
- O
up O
of O
a I-Subject
patient I-Subject
with O
phenytoin I-Treatment.Drug
( I-Effect
PHT I-Effect
) I-Effect
intoxication I-Effect
with I-Effect
unilateral I-Effect
gingival I-Effect
hyperplasia I-Effect
( I-Effect
GH I-Effect
) I-Effect
. O

This O
severe I-Effect
illness I-Effect
was O
likely O
caused I-Adverse_event.Trigger
by O
minocycline I-Treatment.Drug
, O
and O
we O
speculate O
that O
minocycline O
may O
have O
acted O
as O
a O
superantigen O
, O
causing O
lymphocyte O
over O
- O
activation O
and O
massive O
cytokine O
release O
. O

RESULTS O
: O
Three I-Subject.Population
patients I-Subject
who O
developed I-Adverse_event.Trigger
symptoms I-Effect
of I-Effect
inflammatory I-Effect
bowel I-Effect
disease I-Effect
( I-Effect
IBD I-Effect
) I-Effect
during O
rofecoxib I-Treatment.Drug
exposure I-Treatment.Route
are O
described O
along O
with O
pathology O
findings O
. O

Radiation I-Effect
recall I-Effect
refers O
to O
inflammatory I-Effect
reactions I-Effect
triggered I-Adverse_event.Trigger
by O
cytotoxic I-Treatment.Drug
agents I-Treatment
and O
develops O
in O
previously O
irradiated O
areas O
. O

Herein O
, O
we O
describe O
2 I-Subject.Population
patients I-Subject
who O
developed I-Adverse_event.Trigger
unusual O
CD8 I-Effect
+ I-Effect
cutaneous I-Effect
lymphoproliferative I-Effect
disorders O
after O
treatment O
with O
efalizumab I-Treatment.Combination.Drug
and I-Treatment
infliximab I-Treatment.Combination.Drug
. O

Intrathecal O
methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
cerebellar I-Effect
syndrome I-Effect
. O

Barbiturate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
submassive I-Effect
hepatic I-Effect
necrosis I-Effect
. O

The O
possible O
effects O
of O
tamoxifen O
upon O
the O
uterus O
are O
discussed O
in O
this O
article O
, O
in O
view O
of O
reports O
of O
tamoxifen I-Treatment.Drug
associated I-Adverse_event.Trigger
with O
endometrial I-Effect
carcinoma I-Effect
and I-Effect
endometriosis I-Effect
. O

Three I-Subject.Population
patients I-Subject
who O
had O
experienced O
neuroleptic I-Sub_Disorder
- I-Sub_Disorder
induced I-Sub_Disorder
akathisia I-Sub_Disorder
in O
the O
past O
reported O
that O
the O
symptoms O
of O
fluoxetine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
akathisia I-Effect
were O
identical O
, O
although O
somewhat O
milder O
. O

Three I-Subject.Population
patients I-Subject
who O
had O
experienced O
neuroleptic I-Treatment.Drug
- I-Sub_Disorder
induced I-Sub_Disorder
akathisia I-Effect
in O
the O
past O
reported O
that O
the O
symptoms O
of O
fluoxetine O
- O
induced O
akathisia O
were O
identical O
, O
although O
somewhat O
milder O
. O

Intranasal I-Treatment.Route
desmopressin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyponatremia I-Effect
. O

Sunburn I-Effect
may O
sometimes O
be O
a O
major O
injury O
in O
psoralen I-Treatment.Drug
users I-Treatment
because I-Treatment
high I-Treatment.Dosage
doses I-Treatment.Dosage
or I-Treatment
inappropriate I-Treatment
use I-Treatment
of O
the O
drug O
may O
render I-Adverse_event.Trigger
the O
skin I-Effect
extremely I-Effect
sensitive I-Effect
. O

Methotrexate I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
leukoencephalopathy I-Treat_Disorder
is O
treatable I-Potential_therapeutic_event.Trigger
with O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
folinic I-Treatment.Drug
acid I-Treatment.Drug
: O
a O
case O
report O
and O
analysis O
of O
the O
literature O
. O

Methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
leukoencephalopathy I-Effect
is O
treatable O
with O
high O
- O
dose O
folinic O
acid O
: O
a O
case O
report O
and O
analysis O
of O
the O
literature O
. O

We O
reviewed O
the O
records O
of O
3 I-Subject.Population
patients I-Subject
with I-Subject
lymphoproliferative I-Treat_Disorder
disorders I-Treat_Disorder
who O
experienced O
acute I-Effect
coronary I-Effect
syndromes I-Effect
associated I-Adverse_event.Trigger
with O
their I-Treatment
initial I-Treatment
infusion I-Treatment.Route
of I-Treatment
rituximab I-Treatment.Drug
. O

Previous O
successful O
treatment O
with O
one O
ACE I-Treatment.Drug
inhibitor I-Treatment.Drug
does O
not O
rule O
out O
the O
vasculitis I-Effect
caused I-Adverse_event.Trigger
by O
the O
drug O
from O
the O
same O
group O
. O

We O
report O
a I-Subject
patient I-Subject
with I-Subject
pulmonary I-Treat_Disorder
adenocarcinoma I-Treat_Disorder
complicated O
by O
the I-Effect
syndrome I-Effect
of I-Effect
inappropriate I-Effect
secretion I-Effect
of I-Effect
antidiuretic I-Effect
hormone I-Effect
( I-Effect
SIADH I-Effect
) I-Effect
following I-Adverse_event.Trigger
systemic I-Treatment
chemotherapy I-Treatment
with I-Treatment
cisplatin I-Treatment.Combination.Drug
( I-Treatment
CDDP I-Treatment
) I-Treatment
and I-Treatment
vindesine I-Treatment.Combination.Drug
( I-Treatment
VDS I-Treatment
) I-Treatment
. O

Our O
patient O
had O
headache I-Effect
, I-Effect
mild I-Effect
fever I-Effect
, I-Effect
nausea I-Effect
, I-Effect
vomiting I-Effect
, I-Effect
rash I-Effect
, I-Effect
and I-Effect
eosinophilia I-Effect
after I-Treatment.Time_elapsed
3 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
of I-Treatment
disulfiram I-Treatment.Drug
therapy O
. O

Decreased I-Effect
serum I-Effect
linezolid I-Effect
levels I-Effect
in O
a I-Subject
critically I-Subject.Sub_Disorder
ill I-Subject.Sub_Disorder
patient I-Subject
receiving I-Potential_therapeutic_event.Trigger
concomitant I-Treatment
linezolid I-Treatment.Combination.Drug
and I-Treatment
rifampin I-Treatment.Combination.Drug
. O

OBJECTIVE O
: O
To O
report O
the O
first I-Subject
five I-Subject.Population
cases I-Subject
of I-Subject
amphotericin I-Treatment.Drug
B I-Treatment.Drug
overdose I-Treatment.Dosage
with O
secondary I-Adverse_event.Trigger
cardiac I-Effect
complications I-Effect
in O
a I-Subject
pediatric I-Subject.Age
population I-Subject
. O

CONCLUSIONS O
: O
Amphotericin I-Treatment.Drug
B I-Treatment.Drug
seems O
to O
be O
the O
probable O
cause I-Adverse_event.Trigger
of O
the O
seizures I-Effect
. O

We O
describe O
a I-Subject
patient I-Subject
who O
developed I-Adverse_event.Trigger
acute I-Effect
cerebellar I-Effect
syndrome I-Effect
after O
prophylactic I-Treatment
intrathecal I-Treatment.Route
methotrexate I-Treatment.Drug
administration I-Treatment
and O
recovered O
spontaneously O
. O

Levofloxacin I-Treatment.Drug
induced I-Adverse_event.Trigger
polymorphic I-Effect
ventricular I-Effect
tachycardia I-Effect
with I-Effect
normal I-Effect
QT I-Effect
interval I-Effect
. O

Most O
physicians O
are O
aware O
of O
serotonin I-Effect
syndrome I-Effect
secondary I-Adverse_event.Trigger
to O
antidepressants I-Treatment.Drug
but O
do O
not O
think O
about O
other O
classes O
of O
medications O
such O
as O
analgesics I-Drug
. O

Renal I-Effect
toxicity I-Effect
signs I-Effect
, O
induced I-Adverse_event.Trigger
by O
amphotericin I-Treatment.Drug
B I-Treatment.Drug
, O
progression O
of O
infection O
after O
fluconazole O
, O
and O
likely O
in O
vivo O
resistance O
to O
this O
triazole O
made O
this O
case O
difficult O
to O
treat O
. O

Renal O
toxicity O
signs O
, O
induced O
by O
amphotericin O
B O
, O
progression O
of O
infection I-Effect
after I-Adverse_event.Trigger
fluconazole I-Treatment.Drug
, O
and O
likely O
in O
vivo O
resistance O
to O
this O
triazole O
made O
this O
case O
difficult O
to O
treat O
. O

We O
describe O
two I-Subject.Population
patients I-Subject
with O
aspergillus I-Effect
arthritis I-Effect
of I-Effect
the I-Effect
knee I-Effect
joint I-Effect
following I-Adverse_event.Trigger
fludarabine I-Treatment.Drug
- I-Treatment
based I-Treatment
non I-Treatment
- I-Treatment
myeloablative I-Treatment
stem I-Treatment
cell I-Treatment
transplantation I-Treatment
. O

A O
case O
of O
fluoxetine I-Treatment.Drug
induced I-Adverse_event.Trigger
seizures I-Effect
, O
in O
a I-Subject
person I-Subject
with I-Subject
Down I-Subject.Sub_Disorder
syndrome I-Subject.Sub_Disorder
, O
is O
described O
. O

We O
report O
a O
case O
of O
acute I-Effect
generalized I-Effect
exanthematous I-Effect
pustulosis I-Effect
( I-Effect
AGEP I-Effect
) I-Effect
induced I-Adverse_event.Trigger
by I-Adverse_event.Trigger
salazosulfapyridine I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
ulcerative I-Treat_Disorder
colitis I-Treat_Disorder
. O

Diclofenac I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
hepatitis I-Effect
. O

Angioimmunoblastic I-Effect
lymphadenopathy I-Effect
with I-Effect
dysproteinemia I-Effect
following I-Adverse_event.Trigger
doxycycline I-Treatment.Drug
administration I-Treatment
. O

Doxycycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypoglycemia I-Effect
in O
a I-Subject
nondiabetic I-Subject
young I-Subject.Age
man I-Subject.Gender
. O

Case I-Subject
2 I-Subject
demonstrated O
after O
40 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
on I-Treatment
chlorambucil I-Treatment.Drug
the O
presence I-Adverse_event.Trigger
of I-Adverse_event.Trigger
a I-Effect
balanced I-Effect
translocation I-Effect
, I-Effect
t I-Effect
( I-Effect
1;5 I-Effect
) I-Effect
( I-Effect
p36;q31 I-Effect
) I-Effect
in I-Effect
90 I-Effect
% I-Effect
of I-Effect
the I-Effect
cells I-Effect
. O

Within O
6 I-Time_elapsed
months I-Time_elapsed
of O
pranlukast I-Treatment.Drug
withdrawal I-Potential_therapeutic_event.Trigger
, O
anemia I-Treat_Disorder
resolved I-Effect
and I-Effect
urinary I-Treat_Disorder
sediment I-Treat_Disorder
and I-Effect
renal I-Treat_Disorder
function I-Treat_Disorder
normalized I-Effect
. O

Sirolimus I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
hepatotoxicity I-Effect
in O
the O
kidney I-Treat_Disorder
graft I-Treat_Disorder
recipient I-Treat_Disorder
. I-Subject

Although O
vasculitis I-Effect
has O
been O
reported O
in O
the O
course O
of O
hairy I-Treat_Disorder
cell I-Treat_Disorder
leukaemia I-Treat_Disorder
, O
it O
has O
only O
rarely O
been O
reported O
as O
the O
consequence I-Adverse_event.Trigger
of O
cladribine I-Treatment.Drug
treatment O
. O

Despite O
aggressive O
medical O
management O
, O
including O
intravenous I-Treatment.Route
hydration I-Treatment.Combination.Drug
and I-Treatment
broad I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
spectrum I-Treatment.Combination.Drug
antibiotics I-Treatment.Combination.Drug
, O
the O
patient I-Subject
continued I-Potential_therapeutic_event.Trigger
to O
become I-Effect
more I-Effect
confused I-Effect
, I-Effect
agitated I-Effect
, I-Effect
and I-Effect
despondent I-Effect
over I-Effect
the I-Effect
subsequent I-Effect
24 I-Effect
hours I-Effect
. O

Cyclosporine I-Treatment.Drug
is I-Treatment
a I-Treatment
potent I-Treatment
inhibitor I-Treatment
of I-Treatment
simvastatin I-Treatment
metabolism I-Treatment
, O
and O
may O
therefore O
facilitate I-Adverse_event.Trigger
simvastatin O
- O
induced O
rhabdomyolysis O
. O

The O
effect O
of O
food O
consumption O
on O
lumefantrine O
bioavailability O
in O
African I-Subject.Race
children I-Subject.Age
receiving I-Potential_therapeutic_event.Trigger
artemether I-Treatment.Combination.Drug
- I-Treatment
lumefantrine I-Treatment.Combination.Drug
crushed I-Treatment.Route
or I-Treatment
dispersible I-Treatment.Route
tablets I-Treatment.Route
( I-Treatment
Coartem I-Treatment
) I-Treatment
for O
acute I-Treat_Disorder
uncomplicated I-Treat_Disorder
Plasmodium I-Treat_Disorder
falciparum I-Treat_Disorder
malaria I-Treat_Disorder
. O

To O
report O
2 I-Subject.Population
cases I-Subject
of O
serotonin I-Effect
toxicity I-Effect
( I-Effect
ST I-Effect
) I-Effect
associated I-Adverse_event.Trigger
with O
concomitant I-Treatment
use I-Treatment
of I-Treatment
linezolid I-Treatment.Combination.Drug
and I-Treatment
serotonergic I-Treatment.Combination.Drug
drugs I-Treatment
and O
review O
previously O
published O
case O
reports O
. O

This O
case O
illustrates O
that O
the I-Effect
hemophagocytic I-Effect
syndrome I-Effect
associated I-Effect
with I-Effect
reactivation I-Effect
of I-Effect
EBV I-Effect
can O
occur I-Adverse_event.Trigger
as O
part O
of O
drug O
hypersensitivity O
reactions O
in O
RA O
patients O
taking O
sulfasalazine I-Treatment.Drug
. O

Tardive I-Effect
dyskinesia I-Effect
induced I-Adverse_event.Trigger
by O
sulpiride I-Treatment.Drug
. O

Seizures I-Effect
occurred I-Adverse_event.Trigger
in O
two I-Subject.Population
patients I-Subject
with I-Subject
probable I-Subject
Alzheimer I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
who O
were O
receiving O
long I-Treatment
- I-Treatment
term I-Treatment
treatment I-Treatment
with I-Treatment
metrifonate I-Treatment.Drug
, O
an O
irreversible O
acetylcholinesterase O
inhibitor O
. O

High I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
antithrombin I-Treatment.Combination.Drug
III I-Treatment.Combination.Drug
was O
associated O
with O
an O
increased I-Adverse_event.Trigger
risk O
of O
hemorrhage I-Effect
when O
administered O
with O
heparin I-Treatment.Combination.Drug
. O

With O
the O
increasing O
use O
of O
Cyclosporine I-Treatment.Drug
A I-Treatment.Drug
in O
transplant I-Subject.Sub_Disorder
patients I-Subject
, O
the O
incidence I-Adverse_event.Trigger
of O
herpes I-Effect
esophagitis I-Effect
may I-Effect
increase I-Effect
. I-Effect

After O
starting O
nevirapine I-Treatment.Drug
treatment O
, O
nine I-Subject.Population
out I-Subject.Population
of I-Subject.Population
ten I-Subject.Population
patients I-Subject
experienced I-Adverse_event.Trigger
symptoms O
of O
abstinence I-Effect
syndrome I-Effect
, O
and O
methadone O
dose O
had O
to O
be O
increased O
by O
20 O
% O
on O
average O
during O
the O
course O
of O
the O
study O
. O

Treatment O
was O
begun O
with O
amphotericin I-Treatment.Drug
B I-Treatment.Drug
- I-Treatment.Drug
deoxycholate I-Treatment.Drug
but O
renal I-Effect
toxicity I-Effect
signs I-Adverse_event.Trigger
led O
to O
its O
substitution O
by O
fluconazole I-Drug
. O

Post O
marketing O
studies O
of O
Interferon I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
( I-Drug
IFN I-Drug
beta I-Drug
) I-Drug
therapy O
in O
multiple O
sclerosis O
( O
MS O
) O
have O
demonstrated I-Adverse_event.Trigger
surprisingly O
high O
rates O
of O
hepatotoxicity I-Effect
. O

We O
describe O
the O
first O
case O
of O
disseminated I-Effect
salmonellosis I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
treated O
with O
temozolomide I-Treatment.Drug
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
exacerbated I-Effect
mania I-Effect
potentially O
related I-Adverse_event.Trigger
to O
an O
interaction I-Treatment
between I-Treatment
lopinavir I-Treatment.Combination.Drug
/ I-Treatment
ritonavir I-Treatment.Combination.Drug
and I-Treatment
valproic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
( O
VPA O
) O
and O
propose O
a O
mechanism O
of O
action O
for O
this O
interaction O
. O

The O
first O
reported O
case O
, O
in O
an O
adult O
, O
of O
cholestyramine I-Treatment.Drug
induced I-Adverse_event.Trigger
hyperchloremic I-Effect
metabolic I-Effect
acidosis I-Effect
is O
a I-Subject
70 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
with I-Subject
a I-Subject
two I-Subject
year I-Subject
history I-Subject
of I-Subject
primary I-Treat_Disorder
biliary I-Treat_Disorder
cirrhosis I-Treat_Disorder
confirmed O
by O
histologic O
and O
immunologic O
criteria O
. O

We O
report O
a O
case O
of O
fatal I-Effect
C. I-Effect
neoformans I-Effect
fungemia I-Effect
in O
a I-Subject
neutropenic I-Subject
patient I-Subject
with I-Subject
a I-Subject
history I-Subject
of I-Subject
chronic I-Treat_Disorder
lymphocytic I-Treat_Disorder
leukemia I-Treat_Disorder
treated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
alemtuzumab I-Treatment.Drug
. O

Aggressive I-Treatment
hydration I-Treatment
, I-Treatment
urinary I-Treatment
alkalinization I-Treatment
, I-Treatment
and I-Treatment
leucovorin I-Treatment.Drug
were O
continued I-Potential_therapeutic_event.Trigger
during O
the O
period O
of O
elevated I-Treatment
methotrexate I-Treatment.Drug
levels O
, O
with O
the I-Subject
patient I-Subject
receiving O
a O
course I-Treatment
of I-Treatment
hemodialysis I-Treatment
and I-Treatment
a I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
carboxypeptidase I-Treatment.Drug
G2 I-Treatment.Drug
. O

Acute I-Effect
myocardial I-Effect
infarction I-Effect
due I-Effect
to I-Effect
coronary I-Effect
spasm I-Effect
associated I-Adverse_event.Trigger
with O
L I-Treatment.Drug
- I-Treatment.Drug
thyroxine I-Treatment.Drug
therapy O
. O

Only O
patients I-Subject
on O
DT I-Treatment.Drug
- I-Treatment.Drug
PACE I-Treatment.Drug
but I-Treatment
not I-Treatment
DCEP I-Treatment.Drug
- I-Treatment.Drug
T I-Treatment.Drug
experienced I-Adverse_event.Trigger
an I-Effect
increased I-Effect
incidence I-Effect
of I-Effect
DVT I-Effect
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
published O
report O
of O
a O
possible O
drug I-Effect
interaction I-Effect
in O
a I-Subject
critically I-Subject.Sub_Disorder
ill I-Subject.Sub_Disorder
patient I-Subject
receiving I-Adverse_event.Trigger
concomitant I-Treatment
linezolid I-Treatment.Combination.Drug
and I-Treatment
rifampin I-Treatment.Combination.Drug
. O

Within O
24 I-Treatment.Duration
hours I-Treatment.Duration
of I-Treatment
fluid I-Treatment
restriction I-Treatment
and I-Treatment
cessation I-Treatment
of I-Treatment
desmopressin I-Treatment.Drug
, O
her I-Subject.Gender
symptoms I-Effect
and I-Effect
hyponatremia I-Effect
resolved I-Potential_therapeutic_event.Trigger
. O

An O
adverse O
reaction O
to O
IFN I-Treatment.Drug
was O
strongly O
suspected O
as O
the O
cause I-Adverse_event.Trigger
of O
CHF I-Effect
. O

A I-Subject
51 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
old I-Subject.Age
physically I-Subject
fit I-Subject
woman I-Subject.Gender
experienced I-Adverse_event.Trigger
angio I-Effect
- I-Effect
oedema I-Effect
and I-Effect
hypotensive I-Effect
shock I-Effect
after O
irbesartan I-Treatment.Drug
ingestion I-Treatment.Route
requiring O
noradrenaline O
infusion O
. O

Our O
report O
suggested O
that O
CBDCA I-Effect
hypersensitivity I-Effect
was O
correlated I-Adverse_event.Trigger
with O
the O
total I-Treatment
dose I-Treatment
of I-Treatment
previously I-Treatment
administered I-Treatment
platinum I-Treatment.Drug
agents I-Treatment.Drug
and O
that O
CBDCA O
should O
be O
excluded O
in O
patients O
who O
have O
received O
multiple O
platinum O
- O
based O
chemotherapy O
, O
even O
in O
platinum O
- O
sensitive O
cases O
, O
because O
CBDCA O
hypersensitivity O
can O
occur O
even O
with O
low O
- O
dose O
CBDCA O
administration O
. O

Lansoprazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
. O

Cutaneous I-Effect
necrosis I-Effect
as O
a O
result I-Adverse_event.Trigger
of O
interferon I-Treatment.Drug
alfa I-Treatment.Drug
is O
an O
infrequent O
complication O
with O
unknown O
pathogenesis O
, O
in O
which O
a O
cutaneous O
local O
immune O
- O
mediated O
inflammatory O
process O
might O
be O
involved O
. O

Torsade I-Effect
de I-Effect
pointes I-Effect
resulting I-Adverse_event.Trigger
from O
the O
addition O
of O
droperidol I-Treatment.Drug
to O
an O
existing O
cytochrome I-Treatment.Drug
P450 I-Treatment.Drug
drug O
interaction O
. O

Sulfasalazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypersensitivity I-Effect
syndrome I-Effect
and I-Effect
hemophagocytic I-Effect
syndrome I-Effect
associated O
with O
reactivation O
of O
Epstein O
- O
Barr O
virus O
. O

OBJECTIVES O
: O
The O
authors O
described O
a O
case O
of O
Hashimoto I-Effect
's I-Effect
disease I-Effect
during I-Adverse_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
( I-Treatment
IFN I-Treatment
- I-Treatment
alpha I-Treatment
) I-Treatment
treatment I-Treatment
for O
chronic I-Treat_Disorder
viral I-Treat_Disorder
C I-Treat_Disorder
hepatitis I-Treat_Disorder
in O
a I-Subject
patient I-Subject
with I-Subject
the I-Subject
specific I-Subject.Sub_Disorder
genetic I-Subject.Sub_Disorder
susceptibility I-Subject.Sub_Disorder
associated I-Subject
with I-Subject
the I-Subject
thyroid I-Subject
disease I-Subject
. O

Nephrogenic I-Effect
diabetes I-Effect
insipidus I-Effect
( I-Effect
NDI I-Effect
) I-Effect
is O
a O
well O
- O
documented O
complication I-Adverse_event.Trigger
of O
lithium I-Treatment.Drug
use O
. O

Serotonin I-Treatment.Combination.Drug
toxicity I-Effect
associated I-Adverse_event.Trigger
with O
concomitant I-Treatment
use I-Treatment
of I-Treatment
linezolid I-Treatment.Combination.Drug
. O

We O
report O
the I-Subject
case I-Subject
of I-Subject
a I-Subject
30 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
after I-Adverse_event.Trigger
kidney I-Treatment
transplantation I-Treatment
, I-Treatment
treated I-Treatment
with I-Treatment
steroids I-Treatment.Combination.Drug
, I-Treatment
cyclosporin I-Treatment.Combination.Drug
A I-Treatment.Combination.Drug
and I-Treatment
SRL I-Treatment.Combination.Drug
, O
with O
steroid I-Effect
- I-Effect
resistant I-Effect
acute I-Effect
rejection I-Effect
in O
anamnesis O
. O

Infants I-Subject.Age
are O
particularly O
susceptible O
to O
chronic O
nitrate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
methemoglobinemia I-Effect
because O
of O
their O
low O
stomach O
acid O
production O
, O
large O
numbers O
of O
nitrite O
- O
reducing O
bacteria O
, O
and O
the O
relatively O
easy O
oxidation O
of O
fetal O
hemoglobin O
. O

A I-Subject
72 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
renal I-Subject.Sub_Disorder
insufficiency I-Subject.Sub_Disorder
who O
was O
taking I-Treatment
oral I-Treatment.Route
pilsicainide I-Treatment.Combination.Drug
( I-Treatment
150 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
) I-Treatment
complained I-Adverse_event.Trigger
of O
feeling I-Effect
faint I-Effect
3 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
she I-Treatment
was I-Treatment
prescribed I-Treatment
oral I-Treatment.Route
cetirizine I-Treatment.Combination.Drug
( I-Treatment
20 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
) I-Treatment
. O

Chronic I-Treatment
hydroxychloroquine I-Treatment.Drug
use O
associated I-Adverse_event.Trigger
with O
QT I-Effect
prolongation I-Effect
and I-Effect
refractory I-Effect
ventricular I-Effect
arrhythmia I-Effect
. O

This O
increase O
when O
clozapine I-Treatment.Drug
was I-Treatment
switched I-Treatment
to I-Treatment
risperidone I-Treatment.Drug
and I-Treatment
vice I-Treatment
versa I-Treatment
is O
consistent I-Adverse_event.Trigger
with O
our O
previous O
report O
of O
elevated I-Treat_Disorder
serum I-Treat_Disorder
triglyceride I-Treat_Disorder
levels I-Treat_Disorder
in O
clozapine O
- O
treated O
patients I-Subject
. O

Sensorimotor I-Effect
polyneuropathy I-Effect
with I-Adverse_event.Trigger
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
: O
a I-Subject
case I-Subject
report O
. O

Hydrocortisone I-Treatment.Drug
prophylaxis I-Treatment
and I-Treatment
verapamil I-Treatment.Drug
therapy I-Treatment
were O
the O
primary O
therapies I-Potential_therapeutic_event.Trigger
used O
in O
patient I-Subject
1 I-Subject
( I-Subject
the I-Subject
only I-Subject
survivor I-Subject
) I-Subject
. O

The O
clinical O
aspect O
closely O
resembled O
classical I-Effect
transient I-Effect
global I-Effect
amnesia I-Effect
but O
the O
episode O
after I-Adverse_event.Trigger
clioquinol I-Treatment.Drug
lasted O
longer O
( O
24 O
hours O
to O
three O
days O
) O
and O
a I-Effect
more I-Effect
or I-Effect
less I-Effect
extensive I-Effect
retrograde I-Effect
amnesia I-Effect
persisted O
permanently O
. O

We O
report O
a I-Subject
case I-Subject
of I-Subject
AILD I-Subject.Sub_Disorder
in I-Subject
an I-Subject
80 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
who O
presented I-Adverse_event.Trigger
with O
a O
generalized I-Effect
pruritic I-Effect
maculopapular I-Effect
eruption I-Effect
and I-Effect
fever I-Effect
following O
doxycycline I-Treatment.Drug
administration I-Treatment
. O

OBJECTIVE O
: O
To O
our O
knowledge O
, O
this O
is O
the O
first O
published O
case O
report O
of O
an I-Subject
adolescent I-Subject.Age
girl I-Subject.Gender
with I-Subject
a I-Subject
mitochondrial I-Treat_Disorder
disorder I-Treat_Disorder
and I-Subject
depression I-Treat_Disorder
who O
displayed O
both O
new I-Effect
- I-Effect
onset I-Effect
psychotic I-Effect
and I-Effect
increased I-Effect
mood I-Effect
symptoms I-Effect
during I-Adverse_event.Trigger
treatment O
with O
risperidone I-Treatment.Drug
. O

Young I-Subject.Age
children I-Subject.Age
undergoing I-Treatment
cisplatin I-Treatment.Drug
chemotherapy I-Treatment.Route
are O
known O
to O
be O
at O
risk I-Adverse_event.Trigger
for O
progressive I-Effect
sensorineural I-Effect
hearing I-Effect
loss I-Effect
. O

Systemic I-Effect
capillary I-Effect
leak I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
granulocyte I-Treatment.Drug
colony I-Treatment.Drug
- I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
( I-Treatment
G I-Treatment
- I-Treatment
CSF I-Treatment
) I-Treatment
. O

CASE O
SUMMARIES O
: O
Two I-Subject.Population
patients I-Subject
who O
received O
ifosfamide I-Treatment.Drug
- I-Treatment
containing I-Treatment
chemotherapy I-Treatment.Route
developed I-Adverse_event.Trigger
NCSE I-Effect
. O

One O
of O
the O
monohydroxy O
- O
metabolites O
has O
been O
incriminated O
with O
tacrine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatotoxicity I-Effect
. O

BACKGROUND O
: O
To O
assess O
the O
nature O
, O
incidence O
, O
and O
risk O
factors O
of O
retinopathy I-Effect
associated I-Adverse_event.Trigger
with O
pegylated I-Treatment.Combination.Drug
interferon I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
combination I-Treatment
therapy I-Treatment
in O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
patients I-Subject
. O

Thrombogenic I-Effect
activity I-Effect
of O
doxorubicin I-Treatment.Drug
in O
myeloma I-Treat_Disorder
patients I-Subject
receiving I-Adverse_event.Trigger
thalidomide I-Treatment.Drug
: O
implications O
for O
therapy O
. O

Agranulocytosis I-Effect
is O
a O
rare O
adverse O
effect O
associated I-Adverse_event.Trigger
with O
prolonged I-Treatment.Duration
vancomycin I-Treatment.Drug
therapy I-Treatment
, O
and O
is O
potentially O
serious O
, O
especially O
in O
end I-Treat_Disorder
stage I-Treat_Disorder
renal I-Treat_Disorder
disease I-Treat_Disorder
( I-Treat_Disorder
ESRD I-Treat_Disorder
) I-Treat_Disorder
patients I-Subject
. O

Thiopurine O
methyltransferase O
deficiency O
occurs O
at O
a O
frequency O
of O
one O
in O
300 O
and O
is O
associated O
with O
profound I-Effect
myelosuppression I-Effect
after I-Adverse_event.Trigger
a I-Treatment.Time_elapsed
short I-Treatment.Time_elapsed
course I-Treatment.Time_elapsed
of I-Treatment
azathioprine I-Treatment.Drug
. O

Hypotension I-Effect
and I-Effect
sinus I-Effect
arrest I-Effect
with I-Adverse_event.Trigger
nifedipine I-Treatment.Drug
in O
pulmonary I-Treat_Disorder
hypertension I-Treat_Disorder
. O

We O
describe O
children I-Subject.Age
and I-Subject
adolescents I-Subject.Age
with I-Subject
chronic I-Treat_Disorder
hematologic I-Treat_Disorder
and I-Treat_Disorder
oncologic I-Treat_Disorder
diseases I-Treat_Disorder
who O
exhibited I-Adverse_event.Trigger
drug I-Effect
- I-Effect
seeking I-Effect
behavior I-Effect
or I-Effect
anticholinergic I-Effect
symptoms I-Effect
with O
the O
use O
of O
diphenhydramine I-Treatment.Drug
. O

Transient I-Effect
central I-Effect
diabetes I-Effect
insipidus I-Effect
in O
the O
setting O
of O
underlying O
chronic I-Treat_Disorder
nephrogenic I-Treat_Disorder
diabetes I-Treat_Disorder
insipidus I-Treat_Disorder
associated I-Adverse_event.Trigger
with O
lithium I-Treatment.Drug
use O
. O

A O
macrophage I-Effect
activation I-Effect
syndrome I-Effect
, O
possibly O
related O
to O
methotrexate I-Treatment.Drug
toxicity I-Treatment
, O
developed I-Adverse_event.Trigger
in O
a I-Subject
boy I-Subject.Gender
with I-Subject
systemic I-Treat_Disorder
juvenile I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Hyponatremia I-Effect
in O
patients I-Subject
treated I-Adverse_event.Trigger
with O
lorcainide I-Treatment.Drug
, O
a O
new O
antiarrhythmic O
drug O
. O

Electrical I-Effect
proarrhythmia I-Effect
with I-Adverse_event.Trigger
procainamide I-Treatment.Drug
: O
a O
new O
ICD O
- O
drug O
interaction O
. O

To O
report O
a O
case O
of O
QT I-Effect
prolongation I-Effect
associated I-Adverse_event.Trigger
with O
concomitant I-Treatment
cyclobenzaprine I-Treatment.Combination.Drug
and I-Treatment
fluoxetine I-Treatment.Combination.Drug
administration I-Treatment
followed O
by O
torsade O
de O
pointes O
potentiated O
by O
droperidol O
. O

To O
report O
a O
case O
of O
QT O
prolongation O
associated O
with O
concomitant O
cyclobenzaprine O
and O
fluoxetine O
administration O
followed O
by O
torsade I-Effect
de I-Effect
pointes I-Effect
potentiated I-Adverse_event.Trigger
by O
droperidol I-Treatment.Drug
. O

It O
is O
presumed O
that O
her O
hyperchloremic I-Effect
metabolic I-Effect
acidosis I-Effect
was O
secondary I-Adverse_event.Trigger
to O
cholestyramine I-Treatment.Drug
because O
of O
the O
similarity O
to O
pediatric O
reports O
; O
the O
rapid O
and O
lasting O
response O
to O
intravenous O
sodium O
bicarbonate O
; O
the O
absence O
of O
another O
etiology O
; O
normal O
serum O
potassium O
, O
chloride O
and O
bicarbonate O
despite O
continued O
spironolactone O
therapy O
after O
recovery O
. O

Azathioprine I-Treatment.Drug
can O
cause I-Adverse_event.Trigger
severe I-Effect
myelosuppression I-Effect
. O

Secretory I-Effect
endometrial I-Effect
adenocarcinoma I-Effect
in O
a I-Subject
patient I-Subject
on I-Adverse_event.Trigger
tamoxifen I-Treatment.Drug
for I-Treatment
breast I-Treatment.Treat_Disorder
cancer I-Treatment.Treat_Disorder
: O
a O
report O
of O
a O
case O
. O

It O
was O
postulated O
that O
the O
allergic I-Effect
reaction I-Effect
was O
most O
likely O
caused I-Adverse_event.Trigger
by O
capecitabine I-Treatment.Drug
or I-Treatment
the I-Treatment
intermediate I-Treatment
metabolites I-Treatment
based O
on O
the O
immediate O
reappearance O
of O
symptoms O
from O
the O
rechallenge O
, O
pharmacokinetic O
data O
, O
and O
well O
- O
tolerance O
of O
fluorouracil O
. O

Anterior I-Effect
lumbosacral I-Effect
radiculopathy I-Effect
after I-Adverse_event.Trigger
intrathecal I-Treatment.Route
methotrexate I-Treatment.Drug
treatment O
. O

Divalproex I-Treatment.Drug
sodium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
eosinophilic I-Effect
pleural I-Effect
effusion I-Effect
. O

A I-Subject
26 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Japanese I-Subject.Race
man I-Subject.Gender
, I-Subject
who I-Subject
had I-Subject
been I-Subject
receiving I-Subject
medical I-Subject
attention I-Subject
for I-Subject
ulcerative I-Treat_Disorder
colitis I-Treat_Disorder
for I-Subject
one I-Subject
year I-Subject
, O
presented O
with O
diffuse I-Effect
erythema I-Effect
and I-Effect
pustules I-Effect
on I-Effect
his I-Effect
face I-Effect
and I-Effect
trunk I-Effect
, I-Effect
malaise I-Effect
, I-Effect
and I-Effect
fever I-Effect
up I-Effect
to I-Effect
39 I-Effect
degrees I-Effect
C I-Effect
one I-Time_elapsed
day I-Time_elapsed
after I-Adverse_event.Trigger
the O
administration O
of O
salazosulfapyridine I-Treatment.Drug
. O

Amphotericin I-Treatment.Drug
B I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
seizures I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
AIDS I-Subject.Sub_Disorder
. O

Concomitant I-Treatment
irradiation I-Treatment.Combination.Drug
apparently O
enhanced I-Adverse_event.Trigger
the O
skin I-Effect
toxicity I-Effect
of O
aminoglutethimide I-Treatment.Combination.Drug
or O
possibly O
aminoglutethimide O
had O
a O
radiosensitizing O
role O
in O
this I-Subject
patient I-Subject
. O

CASE O
DESCRIPTION O
: O
A I-Subject
59 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
known I-Subject
neurocysticercosis I-Treat_Disorder
developed I-Adverse_event.Trigger
a I-Effect
large I-Effect
cerebral I-Effect
infarction I-Effect
during I-Treatment
praziquantel I-Treatment.Drug
therapy I-Treatment
. O

We O
describe O
a I-Subject
73 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
serious O
systemic I-Effect
vasculitis I-Effect
with I-Effect
associated I-Effect
thrombocytopenia I-Effect
in O
the O
course O
of O
treatment O
with O
cladribine I-Treatment.Drug
. O

All I-Effect
changes I-Effect
disappeared O
4 O
months O
after O
the O
discontinuation O
of O
VAD O
chemotherapy O
, O
which O
further O
pointed O
out O
towards O
adriamycin I-Treatment.Combination.Drug
and I-Treatment
vincristine I-Treatment.Combination.Drug
as O
possible O
etiologic I-Adverse_event.Trigger
agents I-Adverse_event.Trigger
. O

Because O
of O
further O
progression O
combination O
treatment O
of O
bevacizumab I-Treatment.Combination.Drug
and I-Treatment
irinotecan I-Treatment.Combination.Drug
was O
started O
and O
again O
no O
liver I-Effect
toxicity I-Effect
was O
observed I-Adverse_event.Trigger
. O

Torsade I-Effect
de I-Effect
pointes I-Effect
represents O
a O
potential O
complication I-Adverse_event.Trigger
of O
chronic I-Treatment
amiodarone I-Treatment.Drug
therapy I-Treatment
. O

Eosinophilia I-Effect
caused I-Adverse_event.Trigger
by O
clozapine I-Treatment.Drug
was O
observed O
in O
challenge O
, O
preceded I-Effect
by I-Effect
a I-Effect
faster I-Effect
neutrophil I-Effect
production I-Effect
and I-Effect
consecutive I-Effect
decrease I-Effect
( I-Effect
z I-Effect
= I-Effect
2.27 I-Effect
, I-Effect
p I-Effect
= I-Effect
0.01 I-Effect
) I-Effect
. O

The O
first O
case O
is O
a I-Subject
69 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who I-Subject
was I-Subject
admitted I-Subject
for I-Subject
depression I-Treat_Disorder
with I-Treat_Disorder
psychosis I-Treat_Disorder
and O
treated I-Potential_therapeutic_event.Trigger
with O
trazodone I-Treatment.Combination.Drug
, I-Treatment
risperidone I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
sertraline I-Treatment.Combination.Drug
. O

Multiple O
complications I-Adverse_event.Trigger
of O
propylthiouracil I-Treatment.Drug
treatment O
: O
granulocytopenia I-Effect
, I-Effect
eosinophilia I-Effect
, I-Effect
skin I-Effect
reaction I-Effect
and I-Effect
hepatitis I-Effect
with I-Effect
lymphocyte I-Effect
sensitization I-Effect
. O

Whether O
concomitant O
fluvoxamine O
treatment O
reduces O
tacrine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatotoxicity I-Effect
needs O
further O
study O
. O

Whether O
concomitant I-Treatment
fluvoxamine I-Treatment.Drug
treatment O
reduces I-Potential_therapeutic_event.Trigger
tacrine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
hepatotoxicity I-Treat_Disorder
needs O
further O
study O
. O

Severe I-Effect
hyperkalemia I-Effect
occurred O
in O
a I-Subject
patient I-Subject
with I-Subject
radiation I-Treat_Disorder
pneumonitis I-Treat_Disorder
and I-Subject
glaucoma I-Subject.Sub_Disorder
shortly O
after I-Adverse_event.Trigger
beginning O
prednisone I-Treatment.Drug
therapy O
. O

She O
was O
treated O
with O
Pancrease I-Drug
MT I-Drug
16 I-Drug
, O
but O
had O
consistent O
vomiting I-Effect
1 I-Time_elapsed
to I-Time_elapsed
2 I-Time_elapsed
hours I-Time_elapsed
after I-Adverse_event.Trigger
administration O
of O
enzymes I-Treatment.Drug
. O

Following O
are O
two I-Subject.Population
clinical I-Subject
case I-Subject
reports O
demonstrating O
profound I-Effect
cerebral I-Effect
edema I-Effect
associated I-Adverse_event.Trigger
with O
implantation I-Treatment.Route
of I-Treatment
Gliadel I-Treatment.Drug
wafers I-Treatment.Drug
. O

At O
this O
point O
, O
a I-Treatment
new I-Treatment
antifungal I-Treatment.Drug
agent I-Treatment.Drug
had O
been O
commenced O
, O
suggesting I-Adverse_event.Trigger
a I-Effect
possible I-Effect
drug I-Effect
interaction I-Effect
enhancing I-Effect
the I-Effect
risk I-Effect
of I-Effect
known I-Effect
neurological I-Effect
toxicity I-Effect
with I-Effect
this I-Effect
regime I-Effect
. O

The O
knowledge O
concerning O
VGB I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
visual I-Effect
dysfunction I-Effect
in O
pediatric I-Subject.Age
patients I-Subject
, O
particularly O
in O
those O
who O
have O
been O
exposed O
to O
VGB O
in O
utero O
is O
limited O
. O

We O
herein O
described O
an O
additional O
patient I-Subject
with I-Subject
BCR I-Treat_Disorder
- I-Treat_Disorder
ABL I-Treat_Disorder
( I-Treat_Disorder
ela2 I-Treat_Disorder
) I-Treat_Disorder
positive I-Treat_Disorder
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
tumor I-Effect
lysis I-Effect
syndrome I-Effect
after O
10 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
day I-Treatment.Time_elapsed
treatment I-Treatment
with I-Treatment
imatinib I-Treatment.Drug
. O

Tubulointerstitial I-Effect
nephritis I-Effect
induced I-Adverse_event.Trigger
by O
the O
leukotriene O
receptor O
antagonist O
pranlukast I-Treatment.Drug
. O

Two O
drugs O
commonly O
used O
in O
triple O
- O
drug O
therapy O
for O
treatment O
of O
a I-Treat_Disorder
Helicobacter I-Treat_Disorder
pylori I-Treat_Disorder
infection I-Treat_Disorder
, O
clarithromycin I-Treatment.Combination.Drug
and I-Treatment
omeprazole I-Treatment.Combination.Drug
, O
have O
rarely O
been O
associated I-Adverse_event.Trigger
with O
hypoglycemia I-Effect
when O
given O
alone O
. O

We O
describe O
the O
infectious I-Effect
toxicities I-Effect
experienced I-Adverse_event.Trigger
by I-Adverse_event.Trigger
the O
first I-Subject
two I-Subject.Age
patients I-Subject
in I-Subject
our I-Subject
institution I-Subject
treated I-Treatment
with I-Treatment
dexamethasone I-Treatment.Drug
( I-Treatment
10 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m(2)/day I-Treatment.Dosage
for I-Treatment
4 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
with I-Treatment
gradual I-Treatment
tapering I-Treatment
) I-Treatment
during I-Treatment
induction I-Treatment
according I-Treatment
to I-Treatment
the I-Treatment
dexamethasone I-Treatment.Drug
arm I-Treatment
of I-Treatment
BFM I-Treatment
2000 I-Treatment
and O
review O
the O
relevant O
literature O
that O
suggests O
an O
increased O
risk O
of O
infectious O
complications O
with O
dexamethasone O
. O

This O
case O
demonstrates O
that O
there O
is O
no O
cross O
reactivity O
between O
glyburide I-Treatment.Combination.Drug
and I-Treatment
chlorpropamide I-Treatment.Combination.Drug
in O
producing I-Adverse_event.Trigger
hemolytic I-Effect
anemia I-Effect
. O

Codeine I-Treatment.Drug
intoxication I-Effect
in I-Adverse_event.Trigger
the O
neonate I-Subject.Age
. O

However O
, O
1 I-Effect
eye I-Effect
had I-Effect
vitreous I-Effect
hemorrhage I-Effect
after I-Adverse_event.Trigger
repeated I-Treatment
injections I-Treatment.Route
of I-Treatment
tPA I-Treatment.Drug
. O

Dilated I-Effect
cardiomyopathy I-Effect
associated I-Adverse_event.Trigger
with O
chronic I-Treatment.Dosage
overuse I-Treatment.Dosage
of I-Treatment
an I-Treatment
adrenaline I-Treatment.Drug
inhaler I-Treatment.Route
. O

Surgeons O
and O
physicians O
should O
therefore O
be O
aware O
of O
the O
potential O
for O
RTA I-Effect
to O
occur I-Adverse_event.Trigger
with O
FK506 I-Treatment.Drug
after I-Treatment
any I-Treatment
organ I-Treatment
transplantation I-Treatment
. O

Thirty I-Subject.Population
patients I-Subject
with O
hepatic I-Effect
reactions I-Adverse_event.Trigger
to O
cyclofenil I-Treatment.Drug
, O
a O
non O
- O
steroidal O
drug O
with O
a O
stimulating O
effect O
on O
ovulation O
, O
are O
reviewed O
. O

Though O
serotonin I-Effect
syndrome I-Effect
is O
most O
often O
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
ingestion I-Treatment
of I-Treatment
more I-Treatment
than I-Treatment
one I-Treatment
serotonergic I-Treatment.Drug
drug I-Treatment.Drug
, O
many O
other O
mechanisms O
have O
been O
associated O
with O
serotonergic O
excess O
. O

Because O
of O
a O
hypersensitivity I-Effect
reaction I-Effect
, O
initial O
therapy O
with I-Adverse_event.Trigger
penicillin I-Treatment.Combination.Drug
G I-Treatment.Combination.Drug
and O
gentamicin I-Treatment.Combination.Drug
was O
stopped O
and O
substituted O
with O
cefazolin I-Drug
. O

Ophthalmologists O
should O
be O
aware I-Adverse_event.Trigger
of O
the O
ocular I-Effect
side I-Effect
effects I-Effect
of O
IFN I-Treatment.Drug
therapy O
and O
carefully O
monitor O
patients I-Subject
for O
the O
possible O
occurrence O
of O
hypoalbuminemia I-Effect
and I-Effect
thrombocytopenia I-Effect
. O

The I-Subject
third I-Subject
patient I-Subject
had O
been O
suffering O
from O
serious O
akathisia I-Treat_Disorder
while O
on O
risperidone O
, O
and O
was O
cured O
after O
switching I-Treatment
to I-Treatment
olanzapine I-Treatment.Drug
, O
but O
thereafter O
the O
patient O
suffered I-Adverse_event.Trigger
from O
RLS I-Effect
at I-Effect
nighttime I-Effect
. O

The I-Subject
third I-Subject
patient I-Subject
had O
been O
suffering I-Adverse_event.Trigger
from O
serious O
akathisia I-Effect
while O
on O
risperidone I-Treatment.Drug
, O
and O
was O
cured O
after O
switching O
to O
olanzapine O
, O
but O
thereafter O
the O
patient O
suffered O
from O
RLS O
at O
nighttime O
. O

Chlorpropamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hemolytic I-Effect
anemia I-Effect
. O

We O
report O
recrudescence O
of O
imported O
Plasmodium I-Effect
falciparum I-Effect
malaria I-Effect
following I-Adverse_event.Trigger
quinine I-Treatment.Combination.Drug
treatment I-Treatment
in I-Treatment
the I-Treatment
context I-Treatment
of I-Treatment
concurrent I-Treatment
phenytoin I-Treatment.Combination.Drug
use I-Treatment
. O

It O
is O
likely O
that O
RA I-Treatment.Drug
contributed I-Adverse_event.Trigger
to O
the O
deterioration I-Effect
in I-Effect
renal I-Effect
function I-Effect
in O
these O
patients O
. O

Marked I-Effect
sinus I-Effect
tachycardia I-Effect
resulting I-Adverse_event.Trigger
from O
the O
synergistic O
effects O
of O
marijuana I-Treatment.Combination.Drug
and I-Treatment
nortriptyline I-Treatment.Combination.Drug
. O

Infliximab I-Drug
and O
its O
serious O
adverse O
effects O
are O
discussed O
, O
and O
other O
cases O
of O
osteomyelitis I-Effect
with I-Adverse_event.Trigger
infliximab I-Treatment.Drug
use O
are O
also O
reviewed O
. O

A O
new O
type O
of O
minocycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cutaneous I-Effect
hyperpigmentation I-Effect
. O

Stroke I-Effect
is O
an O
infrequent O
but O
recognized O
complication I-Adverse_event.Trigger
of O
heroin I-Treatment.Drug
addiction I-Treatment
. O

Although O
this O
type O
of O
hyperpigmentation O
has O
been O
previously O
seen O
in O
patients O
with O
cancer O
who O
are O
receiving O
bleomycin O
, O
this O
is O
, O
to O
our O
knowledge O
, O
the O
first O
reported O
case O
of O
bleomycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyperpigmentation I-Effect
in O
an I-Subject
AIDS I-Treat_Disorder
patient I-Subject
and O
should O
be O
added O
to O
the O
growing O
list O
of O
cutaneous O
eruptions O
seen O
in O
these O
patients O
. O

Case I-Subject
report O
of O
withdrawal I-Effect
dyskinesia I-Effect
associated I-Adverse_event.Trigger
with O
amoxapine I-Treatment.Drug
. O

Concern O
exists O
that O
preadmission I-Treatment
warfarin I-Treatment.Combination.Drug
use O
may O
be O
associated I-Adverse_event.Trigger
with O
an O
increased I-Effect
risk I-Effect
of I-Effect
intracerebral I-Effect
hemorrhage I-Effect
in O
patients I-Subject
with I-Subject
ischemic I-Treat_Disorder
stroke I-Treat_Disorder
receiving I-Treatment
intravenous I-Treatment.Combination.Drug
tissue I-Treatment.Combination.Drug
plasminogen I-Treatment.Combination.Drug
activator I-Treatment.Combination.Drug
, O
even O
in O
those O
with O
an O
international O
normalized O
ratio O
< O
1.7 O
. O

Transient I-Effect
anuria I-Effect
following I-Adverse_event.Trigger
administration O
of O
angiotensin I-Treatment.Drug
I I-Treatment.Drug
- I-Treatment.Drug
converting I-Treatment.Drug
enzyme I-Treatment.Drug
inhibitor I-Treatment.Drug
( I-Treatment
SQ I-Treatment
14225 I-Treatment
) I-Treatment
in O
a I-Subject
patient I-Subject
with I-Subject
renal I-Treat_Disorder
artery I-Treat_Disorder
stenosis I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
solitary I-Treat_Disorder
kidney I-Treat_Disorder
successfully O
treated O
with O
renal O
autotransplantation O
. O

Transient I-Treat_Disorder
anuria I-Treat_Disorder
following O
administration O
of O
angiotensin O
I O
- O
converting O
enzyme O
inhibitor O
( O
SQ O
14225 O
) O
in O
a I-Subject
patient I-Subject
with I-Subject
renal I-Subject
artery I-Subject
stenosis I-Subject
of I-Subject
the I-Subject
solitary I-Subject
kidney I-Subject
successfully O
treated I-Potential_therapeutic_event.Trigger
with O
renal I-Treatment
autotransplantation I-Treatment
. O

Development I-Adverse_event.Trigger
of O
essential I-Effect
thrombocythemia I-Effect
in O
a I-Subject
patient I-Subject
treated O
with O
interferon I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
and I-Treatment
pentostatin I-Treatment.Combination.Drug
for O
hairy I-Treat_Disorder
cell I-Treat_Disorder
leukemia I-Treat_Disorder
. O

A I-Subject
case I-Subject
of O
SIADH I-Effect
induced I-Adverse_event.Trigger
by O
mizoribin I-Treatment.Drug
administration I-Treatment
. O

The O
agranulocytosis I-Effect
was O
rapidly O
resolved I-Potential_therapeutic_event.Trigger
by O
granulocyte I-Treatment.Drug
colony I-Treatment.Drug
- I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
( I-Treatment
G I-Treatment
- I-Treatment
CSF I-Treatment
) I-Treatment
therapy I-Treatment
and I-Treatment
by I-Treatment
the I-Treatment
discontinuation I-Treatment
of I-Treatment
vancomycin I-Treatment.Drug
. O

A I-Subject
patient I-Subject
that O
received O
methadone I-Treatment.Drug
for O
cancer I-Treat_Disorder
- I-Treat_Disorder
associated I-Treat_Disorder
pain I-Treat_Disorder
developed I-Adverse_event.Trigger
myoclonus I-Effect
as O
a O
side O
effect O
. O

These O
cases O
were O
considered O
unusual O
in O
light O
of O
the O
short O
delay O
of O
their O
onset O
after O
initiation O
of O
immunosuppressive O
therapy O
and O
their O
fulminant O
course O
: O
3 I-Subject.Population
of I-Subject
these I-Subject
patients I-Subject
died I-Adverse_event.Trigger
of O
PCP I-Effect
occurring O
during O
the O
first I-Treatment.Duration
month I-Treatment.Duration
of I-Treatment
treatment I-Treatment
with I-Treatment
prednisone I-Treatment.Drug
. O

Five I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
fourth I-Treatment
dose I-Treatment
of I-Treatment
vincristine I-Treatment.Drug
, O
she I-Subject.Gender
presented I-Adverse_event.Trigger
with O
bilateral I-Effect
ptosis I-Effect
. O

As O
it O
had O
been O
10 O
months O
since O
her O
last O
dosage O
adjustment O
of O
diltiazem O
, O
it O
was O
unlikely O
that O
the O
statin I-Effect
- I-Effect
induced I-Effect
rhabdomyolysis I-Effect
was O
precipitated I-Adverse_event.Trigger
by O
diltiazem I-Treatment.Drug
. O

After O
the O
chlorambucil I-Treatment.Drug
was O
discontinued O
, O
the O
wbc I-Effect
count I-Effect
began I-Effect
to I-Effect
slowly I-Effect
rise I-Effect
and O
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
clinical I-Effect
AML I-Effect
. O

She I-Subject.Gender
received O
3.8 I-Treatment.Dosage
mg I-Treatment.Dosage
cumulative I-Treatment
dose I-Treatment
of I-Treatment
vincristin I-Treatment.Drug
before O
development I-Adverse_event.Trigger
of O
ptosis I-Effect
. O

In O
addition O
, O
the O
tachycardia I-Effect
persisted I-Effect
and I-Effect
was I-Effect
repeatedly I-Effect
spontaneously I-Effect
reinitiated I-Effect
for I-Effect
prolonged I-Effect
periods I-Effect
after I-Adverse_event.Trigger
procainamide I-Treatment.Drug
. O

One O
patient O
had O
a O
lower O
average O
heart O
rate O
and O
two I-Subject.Population
patients I-Subject
had O
lower I-Effect
average I-Effect
mean I-Effect
blood I-Effect
pressure I-Effect
values I-Effect
during I-Adverse_event.Trigger
propranolol I-Treatment.Drug
treatment O
, O
none O
of O
which O
was O
clinically O
significant O
. O

One I-Subject.Population
patient I-Subject
had O
a O
lower I-Effect
average I-Effect
heart I-Effect
rate I-Effect
and O
two O
patients O
had O
lower O
average O
mean O
blood O
pressure O
values O
during I-Adverse_event.Trigger
propranolol I-Treatment.Drug
treatment O
, O
none O
of O
which O
was O
clinically O
significant O
. O

We O
have O
successfully O
overcome I-Potential_therapeutic_event.Trigger
severe I-Treat_Disorder
neutropenia I-Treat_Disorder
in O
an I-Subject
RA I-Subject.Sub_Disorder
patient I-Subject
treated I-Subject
with I-Subject
gold I-Subject
salts I-Subject
, O
using O
granulocyte I-Treatment.Drug
colony I-Treatment.Drug
- I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
( I-Treatment
G I-Treatment
- I-Treatment
CSF I-Treatment
) I-Treatment
, O
reducing I-Effect
the I-Effect
duration I-Effect
of I-Effect
neutropenia I-Effect
and I-Effect
risk I-Effect
of I-Effect
infection I-Effect
. O

We O
have O
successfully O
overcome O
severe I-Effect
neutropenia I-Effect
in I-Adverse_event.Trigger
an O
RA I-Treat_Disorder
patient O
treated O
with O
gold I-Treatment.Drug
salts I-Treatment.Drug
, O
using O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
, O
reducing O
the O
duration O
of O
neutropenia O
and O
risk O
of O
infection O
. O

A I-Subject
third I-Subject
patient I-Subject
experienced I-Adverse_event.Trigger
disabling I-Effect
neurotoxicity I-Effect
in I-Effect
the I-Effect
extremity I-Effect
of I-Effect
a I-Effect
prior I-Effect
ulnar I-Effect
nerve I-Effect
and I-Effect
tendon I-Effect
transposition I-Effect
after O
receiving O
paclitaxel I-Treatment.Drug
. O

While O
40 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
of I-Treatment
prednisolone I-Treatment.Drug
improved O
hepatic I-Treat_Disorder
dysfunction I-Treat_Disorder
dramatically O
, O
her O
diabetic I-Effect
milieu I-Effect
deteriorated I-Effect
seriously O
. O

While O
40 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
of I-Treatment
prednisolone I-Treatment.Drug
improved I-Potential_therapeutic_event.Trigger
hepatic I-Treat_Disorder
dysfunction I-Treat_Disorder
dramatically O
, O
her O
diabetic O
milieu O
deteriorated O
seriously O
. O

Acute I-Effect
renal I-Effect
insufficiency I-Effect
is O
known O
to O
occur I-Adverse_event.Trigger
in O
patients I-Subject
who O
are O
taking O
ciprofloxacin I-Treatment.Drug
, O
particularly O
the O
elderly I-Subject.Age
. O

A O
61 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
clinical I-Effect
lupus I-Effect
syndrome I-Effect
with I-Effect
positive I-Effect
antinuclear I-Effect
antibody I-Effect
, I-Effect
positive I-Effect
lupus I-Effect
erythematosus I-Effect
( I-Effect
LE I-Effect
) I-Effect
cell I-Effect
preparation I-Effect
, I-Effect
and I-Effect
diffuse I-Effect
proliferative I-Effect
glomerulonephritis I-Effect
following O
26 I-Treatment.Duration
months I-Treatment.Duration
of I-Treatment
procainamide I-Treatment.Drug
therapy I-Treatment
. O

We O
report O
the O
successful O
treatment O
of O
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
and I-Effect
subsequent I-Effect
hemorrhagic I-Effect
complications I-Effect
postoperatively O
in O
a I-Subject
2 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
child I-Subject.Age
with O
Danaparoid O
( O
orgaran O
) O
. O

We O
report O
the O
successful O
treatment I-Potential_therapeutic_event.Trigger
of O
heparin I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
thrombocytopenia I-Treat_Disorder
and I-Treat_Disorder
subsequent I-Treat_Disorder
hemorrhagic I-Treat_Disorder
complications I-Treat_Disorder
postoperatively O
in O
a I-Subject
2 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
child I-Subject.Age
with O
Danaparoid I-Treatment.Drug
( I-Treatment
orgaran I-Treatment
) I-Treatment
. O

Laryngeal I-Effect
dyspnea I-Effect
in O
relation I-Adverse_event.Trigger
to O
an O
interaction O
between O
acenocoumarol I-Treatment.Combination.Drug
and O
topical I-Treatment.Combination.Drug
econazole I-Treatment.Combination.Drug
lotion I-Treatment
. O

A I-Subject
46 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
a I-Treat_Disorder
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
virus I-Treat_Disorder
infection I-Treat_Disorder
received I-Potential_therapeutic_event.Trigger
triple I-Treatment
therapy I-Treatment
with I-Treatment
ribavirin I-Treatment.Combination.Drug
, I-Treatment
pegylated I-Treatment.Combination.Drug
interferon I-Treatment.Combination.Drug
and I-Treatment
telaprevir I-Treatment.Combination.Drug
. O

Leishmania I-Effect
infantum I-Effect
leishmaniasis I-Effect
in O
corticosteroid I-Treatment.Drug
-- O
treated I-Adverse_event.Trigger
patients O
. O

The I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
occipital I-Effect
infarcts I-Effect
and O
was O
found O
to O
have O
extremely I-Treatment
elevated I-Treatment
levels I-Treatment
of I-Treatment
PPA I-Treatment.Drug
in O
his O
blood O
and O
dialysis O
fluid O
. O

As O
atypical I-Treatment.Drug
antipsychotics I-Treatment.Drug
are O
increasingly O
used O
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
childhood I-Treat_Disorder
behavioural I-Treat_Disorder
disorders I-Treat_Disorder
either O
as I-Treatment
monotherapy I-Treatment
or I-Treatment
in I-Treatment
combination I-Treatment
with I-Treatment
other I-Treatment
medications I-Treatment
, O
there O
is O
a O
need O
to O
know O
more O
about O
their O
safety O
, O
in O
particular O
during O
switching O
to O
and O
from O
methylphenidate O
treatment O
, O
as O
antipsychotics O
and O
methylphenidate O
have O
opposing O
effects O
on O
dopaminergic O
neurotransmission O
. O

Sensory I-Effect
neuropathy I-Effect
revealing I-Effect
necrotizing I-Effect
vasculitis I-Effect
during I-Adverse_event.Trigger
infliximab I-Treatment.Drug
therapy I-Treatment
for O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Because O
etoposide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
is O
an O
uncommon O
but O
serious O
adverse O
event O
, O
clinicians O
must O
be O
vigilant O
about O
the O
possibility O
of O
it O
, O
so O
that O
the O
optimal O
treatment O
can O
start O
as O
soon O
as O
possible O
. O

On O
March O
13 O
the I-Subject
patient I-Subject
was I-Subject
again I-Subject
admitted I-Subject
for I-Subject
worsening I-Subject
CHF I-Subject
and O
was O
started I-Potential_therapeutic_event.Trigger
on I-Potential_therapeutic_event.Trigger
continuous I-Treatment.Freq
dobutamine I-Treatment.Drug
infusion I-Treatment.Route
. O

Suspected O
methotrexate O
toxicity O
from O
omeprazole O
: O
a O
case O
review O
of O
carboxypeptidase I-Treatment.Drug
G2 I-Treatment.Drug
use I-Potential_therapeutic_event.Trigger
in O
a O
methotrexate I-Subject
- I-Subject
experienced I-Subject
patient I-Subject
with O
methotrexate I-Treat_Disorder
toxicity I-Treat_Disorder
and O
a O
review O
of O
the O
literature O
. O

Suspected O
methotrexate I-Effect
toxicity I-Effect
from I-Adverse_event.Trigger
omeprazole I-Treatment.Drug
: O
a O
case O
review O
of O
carboxypeptidase O
G2 O
use O
in O
a O
methotrexate O
- O
experienced O
patient O
with O
methotrexate O
toxicity O
and O
a O
review O
of O
the O
literature O
. O

Suspected O
methotrexate O
toxicity O
from O
omeprazole O
: O
a O
case O
review O
of O
carboxypeptidase O
G2 O
use O
in O
a O
methotrexate O
- O
experienced O
patient O
with O
methotrexate I-Treatment.Drug
toxicity I-Effect
and O
a O
review O
of O
the O
literature O
. O

We O
report O
a I-Subject
53 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
- I-Subject
man I-Subject.Gender
who O
developed I-Adverse_event.Trigger
rippling I-Effect
muscle I-Effect
disease I-Effect
( I-Effect
RMD I-Effect
) I-Effect
2 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
starting I-Treatment
simvastatin I-Treatment.Drug
therapy I-Treatment
for O
hypercholesterolemia I-Treat_Disorder
. O

After I-Adverse_event.Trigger
taking O
cholestyramine I-Treatment.Drug
II I-Treatment.Drug
sachets I-Treatment.Route
twice I-Treatment.Freq
daily I-Treatment.Freq
for I-Treatment
two I-Treatment.Duration
months I-Treatment.Duration
she I-Subject
presented O
with O
lethargy I-Effect
, I-Effect
confusion I-Effect
and I-Effect
drowsiness I-Effect
. O

Escape O
atrial O
complexes O
, O
which O
occurred O
following O
junctional O
premature O
complexes O
, O
failed O
to O
initiate O
tachycardia O
in O
the O
control O
state O
but O
tachycardia I-Effect
was O
always O
reinitiated I-Adverse_event.Trigger
by O
an O
identical O
escape O
sequence O
after O
procainamide I-Treatment.Drug
. O

Ten O
percent O
of O
newly O
diagnosed O
myeloma I-Treat_Disorder
patients I-Subject
treated O
with O
any I-Treatment
type I-Treatment
of I-Treatment
chemotherapy I-Treatment.Route
develop I-Adverse_event.Trigger
deep I-Effect
venous I-Effect
thrombosis I-Effect
( I-Effect
DVT I-Effect
) I-Effect
. O

In O
summary O
, O
we O
report O
herein O
the I-Subject
first I-Subject
case I-Subject
of O
SIADH I-Effect
believed O
to O
be O
an O
adverse I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
mizoribin I-Treatment.Drug
, O
which O
may O
therefore O
needed O
to O
be O
added O
to O
the O
list O
of O
drugs O
which O
can O
induce O
SIADH O
. O

Isoniazid I-Treatment.Combination.Drug
and I-Treatment
ethambutol I-Treatment.Combination.Drug
as O
a O
cause I-Adverse_event.Trigger
of O
optic I-Effect
neuropathy I-Effect
. O

Fluorouracil O
for O
allergic I-Effect
reactions I-Effect
to I-Adverse_event.Trigger
capecitabine I-Treatment.Drug
. O

Fluorouracil I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
allergic I-Treat_Disorder
reactions I-Treat_Disorder
to I-Treat_Disorder
capecitabine I-Treat_Disorder
. O

Administration O
of O
pyridoxine I-Treatment.Drug
to O
an I-Subject
infant I-Subject.Age
after O
a O
long O
period O
of O
convulsions I-Treat_Disorder
was O
followed I-Adverse_event.Trigger
by O
acute I-Effect
hypotonia I-Effect
. O

Acute I-Effect
pancreatitis I-Effect
in I-Adverse_event.Trigger
a I-Subject
child I-Subject.Age
with I-Subject
idiopathic I-Treat_Disorder
ulcerative I-Treat_Disorder
colitis I-Treat_Disorder
on O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
therapy I-Treatment
. O

High I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
antithrombin I-Treatment.Drug
III I-Treatment.Drug
in I-Potential_therapeutic_event.Trigger
severe I-Treat_Disorder
sepsis I-Treat_Disorder
: O
a O
randomized O
controlled O
trial O
. O

Fatal I-Effect
interstitial I-Effect
pneumonitis I-Effect
following I-Adverse_event.Trigger
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
intermittent I-Treatment
chlorambucil I-Treatment.Drug
therapy I-Treatment
for O
chronic I-Treat_Disorder
lymphocyte I-Treat_Disorder
leukemia I-Treat_Disorder
. O

These O
findings O
suggest O
that O
the O
corneal I-Effect
and I-Effect
retinal I-Effect
changes I-Effect
are O
the O
result I-Adverse_event.Trigger
of O
a O
toxic O
effect O
of O
tamoxifen I-Treatment.Drug
when O
used O
in O
the O
doses O
and O
duration O
described O
. O

Common O
adverse O
events O
( O
frequency O
10 O
% O
) O
of O
lacosamide I-Treatment.Drug
doses I-Treatment
up I-Treatment
to I-Treatment
600 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
include I-Adverse_event.Trigger
nonspecific I-Effect
central I-Effect
nervous I-Effect
system I-Effect
effects I-Effect
( I-Effect
e.g. I-Effect
, I-Effect
dizziness I-Effect
, I-Effect
ataxia I-Effect
, I-Effect
diplopia I-Effect
, I-Effect
and I-Effect
somnolence I-Effect
) I-Effect
. O

We O
report O
two O
cases O
of O
serotonin I-Effect
syndrome I-Effect
in O
elderly I-Subject.Age
patients I-Subject
during I-Adverse_event.Trigger
treatment O
of O
psychotic I-Treat_Disorder
depression I-Treat_Disorder
with O
atypical I-Treatment.Combination.Drug
antipsychotics I-Treatment.Combination.Drug
and I-Treatment
antidepressants I-Treatment.Combination.Drug
. O

Piritrexim I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
. O

Progression I-Effect
of I-Effect
chronic I-Effect
myeloid I-Effect
leukemia I-Effect
to I-Effect
blast I-Effect
crisis I-Effect
during I-Adverse_event.Trigger
treatment O
with O
imatinib I-Treatment.Drug
mesylate I-Treatment.Drug
. O

Presentation O
of O
three I-Subject.Population
palliative I-Subject
care I-Subject
patients I-Subject
who O
were O
given O
ketamine I-Treatment.Drug
as O
an O
analgesic O
and O
subsequently O
developed I-Adverse_event.Trigger
significant O
and O
debilitating O
urological I-Effect
symptoms I-Effect
. O

A I-Subject
52 I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
patient I-Subject
diagnosed I-Subject
of I-Subject
ankylosing I-Treat_Disorder
spondylitis I-Treat_Disorder
presented I-Adverse_event.Trigger
with O
an I-Effect
iron I-Effect
deficiency I-Effect
anemia I-Effect
after O
a I-Treatment
ten I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
treatment I-Treatment
of I-Treatment
methotrexate I-Treatment.Drug
. O

The O
international O
literature O
regarding O
opportunistic I-Effect
infections I-Effect
after I-Adverse_event.Trigger
immunosuppressive I-Treatment
therapy I-Treatment
with I-Treatment
alemtuzumab I-Treatment.Drug
with O
particular O
attention O
on O
fungal O
infections O
has O
also O
been O
reviewed O
. O

Clinicians O
should O
be O
aware O
of O
the O
dysrhythmic I-Effect
potential I-Adverse_event.Trigger
of O
cyclobenzaprine I-Treatment.Combination.Drug
and I-Treatment
fluoxetine I-Treatment.Combination.Drug
, O
monitor O
for O
other O
cytochrome O
P450 O
inhibitors O
, O
and O
avoid O
concomitant O
drugs O
known O
to O
prolong O
the O
QT O
interval O
. O

Acute I-Effect
generalized I-Effect
exanthematous I-Effect
pustulosis I-Effect
induced I-Adverse_event.Trigger
by O
salazosulfapyridine I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
ulcerative I-Treat_Disorder
colitis I-Treat_Disorder
. O

CONCLUSION O
: O
Acetic I-Treatment.Drug
acid I-Treatment.Drug
is O
corrosive O
and O
may O
cause I-Adverse_event.Trigger
vagina I-Effect
bleeding I-Effect
. O

We O
report O
a O
case O
admitted O
with O
a O
first O
- O
detected O
, O
symptomatic I-Effect
paroxysmal I-Effect
atrial I-Effect
fibrillation I-Effect
in O
a I-Subject
healthy I-Subject
patient I-Subject
after I-Adverse_event.Trigger
self O
- O
medication O
with O
vardenafil I-Treatment.Drug
. O

Propranolol I-Treatment.Drug
: O
an O
unrecognized O
cause I-Adverse_event.Trigger
of O
central I-Effect
nervous I-Effect
system I-Effect
dysfunction I-Effect
in O
patients I-Subject
undergoing I-Subject
cardiopulmonary I-Subject.Sub_Disorder
bypass I-Subject.Sub_Disorder
. O

CONCLUSIONS O
: O
Symptoms I-Effect
and I-Effect
pathologic I-Effect
changes I-Effect
of I-Effect
colitis I-Effect
are O
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
exposure I-Route
to O
rofecoxib I-Treatment.Drug
. O

A O
possible O
drug I-Treatment
- I-Treatment
drug I-Treatment
interaction I-Treatment
between I-Treatment
IFN I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
11 I-Treatment.Dosage
MU I-Treatment.Dosage
TIW I-Treatment.Freq
and I-Treatment
gemfibrozil I-Treatment.Combination.Drug
600 I-Treatment.Dosage
mg I-Treatment.Dosage
BID I-Treatment.Freq
was O
reported I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
undergoing O
treatment O
for O
IFN I-Effect
- I-Effect
induced I-Effect
hypertriglyceridemia I-Effect
. O

Systemic I-Effect
vasculitis I-Effect
complicating O
hairy I-Treat_Disorder
cell I-Treat_Disorder
leukaemia I-Treat_Disorder
treatment I-Adverse_event.Trigger
with O
cladribine I-Treatment.Drug
. O

Quinine I-Treatment.Drug
is O
universally O
used I-Potential_therapeutic_event.Trigger
for O
the O
very O
common O
symptom O
of O
night I-Treat_Disorder
leg I-Treat_Disorder
cramps I-Treat_Disorder
. O

However O
, O
continued O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
MTX I-Treatment.Drug
led I-Adverse_event.Trigger
, O
in O
spite O
of O
normal O
liver O
tests O
, O
8 O
years O
after O
the O
last O
biopsy O
to O
liver I-Effect
failure I-Effect
and I-Effect
death I-Effect
in O
1 O
of O
our O
patients O
. O

Antithrombin I-Treatment.Drug
III I-Treatment.Drug
may O
provide I-Potential_therapeutic_event.Trigger
protection I-Potential_therapeutic_event.Trigger
from O
multiorgan I-Treatment.Treat_Disorder
failure I-Treatment.Treat_Disorder
and O
improve O
survival O
in O
severely I-Treat_Disorder
ill I-Treat_Disorder
patients I-Subject
. O

In I-Subject
the I-Subject
second I-Subject
case I-Subject
, O
five I-Effect
cardiac I-Effect
arrests I-Effect
due I-Effect
to I-Effect
ventricular I-Effect
tachycardia I-Effect
and I-Effect
fibrillation I-Effect
occurred I-Adverse_event.Trigger
during O
several I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
beginning I-Treatment
a I-Treatment
trial I-Treatment
of I-Treatment
bretylium I-Treatment.Drug
maintenance I-Treatment
therapy I-Treatment
for O
complex I-Treat_Disorder
ventricular I-Treat_Disorder
ectopy I-Treat_Disorder
. O

The O
association I-Adverse_event.Trigger
of O
central I-Effect
diabetes I-Effect
insipidus I-Effect
( I-Effect
CDI I-Effect
) I-Effect
with O
lithium I-Treatment.Drug
use O
is O
rare O
. O

However O
, O
a O
new O
episode O
of O
neutropenia I-Effect
, I-Effect
with I-Effect
a I-Effect
WBC I-Effect
count I-Effect
of I-Effect
2.8 I-Effect
x I-Effect
10(3)/mm3 I-Effect
and I-Effect
ANC I-Effect
of I-Effect
0.448 I-Effect
x I-Effect
10(3)/mm3 I-Effect
, O
occurred I-Adverse_event.Trigger
11 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
teicoplanin I-Treatment.Drug
initiation I-Treatment
. O

In O
a O
phase O
II O
study O
of O
hycanthone I-Treatment.Drug
in O
patients I-Subject
with I-Subject
breast I-Treat_Disorder
cancer I-Treat_Disorder
we O
have O
recently O
observed I-Adverse_event.Trigger
severe O
hepatotoxicity I-Effect
, O
even O
at O
lower I-Dosage
doses I-Dosage
, O
which O
resulted O
in O
two O
drug O
- O
related O
deaths O
. O

This O
is O
the O
first O
report O
of O
non I-Effect
- I-Effect
convulsive I-Effect
status I-Effect
epilepticus I-Effect
provoked I-Adverse_event.Trigger
by O
tiagabine I-Treatment.Drug
in O
adolescent I-Subject.Age
patients I-Subject
. O

Two I-Subject.Population
patients I-Subject
are O
described O
who O
developed O
sensory I-Effect
neuropathy I-Effect
after I-Adverse_event.Trigger
the I-Treatment
ingestion I-Treatment
of I-Treatment
30.6 I-Treatment.Dosage
and I-Treatment
114 I-Treatment.Dosage
g I-Treatment.Dosage
metronidazole I-Treatment.Drug
respectively O
. O

We O
report O
two I-Subject.Population
young I-Subject.Age
patients I-Subject
with I-Subject
cystic I-Treat_Disorder
fibrosis I-Treat_Disorder
who O
presented I-Adverse_event.Trigger
with O
acute I-Effect
renal I-Effect
insufficiency I-Effect
after O
2 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
3 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
of I-Treatment
oral I-Treatment.Route
ciprofloxacin I-Treatment.Drug
therapy I-Treatment
. O

A I-Subject
37 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
with I-Subject
multiple I-Subject.Sub_Disorder
myeloma I-Subject.Sub_Disorder
received O
citalopram I-Treatment.Combination.Drug
40 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
and I-Treatment
trazodone I-Treatment.Combination.Drug
150 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
for I-Potential_therapeutic_event.Trigger
anxiety I-Treat_Disorder
- I-Treat_Disorder
related I-Treat_Disorder
disorders I-Treat_Disorder
. O

Hashimoto I-Effect
's I-Effect
disease I-Effect
during I-Adverse_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
therapy O
in O
a I-Subject
patient I-Subject
with I-Subject
pre I-Subject
- I-Subject
treatment I-Subject
negative I-Subject
anti I-Subject
- I-Subject
thyroid I-Subject
autoantibodies I-Subject
and I-Subject
with I-Subject
the I-Subject
specific I-Subject.Sub_Disorder
genetic I-Subject.Sub_Disorder
susceptibility I-Subject.Sub_Disorder
to I-Subject.Sub_Disorder
the I-Subject.Sub_Disorder
thyroid I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
. O

Fever I-Effect
, I-Effect
lymphadenopathy I-Effect
, I-Effect
eosinophilia I-Effect
, I-Effect
lymphocytosis I-Effect
, I-Effect
hepatitis I-Effect
, I-Effect
and I-Effect
dermatitis I-Effect
: O
a O
severe O
adverse I-Adverse_event.Trigger
reaction I-Adverse_event.Trigger
to O
minocycline I-Treatment.Drug
. O

CONCLUSIONS O
: O
This O
observation O
of O
" O
on O
- O
off O
" O
risperidone O
treatment O
suggests O
that O
risperidone I-Treatment.Drug
may O
have I-Adverse_event.Trigger
worsened I-Adverse_event.Trigger
both O
psychiatric I-Effect
and I-Effect
physical I-Effect
manifestations I-Effect
of O
the O
mitochondrial I-Subject.Sub_Disorder
disorder I-Subject.Sub_Disorder
in I-Subject
this I-Subject
adolescent I-Subject.Age
. O

The O
events O
of O
non I-Effect
- I-Effect
convulsive I-Effect
status I-Effect
epilepticus I-Effect
subsided I-Effect
following I-Adverse_event.Trigger
reduction I-Treatment
in I-Treatment
tiagabine I-Treatment.Drug
dosages I-Treatment
. O

CONCLUSIONS O
: O
For O
all O
patients I-Subject
with O
vancomycin I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
neutropenia I-Effect
, O
possible O
cross O
- O
reactivity O
of O
teicoplanin I-Combination.Drug
should O
be O
monitored O
. O

Methotrexate I-Treatment.Drug
induced I-Adverse_event.Trigger
sprue I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
. O

Because O
of O
the O
described O
effects O
of O
niacin I-Treatment.Combination.Drug
on O
the O
coagulation O
cascade O
and O
the O
possibility O
for O
pharmacokinetic O
interactions O
, O
there O
is O
a O
potential I-Adverse_event.Trigger
for O
synergistic I-Effect
coagulopathy I-Effect
when O
combined I-Treatment
with I-Treatment
warfarin I-Treatment.Combination.Drug
therapy I-Treatment
. O

The O
failure O
of O
therapy O
with O
disopyramide O
and O
mexiletine O
to O
reproduce O
this O
observation O
suggests O
either O
a O
previously O
unreported O
electrophysiologic I-Effect
effect I-Effect
of O
, O
or O
idiosyncratic O
response I-Adverse_event.Trigger
to O
, O
procainamide I-Treatment.Drug
. O

The I-Subject
former I-Subject
patient I-Subject
had O
complained O
once O
that O
his O
visual I-Effect
acuity I-Effect
had I-Effect
decreased I-Effect
after I-Adverse_event.Trigger
the O
termination O
of O
IFN I-Treatment.Drug
therapy O
, O
and O
the O
latter O
patient O
complained O
twice O
during O
IFN O
therapy O
that O
his O
visual O
acuity O
had O
decreased O
. O

The O
former O
patient O
had O
complained O
once O
that O
his O
visual O
acuity O
had O
decreased O
after O
the O
termination O
of O
IFN O
therapy O
, O
and O
the O
latter O
patient I-Subject
complained O
twice O
during I-Adverse_event.Trigger
IFN I-Treatment.Drug
therapy I-Treatment
that O
his O
visual I-Effect
acuity I-Effect
had I-Effect
decreased I-Effect
. O

Despite O
administration O
of O
phenytoin O
and O
lorazepam O
, O
the O
seizures I-Effect
persisted O
and O
occurred O
only O
during I-Adverse_event.Trigger
amphotercin I-Treatment.Drug
B I-Treatment.Drug
administration O
. O

We O
describe O
a I-Subject
patient I-Subject
who I-Subject
presented I-Subject
with I-Subject
bloody I-Effect
diarrhoea I-Effect
after I-Adverse_event.Trigger
15 I-Treatment.Dosage
mg I-Treatment.Dosage
meloxicam I-Treatment.Drug
daily I-Treatment.Freq
for I-Treatment
10 I-Treatment.Duration
days I-Treatment.Duration
for O
osteoarthritis I-Treat_Disorder
. O

In O
the O
first I-Subject
patient I-Subject
, O
two I-Effect
episodes I-Effect
of I-Effect
ventricular I-Effect
tachycardia I-Effect
requiring I-Effect
cardioversion I-Effect
occurred I-Adverse_event.Trigger
in O
close I-Treatment.Time_elapsed
temporal I-Treatment.Time_elapsed
sequence I-Treatment.Time_elapsed
with I-Treatment
administering I-Treatment
bretylium I-Treatment.Drug
. O

Transient O
phenytoin I-Treatment.Drug
induced I-Adverse_event.Trigger
IgA I-Effect
deficiency I-Effect
and I-Effect
permanent I-Effect
IgE I-Effect
increase I-Effect
. O

Cerebral I-Effect
edema I-Effect
associated I-Adverse_event.Trigger
with O
Gliadel I-Treatment.Drug
wafers I-Treatment
: O
two O
case O
studies O
. O

Following O
the O
development O
of O
restless I-Treat_Disorder
leg I-Treat_Disorder
syndrome I-Treat_Disorder
, O
therapy I-Potential_therapeutic_event.Trigger
with O
clonazepam I-Treatment.Drug
0.5 I-Treatment.Dosage
mg I-Treatment.Dosage
qhs I-Treatment.Dosage
was O
initiated O
. O

We O
present O
a I-Subject
case I-Subject
of I-Subject
a I-Subject
diabetic I-Treat_Disorder
patient I-Subject
taking I-Subject
glyburide I-Combination.Drug
who O
was O
prescribed O
ciprofloxacin I-Treatment.Combination.Drug
and O
developed I-Adverse_event.Trigger
prolonged I-Effect
hypoglycemia I-Effect
, I-Effect
which I-Effect
persisted I-Effect
for I-Effect
over I-Effect
24 I-Effect
hours I-Effect
. O

We O
describe O
a I-Subject
74 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
( I-Subject
RA I-Subject
) I-Subject
who O
developed I-Adverse_event.Trigger
syndrome I-Effect
of I-Effect
inappropriate I-Effect
secretion I-Effect
of I-Effect
antidiuretic I-Effect
hormone I-Effect
( I-Effect
SIADH I-Effect
) I-Effect
1.5 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
commencement I-Treatment
of I-Treatment
mizoribin I-Treatment.Drug
prescription I-Treatment
when O
his O
arthritis O
was O
improved O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
ivermectin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
severe I-Effect
liver I-Effect
disease I-Effect
published O
in O
the O
literature O
. O

This O
is O
the O
first O
case O
of O
hydroxyurea I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
interstitial I-Effect
pneumonitis I-Effect
reported O
in O
the O
literature O
. O

A I-Subject
32 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
a I-Subject
family I-Subject
history I-Subject
of I-Subject
type I-Subject.Sub_Disorder
2 I-Subject.Sub_Disorder
diabetes I-Subject.Sub_Disorder
mellitus I-Subject.Sub_Disorder
presented O
with O
circulatory I-Effect
collapse I-Effect
and I-Effect
deep I-Effect
coma I-Effect
after I-Time_elapsed
9 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
treatment I-Treatment
with I-Treatment
perospirone I-Treatment.Drug
hydrochloride I-Treatment.Drug
, O
a O
recently O
developed O
atypical O
antipsychotic O
agent O
available O
only O
in O
Japan O
. O

CONCLUSION O
: O
The O
chronic I-Treatment.Duration
use I-Treatment
of I-Treatment
HCQ I-Treatment.Drug
for O
rheumatic I-Treat_Disorder
diseases I-Treat_Disorder
, O
or O
as O
an O
anti O
- O
malarial O
drug O
, O
should O
be O
balanced O
against I-Adverse_event.Trigger
the O
risk O
of O
developing O
potentially O
lethal I-Effect
cardiac I-Effect
arrhythmias I-Effect
. O

Myoclonic I-Effect
spasms I-Effect
following I-Adverse_event.Trigger
intrathecal I-Treatment
morphine I-Treatment.Drug
. I-Drug

This O
is O
the O
first O
report O
of O
a O
disulfiram I-Effect
- I-Effect
like I-Effect
reaction I-Effect
with I-Adverse_event.Trigger
cefmenoxime I-Treatment.Drug
. O

To O
report O
a O
case O
of O
a O
probable O
interaction O
between O
warfarin I-Treatment.Combination.Drug
and I-Treatment
extended I-Treatment
- I-Treatment
release I-Treatment
niacin I-Treatment.Combination.Drug
that O
may O
have O
led I-Adverse_event.Trigger
to O
synergistic I-Effect
coagulopathy I-Effect
and O
to O
inform O
health O
care O
providers O
of O
a O
need O
for O
more O
frequent O
monitoring O
of O
international O
normalized O
ratio O
( O
INR O
) O
in O
patients O
taking O
these O
drugs O
concomitantly O
. O

Dasatinib I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pleural I-Effect
effusions I-Effect
: O
a O
lymphatic O
network O
disorder O
? O

This O
article O
reports O
the O
case O
of O
an I-Subject
otherwise I-Subject
healthy I-Subject
patient I-Subject
who O
experienced O
permanent I-Effect
sensorineural I-Effect
hearing I-Effect
loss I-Effect
after I-Adverse_event.Trigger
a I-Treatment
brief I-Treatment.Duration
course I-Treatment.Duration
of I-Treatment
naproxen I-Treatment.Drug
and O
reviews O
the O
literature O
on O
NSAID O
- O
related O
permanent O
sensorineural O
hearing O
loss O
. O

Administration O
of O
steroid I-Treatment.Drug
and O
decreasing O
the O
dose O
of O
PTU I-Treatment.Drug
produced I-Potential_therapeutic_event.Trigger
a I-Effect
good I-Effect
clinical I-Effect
response I-Effect
and I-Effect
the I-Effect
ANCA I-Effect
disappeared I-Effect
. O

The I-Subject
second I-Subject
patient I-Subject
exhibited O
sudden I-Effect
PLMS I-Effect
following I-Adverse_event.Trigger
olanzapine I-Treatment.Drug
injection I-Treatment.Route
. O

However O
, O
adenosine I-Treatment.Drug
shortens O
the O
antegrade O
refractoriness O
of O
accessory O
atrioventricular O
connections O
and O
may O
cause I-Adverse_event.Trigger
acceleration I-Effect
of I-Effect
the I-Effect
ventricular I-Effect
rate I-Effect
during I-Effect
atrial I-Effect
fibrillation I-Effect
. O

A O
cardiology O
consultation O
performed O
on O
the O
day O
of O
admission O
determined O
that O
a O
markedly O
elevated I-Effect
creatine I-Effect
kinase I-Effect
- I-Effect
myocardial I-Effect
band I-Effect
isoenzyme I-Effect
level I-Effect
and I-Effect
borderline I-Effect
- I-Effect
high I-Effect
troponin I-Effect
I I-Effect
level I-Effect
were O
diagnostic O
of O
rhabdomyolysis I-Effect
secondary I-Adverse_event.Trigger
to O
statin I-Treatment.Drug
use O
. O

METHODS O
: O
Double O
- O
blind O
, O
placebo O
- O
controlled O
titrated O
oral O
challenges O
with O
pancreatic O
enzymes O
resulted I-Adverse_event.Trigger
in I-Adverse_event.Trigger
definite O
vomiting I-Effect
within O
1 O
to O
1.5 O
hours O
after O
challenges O
with O
Viokase I-Treatment.Combination.Drug
and I-Treatment
Pancrease I-Treatment.Combination.Drug
MT I-Treatment.Combination.Drug
16 I-Treatment.Combination.Drug
, O
but O
not O
with O
placebo O
. O

Abiraterone I-Treatment.Drug
acetate I-Treatment.Drug
, I-Treatment
an I-Treatment
androgen I-Treatment
biosynthesis I-Treatment
inhibitor I-Treatment
, O
prolongs I-Potential_therapeutic_event.Trigger
survival I-Potential_therapeutic_event.Trigger
in O
men I-Subject.Gender
with I-Subject
metastatic I-Treat_Disorder
castration I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
prostate I-Treat_Disorder
cancer I-Treat_Disorder
( I-Subject
mCRPC I-Subject
) I-Subject
in O
the O
pre O
- O
and O
post O
- O
chemotherapy O
setting O
as O
demonstrated O
by O
the O
pivotal O
phase O
III O
studies O
COU O
- O
AA O
- O
301 O
and O
COU O
- O
AA O
- O
302 O
. O

Reduction I-Treatment.Dosage
of I-Treatment
methylprednisolone I-Treatment.Drug
dosage I-Treatment
rather I-Treatment
than I-Treatment
insulin I-Treatment
therapy I-Treatment
resulted I-Potential_therapeutic_event.Trigger
in O
better O
control O
of O
glycemia I-Treat_Disorder
. O

Here O
, O
we O
report O
a O
case O
of O
RFP I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypothyroidism I-Effect
without I-Effect
underlying I-Effect
thyroid I-Effect
disease I-Effect
. O

Here O
we O
report O
ramipril I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cutaneous I-Effect
vasculitis I-Effect
in O
a I-Subject
patient I-Subject
who O
required O
steroid O
therapy O
to O
control O
it O
. O

A I-Subject
78 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
a I-Treat_Disorder
transvenous I-Treat_Disorder
cardioverter I-Treat_Disorder
defibrillator I-Treat_Disorder
system I-Treat_Disorder
developed I-Adverse_event.Trigger
frequent I-Effect
shocks I-Effect
during I-Treatment
oral I-Treatment.Route
procainamide I-Treatment.Drug
therapy I-Treatment
. O

A I-Subject
53 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
Greenlandic I-Subject.Race
male I-Subject.Gender
was I-Effect
admitted I-Effect
twice I-Effect
over I-Effect
a I-Effect
period I-Effect
of I-Effect
4 I-Effect
years I-Effect
with I-Effect
a I-Effect
new I-Effect
complete I-Effect
right I-Effect
bundle I-Effect
branch I-Effect
block I-Effect
after I-Adverse_event.Trigger
ingestion I-Treatment.Route
of I-Treatment
10 I-Treatment.Dosage
g I-Treatment.Dosage
and I-Treatment.Dosage
4 I-Treatment.Dosage
g I-Treatment.Dosage
of I-Treatment
carbamazepine I-Treatment.Drug
respectively O
. O

In O
contrast O
, O
other I-Treatment.Drug
common I-Treatment.Drug
agents I-Treatment.Drug
for I-Treatment
the I-Treatment
most I-Treatment
part I-Treatment
trigger I-Adverse_event.Trigger
cutaneous I-Effect
inflammation I-Effect
. O

In O
both I-Subject.Population
patients I-Subject
the O
rippling I-Effect
phenomena I-Effect
worsened I-Adverse_event.Trigger
with O
pyridostigmine I-Treatment.Drug
treatment O
but O
markedly O
improved O
after O
immunosuppression O
with O
azathioprine O
. O

We O
present O
findings O
from O
three I-Subject.Population
patients I-Subject
who O
experienced O
a O
psoriasiform I-Effect
eruption I-Effect
apparently O
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
the O
antiepileptic I-Treatment
agents I-Treatment
sodium I-Treatment.Combination.Drug
valproate I-Treatment.Combination.Drug
and I-Treatment
carbamazepine I-Treatment.Combination.Drug
. O

We O
report O
here O
such O
a I-Subject
case I-Subject
with I-Subject
bilateral I-Treat_Disorder
Mooren I-Treat_Disorder
's I-Treat_Disorder
ulcer I-Treat_Disorder
that O
failed O
to O
respond I-Potential_therapeutic_event.Trigger
to O
local I-Treatment
therapy I-Treatment
with I-Treatment
topical I-Treatment.Route
corticosteroids I-Treatment.Combination.Drug
, I-Treatment
silver I-Treatment.Combination.Drug
nitrate I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
conjunctival I-Treatment
resection I-Treatment
, I-Treatment
as I-Treatment
well I-Treatment
as I-Treatment
systemic I-Treatment
immunosuppression I-Treatment
with I-Treatment
corticosteroids I-Treatment.Combination.Drug
, I-Treatment
cyclophosphamide I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
azathioprine I-Treatment.Combination.Drug
. O

Successful I-Potential_therapeutic_event.Trigger
treatment I-Potential_therapeutic_event.Trigger
with O
carbimazole I-Treatment.Drug
of O
a I-Treat_Disorder
hyperthyroid I-Treat_Disorder
pregnancy I-Treat_Disorder
with I-Treat_Disorder
hepatic I-Treat_Disorder
impairment I-Treat_Disorder
after I-Treat_Disorder
propylthiouracil I-Treat_Disorder
administration I-Treat_Disorder
: O
a O
case O
report O
. O

Successful O
treatment O
with O
carbimazole O
of O
a I-Effect
hyperthyroid I-Effect
pregnancy I-Effect
with I-Effect
hepatic I-Effect
impairment I-Effect
after I-Adverse_event.Trigger
propylthiouracil I-Treatment.Drug
administration O
: O
a O
case O
report O
. O

Jaundice I-Effect
induced I-Adverse_event.Trigger
by O
streptokinase I-Treatment.Drug
. O

When O
thrombosis I-Effect
develops I-Adverse_event.Trigger
during O
heparin I-Treatment.Drug
treatment O
, O
it O
is O
important O
to O
suspect O
HITTs I-Effect
and O
to O
assay O
for O
the O
associated O
antibodies O
, O
regardless O
of O
the O
actual O
platelet O
count O
. O

The O
results O
in O
this O
case O
suggest O
that O
cyclosporin I-Treatment.Drug
is I-Effect
an I-Effect
effective I-Effect
agent I-Effect
in O
patients I-Subject
with I-Subject
severe I-Subject
sight I-Subject
threatening I-Subject
Mooren I-Treat_Disorder
's I-Treat_Disorder
ulcer I-Treat_Disorder
. O

CONCLUSIONS O
: O
Amphotericin I-Treatment.Drug
B I-Treatment.Drug
overdose I-Treatment.Dosage
can O
be I-Adverse_event.Trigger
fatal O
in O
children I-Subject.Age
and I-Subject
infants I-Subject.Age
. O

Five O
and O
one O
- O
half O
years O
after O
the O
diagnosis I-Subject
of I-Subject
myeloma I-Treat_Disorder
, O
while O
in O
remission O
on O
cyclophosphamide I-Treatment.Drug
therapy I-Treatment
, O
the O
patient I-Subject
experienced I-Adverse_event.Trigger
severe I-Effect
abdominal I-Effect
right I-Effect
lower I-Effect
quadrant I-Effect
pain I-Effect
due O
to O
a O
large I-Effect
cecal I-Effect
lymphoma I-Effect
. O

Leukaemoid I-Effect
monocytosis I-Effect
in I-Effect
M4 I-Effect
AML I-Effect
following I-Adverse_event.Trigger
chemotherapy I-Treatment
and I-Treatment
G I-Treatment.Drug
- I-Treatment.Drug
CSF I-Treatment.Drug
. O

Vitiligo I-Effect
associated I-Adverse_event.Trigger
with O
alpha I-Treatment.Drug
- I-Treatment.Drug
interferon I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
active I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

We O
report O
a O
case O
of O
fulminant I-Effect
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
in O
a I-Subject
man I-Subject.Gender
aged I-Subject.Age
70 I-Subject.Age
developing I-Adverse_event.Trigger
within I-Time_elapsed
12 I-Time_elapsed
hours I-Time_elapsed
of O
starting O
six I-Treatment.Freq
- I-Treatment.Freq
hourly I-Treatment.Freq
intravenous I-Treatment.Route
metoclopramide I-Treatment.Drug
. O

CASE O
PRESENTATION O
: O
We O
report O
a I-Subject
patient I-Subject
with I-Subject
CF I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
recurrent I-Effect
eosinophilia I-Effect
and I-Effect
severe I-Effect
persistent I-Effect
bronchospasm I-Effect
following O
repeated I-Treatment
administration I-Treatment
of I-Treatment
preservative I-Treatment
- I-Treatment
free I-Treatment
tobramycin I-Treatment.Drug
by I-Treatment
inhalation I-Treatment.Route
, O
beginning I-Subject
at I-Subject
16 I-Subject.Age
months I-Subject.Age
of I-Subject
age I-Subject
. O

Ballistic I-Effect
movements I-Effect
due I-Effect
to I-Effect
ischemic I-Effect
infarcts I-Effect
after I-Adverse_event.Trigger
intravenous I-Treatment
heroin I-Treatment.Drug
overdose I-Treatment
: O
report O
of O
two I-Subject.Population
cases I-Subject
. O

A I-Subject
case I-Subject
of O
barbiturate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
submassive I-Effect
hepatic I-Effect
necrosis I-Effect
is O
presented O
and O
the O
literature O
is O
reviewed O
. O

With O
combined O
use O
, O
clinicians O
should O
be O
aware O
, O
when O
phenytoin I-Treatment.Combination.Drug
is I-Treatment
added I-Treatment
, O
of O
the O
potential O
for O
reexacerbation I-Effect
of I-Effect
pulmonary I-Effect
symptomatology I-Effect
due I-Adverse_event.Trigger
to O
lowered O
serum O
theophylline I-Treatment.Combination.Drug
concentrations O
. O

Fluoxetine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
akathisia I-Effect
: O
clinical O
and O
theoretical O
implications O
. O

Lansoprazole I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
collagenous I-Effect
colitis I-Effect
: O
a O
case O
report O
. O

We O
discuss O
a I-Effect
variety I-Effect
of I-Effect
bronchopulmonary I-Effect
complications I-Effect
of I-Effect
IBD I-Effect
and O
their O
association I-Adverse_event.Trigger
with O
sulfasalazine I-Treatment.Drug
. O

OBJECTIVE O
: O
To O
report O
the I-Effect
late I-Effect
development I-Effect
of I-Effect
immune I-Effect
- I-Effect
mediated I-Effect
diabetes I-Effect
mellitus I-Effect
after I-Adverse_event.Trigger
completion O
of O
alfa I-Treatment.Drug
- I-Treatment.Drug
interferon I-Treatment.Drug
therapy O
for O
hepatitis I-Treat_Disorder
C I-Treat_Disorder
in O
an I-Subject
Asian I-Subject.Race
patient I-Subject
. O

The O
tirapazamine I-Treatment.Combination.Drug
- I-Treatment
plus I-Treatment
- I-Treatment
cisplatin I-Treatment.Combination.Drug
regimen I-Treatment
was O
associated I-Adverse_event.Trigger
with O
mild I-Effect
to I-Effect
moderate I-Effect
adverse I-Effect
events I-Effect
, I-Effect
including I-Effect
acute I-Effect
, I-Effect
reversible I-Effect
hearing I-Effect
loss I-Effect
, I-Effect
reversible I-Effect
, I-Effect
intermittent I-Effect
muscle I-Effect
cramping I-Effect
, I-Effect
diarrhea I-Effect
, I-Effect
skin I-Effect
rash I-Effect
, I-Effect
nausea I-Effect
, I-Effect
and I-Effect
vomiting I-Effect
. O

To O
the O
best O
of O
our O
knowledge O
, O
corneoscleral I-Effect
melting I-Effect
in O
the O
first O
postoperative O
week O
after I-Adverse_event.Trigger
a I-Treatment.Dosage
single I-Treatment.Dosage
intraoperative I-Treatment.Dosage
application I-Treatment.Dosage
of I-Treatment
mitomycin I-Treatment.Drug
C I-Treatment.Drug
has O
not O
been O
reported O
. O

Thrombo I-Effect
- I-Effect
embolic I-Effect
complication I-Effect
after I-Adverse_event.Trigger
streptokinase I-Treatment.Drug
therapy O
of O
pulmonary I-Treat_Disorder
emboli I-Treat_Disorder
. I-Treat_Disorder

Amebic I-Effect
abscess I-Effect
of I-Effect
the I-Effect
spleen I-Effect
complicated I-Effect
by O
metronidazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
neurotoxicity I-Effect
: O
case I-Subject
report O
. O

Subfulminant I-Effect
hepatitis I-Effect
B I-Effect
after I-Adverse_event.Trigger
infliximab I-Treatment.Drug
in O
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
: O
need O
for O
HBV O
- O
screening O
? O

Disseminated I-Effect
salmonellosis I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
treated O
with O
temozolomide I-Treatment.Drug
. O

The O
aim O
of O
our O
paper O
was O
to O
describe O
hepatotoxicity I-Effect
of O
sirolimus I-Treatment.Drug
( I-Treatment
SRL I-Treatment
) I-Treatment
in I-Adverse_event.Trigger
a I-Subject
kidney I-Subject.Sub_Disorder
graft I-Subject.Sub_Disorder
recipient I-Subject
. O

Idiosyncratic I-Effect
pulmonary I-Effect
reactions I-Effect
to I-Adverse_event.Trigger
nitrofurantoin I-Treatment.Drug
are O
not O
unusual O
, O
often O
presenting O
as O
eosinophilic I-Effect
pneumonia I-Effect
. O

The O
NZ O
Pharmacovigilance O
Centre O
has O
received O
7 O
additional O
reports O
of O
severe I-Effect
infections I-Effect
in O
patients I-Subject
with I-Subject
RA I-Treat_Disorder
taking I-Adverse_event.Trigger
leflunomide I-Treatment.Drug
. O

In O
addition O
, O
loading I-Adverse_event.Trigger
with O
one I-Treatment
low I-Treatment.Dosage
oral I-Treatment.Route
dose I-Treatment.Dosage
of I-Treatment
serine I-Treatment.Drug
produced O
psychotic I-Effect
symptoms I-Effect
5 I-Treatment.Time_elapsed
h I-Treatment.Time_elapsed
later I-Treatment
which O
lasted O
3 O
- O
6 O
h. O

Localized I-Effect
purpura I-Effect
associated I-Adverse_event.Trigger
with O
lamotrigine I-Treatment.Drug
. O

Aseptic I-Effect
meningitis I-Effect
, I-Effect
hemolytic I-Effect
anemia I-Effect
, I-Effect
hepatitis I-Effect
, I-Effect
and I-Effect
orthostatic I-Effect
hypotension I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
treated O
with O
trimethoprim I-Treatment.Combination.Drug
- I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
. O

Torsemide I-Treatment.Drug
appears O
to O
also O
be O
a O
part O
of O
a O
long O
list O
of O
agents O
that O
can O
cause I-Adverse_event.Trigger
pancreatitis I-Effect
. O

Sulfasalazine I-Treatment.Drug
has O
been O
associated I-Adverse_event.Trigger
with O
bronchopulmonary I-Effect
complications I-Effect
of I-Effect
inflammatory I-Effect
bowel I-Effect
disease I-Effect
( I-Effect
IBD I-Effect
) I-Effect
in O
adults I-Subject.Age
. O

Hydroxyurea I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute O
interstitial I-Effect
pneumonitis I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
essential I-Treat_Disorder
thrombocythemia I-Treat_Disorder
. O

The O
reported O
case O
represents O
an O
unusual O
association I-Adverse_event.Trigger
between O
medication O
with O
the O
proton I-Treatment
pump I-Treatment
inhibitor I-Treatment
lansoprazole I-Treatment.Drug
and O
the O
development O
of O
collagenous I-Effect
colitis I-Effect
suggesting O
the O
importance O
of O
evaluation O
of O
drug O
use O
in O
patients I-Subject
with I-Subject
microscopic I-Subject.Sub_Disorder
colitis I-Subject.Sub_Disorder
. O

The O
temporal O
sequence O
of O
the O
respiratory O
insufficiency O
and O
the O
histopathology O
, O
when O
compared O
to O
the O
previous O
examples O
in O
the O
literature O
, O
suggest O
that O
cyclophosphamide I-Treatment.Drug
was O
aetiologically O
responsible I-Adverse_event.Trigger
for O
the O
lung I-Effect
disease I-Effect
. O

A O
57 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
chronic I-Effect
, I-Effect
watery I-Effect
diarrhea I-Effect
four I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
Helicobacter I-Treatment
pylori I-Treatment
eradication I-Treatment
therapy I-Treatment
including I-Treatment
lansoprazole I-Treatment.Combination.Drug
followed I-Treatment
by I-Treatment
lansoprazole I-Treatment.Combination.Drug
monotherapy I-Treatment
for I-Treatment
gastroesophageal I-Treatment.Treat_Disorder
reflux I-Treatment.Treat_Disorder
disease I-Treatment.Treat_Disorder
. O

We O
believe O
that O
this O
represents O
an O
unusual O
case O
of O
moderate I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
MTX I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
neurotoxicity I-Effect
in O
a O
patient I-Subject
with I-Subject
gastric I-Treat_Disorder
cancer I-Treat_Disorder
, O
which O
has O
not O
previously O
been O
reported O
. O

The I-Subject
patient I-Subject
expired I-Effect
after I-Adverse_event.Trigger
seven I-Treatment.Duration
cycles I-Treatment.Duration
of I-Treatment
treatment I-Treatment
had O
been O
completed O
because O
of O
pulmonary O
fibrosis O
and O
the O
drug I-Treatment
toxicity I-Treatment
of I-Treatment
bleomycin I-Treatment.Drug
. O

A O
statistical O
association I-Adverse_event.Trigger
between O
the O
incidence O
of O
DVT I-Effect
and O
combination I-Treatment
chemotherapy I-Treatment.Combination.Drug
including I-Treatment
doxorubicin I-Treatment.Combination.Drug
( I-Treatment
P I-Treatment
= I-Treatment
.02 I-Treatment
) I-Treatment
was O
observed O
; O
this O
association O
was O
confirmed O
on O
multivariate O
analysis O
. O

Bleomycin I-Effect
pneumonitis I-Effect
potentiated O
by I-Adverse_event.Trigger
oxygen I-Treatment.Drug
administration I-Treatment
. O

After I-Treatment.Duration
five I-Treatment.Duration
and I-Treatment.Duration
six I-Treatment.Duration
weeks I-Treatment.Duration
of I-Treatment
continuous I-Treatment
oral I-Treatment.Route
administration I-Treatment
of I-Treatment
methylprednisolone I-Treatment.Drug
, O
the O
boys I-Subject.Gender
developed I-Adverse_event.Trigger
steroid I-Effect
diabetes I-Effect
. O

CONCLUSION O
: O
This O
report O
describes O
a O
case O
of O
a I-Treatment
probable I-Treatment
interaction I-Treatment
between I-Treatment
topical I-Treatment.Route
econazole I-Treatment.Combination.Drug
lotion I-Treatment.Route
1 I-Treatment
% I-Treatment
and I-Treatment
acenocoumarol I-Treatment.Combination.Drug
that O
resulted I-Adverse_event.Trigger
in O
overanticoagulation I-Effect
and I-Effect
a I-Effect
life I-Effect
- I-Effect
threatening I-Effect
laryngeal I-Effect
hematoma I-Effect
in O
this O
elderly I-Subject.Age
patient I-Subject
. O

Pulmonary I-Effect
lymphohistiocytic I-Effect
reactions I-Effect
temporally O
related I-Adverse_event.Trigger
to O
etanercept I-Treatment.Drug
therapy O
. O

Disseminated I-Effect
tuberculous I-Effect
lesions I-Effect
post I-Adverse_event.Trigger
intravesical O
BCG I-Treatment.Drug
therapy O
are O
rare O
but O
need O
to O
be O
identified O
and O
treated O
quickly O
. O

Rhabdomyolysis I-Effect
can O
occur I-Adverse_event.Trigger
with O
all O
statins I-Treatment.Drug
when O
used O
alone O
and O
particularly O
when O
combined O
with O
other I-Treatment
drugs I-Treatment
that I-Treatment
are I-Treatment
themselves I-Treatment
myotoxic I-Treatment
or I-Treatment
that I-Treatment
elevate I-Treatment
the I-Treatment
concentration I-Treatment
of I-Treatment
the I-Treatment
statin I-Treatment
. O

Amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
dysthyroidism I-Effect
. O

Two I-Subject.Population
patients I-Subject
with O
imminent I-Effect
gangrene I-Effect
of I-Effect
the I-Effect
extremities I-Effect
caused I-Adverse_event.Trigger
by O
ergot I-Treatment.Drug
- I-Sub_Disorder
induced I-Sub_Disorder
arteriospasm I-Sub_Disorder
underwent O
mechanical O
dilatation O
of O
the O
arteries O
when O
conventional O
measures O
such O
as O
anticoagulation O
, O
vasodilation O
, O
and O
sympathetic O
blockade O
produced O
no O
improvement O
. O

Two O
patients O
with O
imminent O
gangrene O
of O
the O
extremities O
caused O
by O
ergot I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
arteriospasm I-Effect
underwent O
mechanical O
dilatation O
of O
the O
arteries O
when O
conventional O
measures O
such O
as O
anticoagulation O
, O
vasodilation O
, O
and O
sympathetic O
blockade O
produced O
no O
improvement O
. O

Acute I-Effect
coronary I-Effect
syndromes I-Effect
can O
be O
associated I-Adverse_event.Trigger
with O
the O
infusion I-Treatment.Route
of I-Treatment
rituximab I-Treatment.Drug
. O

Approximately O
15 I-Time_elapsed
min I-Time_elapsed
after O
the O
first O
administration O
of O
nebulised I-Treatment.Route
morphine I-Treatment.Drug
the O
patient I-Subject
became I-Adverse_event.Trigger
markedly I-Effect
bradypneic I-Effect
( I-Effect
respiratory I-Effect
rate I-Effect
: I-Effect
4 I-Effect
- I-Effect
5 I-Effect
bpm I-Effect
) I-Effect
, I-Effect
hypotensive I-Effect
( I-Effect
BP I-Effect
70/40 I-Effect
mmHg I-Effect
) I-Effect
, I-Effect
and I-Effect
responded I-Effect
only I-Effect
partially I-Effect
to I-Effect
command I-Effect
. O

Akathisia I-Treat_Disorder
appeared O
to O
be O
a O
common O
side O
effect O
of O
fluoxetine I-Drug
and O
generally O
responded I-Potential_therapeutic_event.Trigger
well O
to O
treatment O
with O
the O
beta I-Treatment
- I-Treatment
adrenergic I-Treatment
antagonist I-Treatment
propranolol I-Treatment
, O
dose O
reduction O
, O
or O
both O
. O

An O
unusual O
cause I-Adverse_event.Trigger
of O
burn I-Effect
injury I-Effect
: O
unsupervised O
use I-Treatment
of I-Treatment
drugs I-Treatment
that I-Treatment
contain I-Treatment
psoralens I-Treatment.Drug
. I-Treatment

The O
patient I-Subject
suffered I-Adverse_event.Trigger
a O
life I-Effect
- I-Effect
threatening I-Effect
anaphylactoid I-Effect
reaction I-Effect
to O
amifostine I-Treatment.Drug
. O

We O
report O
three I-Population
cases O
of O
severe I-Effect
hypocalcaemia I-Effect
associated I-Adverse_event.Trigger
with O
i.v I-Treatment.Route
. I-Treatment.Route
bisphosphonate I-Treatment.Drug
treatment I-Treatment
in O
patients I-Subject
with I-Subject
multiple I-Treat_Disorder
myeloma I-Treat_Disorder
. O

We O
report O
a I-Subject
case I-Subject
of O
exfoliative I-Effect
dermatitis I-Effect
clearly O
linked I-Adverse_event.Trigger
to O
intravenous I-Treatment.Route
and I-Treatment
intraperitoneal I-Treatment.Route
administration I-Treatment
of I-Treatment
tobramycin I-Treatment.Drug
. O

Glomerulonephritis I-Effect
in O
procainamide I-Treatment.Drug
induced I-Adverse_event.Trigger
lupus I-Effect
erythematosus I-Effect
: O
report O
of O
a O
case O
and O
review O
of O
the O
literature O
. O

Patients I-Subject
treated O
with O
captopril I-Drug
who O
develop O
" O
atypical I-Effect
cholangitis I-Effect
" O
should O
be O
suspected O
of O
having O
captopril I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
liver I-Effect
damage I-Effect
. O

We O
report O
a O
case O
of O
codeine I-Treatment.Drug
intoxication I-Effect
in I-Subject
the I-Subject
neonate I-Subject.Age
, O
in O
which O
the O
drug O
was O
prescribed I-Adverse_event.Trigger
for I-Subject
cough I-Treat_Disorder
control I-Subject
during I-Subject
an I-Subject
emergency I-Subject
department I-Subject
visit I-Subject
. O

Discontinuation I-Treatment
of I-Treatment
simvastatin I-Treatment.Drug
and I-Treatment
cyclosporine I-Treatment.Drug
resulted I-Potential_therapeutic_event.Trigger
in O
resolution O
of O
rhabdomyolysis I-Treat_Disorder
and O
normalization I-Effect
of I-Effect
renal I-Effect
function I-Effect
. O

Phenylpropanolamine I-Treatment.Drug
( I-Treatment
PPA I-Treatment
) I-Treatment
recently O
has O
been O
publicly O
implicated O
as O
a O
cause I-Adverse_event.Trigger
of O
stroke I-Effect
and I-Effect
other I-Effect
neurologic I-Effect
events I-Effect
. O

Critically O
elevated I-Effect
INR I-Effect
in O
a I-Subject
patient I-Subject
on O
warfarin I-Treatment.Drug
after I-Adverse_event.Trigger
increase I-Treatment.Dosage
in I-Treatment.Dosage
extended I-Treatment
- I-Treatment
release I-Treatment
niacin I-Treatment.Drug
dose I-Treatment.Dosage
. O

He I-Subject.Gender
developed I-Adverse_event.Trigger
severe O
hyperactivity I-Effect
and I-Effect
agitation I-Effect
on O
taking O
methylphenidate I-Treatment.Drug
after I-Treatment
the I-Treatment
discontinuation I-Treatment
of I-Treatment
risperidone I-Treatment.Drug
treatment O
. O

We O
suggest O
that O
objective O
evaluation O
of O
retinal O
function O
with O
electrophysiological O
methods O
should O
be O
performed O
in O
patients O
with O
visual I-Effect
disturbance I-Effect
during I-Adverse_event.Trigger
treatment O
with O
rifabutin I-Treatment.Drug
. O

A O
clinically O
atypical O
, O
neuropathologically O
verified O
case O
of O
Creutzfeldt I-Effect
- I-Effect
Jakob I-Effect
disease I-Effect
is O
described I-Adverse_event.Trigger
in O
a I-Subject
32 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
New I-Subject.Race
Zealand I-Subject.Race
woman I-Subject.Gender
with I-Subject
idiopathic I-Treat_Disorder
hypopituitarism I-Treat_Disorder
who O
had O
been O
treated O
in O
late O
adolescence O
( O
1970 O
to O
1973 O
) O
with O
human I-Treatment.Drug
growth I-Treatment.Drug
hormone I-Treatment.Drug
processed O
from O
pooled O
cadaveric O
pituitary O
glands O
. O

Quinine I-Treatment.Drug
remains O
a O
reliable O
treatment I-Potential_therapeutic_event.Trigger
for O
falciparum I-Treat_Disorder
malaria I-Treat_Disorder
in O
most O
parts O
of O
the O
world O
. O

Severe O
corneal I-Effect
toxicity I-Effect
after I-Adverse_event.Trigger
topical I-Treatment
fluoroquinolone I-Treatment.Drug
therapy I-Treatment
: O
report O
of O
two O
cases O
. O

She O
developed I-Adverse_event.Trigger
a I-Effect
generalized I-Effect
rash I-Effect
and I-Effect
itching I-Effect
, I-Effect
sore I-Effect
throat I-Effect
, I-Effect
and I-Effect
dizziness I-Effect
approximately I-Treatment
4 I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
first I-Treatment
dose I-Treatment
of I-Treatment
capecitabine I-Treatment.Drug
. O

Seizures I-Effect
associated I-Adverse_event.Trigger
with O
fluoxetine I-Treatment.Drug
therapy I-Treatment
are O
uncommon O
. O

A I-Subject
14 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
with I-Subject
newly I-Subject
diagnosed I-Subject
SLE I-Treat_Disorder
developed I-Adverse_event.Trigger
a I-Effect
pruritic I-Effect
bullous I-Effect
eruption I-Effect
while O
on O
prednisone I-Treatment.Drug
. O

Sodium I-Treatment.Drug
valproate I-Treatment.Drug
and I-Treatment
carbamazepine I-Treatment.Drug
, O
antiepileptic O
drugs O
that O
are O
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
a O
relatively O
low O
rate O
of O
adverse I-Effect
cutaneous I-Effect
reactions I-Effect
, O
should O
be O
added O
to O
the O
growing O
list O
of O
drugs O
that O
produce O
psoriasiform O
eruptions O
. O

Tirapazamine I-Treatment.Combination.Drug
plus I-Treatment
cisplatin I-Treatment.Combination.Drug
versus O
cisplatin O
in I-Potential_therapeutic_event.Trigger
advanced I-Treat_Disorder
non I-Treat_Disorder
- I-Treat_Disorder
small I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lung I-Treat_Disorder
cancer I-Treat_Disorder
: O
A O
report O
of O
the O
international O
CATAPULT O
I O
study O
group O
. O

Exfoliative I-Effect
dermatitis I-Effect
secondary I-Adverse_event.Trigger
to I-Adverse_event.Trigger
tobramycin I-Treatment.Drug
sulfate I-Treatment.Drug
. I-Treatment

Kaposi I-Effect
's I-Effect
sarcoma I-Effect
in O
a I-Subject
patient I-Subject
treated I-Adverse_event.Trigger
with O
imatinib I-Treatment.Drug
mesylate I-Treatment.Drug
for O
chronic I-Treat_Disorder
myeloid I-Treat_Disorder
leukemia I-Treat_Disorder
. O

A O
young I-Subject.Age
patient I-Subject
experienced I-Adverse_event.Trigger
marked O
sinus I-Effect
tachycardia I-Effect
while O
smoking O
marijuana O
and O
receiving O
therapeutic O
doses O
of O
nortriptyline I-Treatment.Drug
. O

Hypogammaglobulinemia I-Effect
associated I-Adverse_event.Trigger
with O
gold I-Treatment.Drug
therapy I-Treatment
: O
evidence O
for O
a I-Effect
partial I-Effect
maturation I-Effect
blockade I-Effect
of I-Effect
B I-Effect
cells I-Effect
. O

Experience O
with O
five I-Subject.Population
patients I-Subject
in O
whom O
impaired I-Effect
renal I-Effect
function I-Effect
developed I-Adverse_event.Trigger
early O
during O
amphotericin I-Treatment.Drug
B I-Treatment.Drug
therapy I-Treatment
is O
reported O
. O

This O
report O
details O
the O
pulmonary O
pathologic O
findings O
in O
four I-Subject.Population
patients I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
, O
who O
developed I-Effect
new I-Effect
onset I-Effect
of I-Effect
pulmonary I-Effect
signs I-Effect
and I-Effect
symptoms I-Effect
with I-Effect
alveolar I-Effect
infiltrates I-Effect
temporally O
related I-Adverse_event.Trigger
to I-Adverse_event.Trigger
the O
institution I-Treatment
of I-Treatment
etanercept I-Treatment.Drug
therapy I-Treatment
. O

CONCLUSION O
: O
Hypersensitivity O
reaction O
should O
be O
considered O
in O
patients I-Subject
who O
develop I-Adverse_event.Trigger
recurrent I-Effect
eosinophilia I-Effect
and I-Effect
deterioration I-Effect
of I-Effect
pulmonary I-Effect
function I-Effect
following O
the O
use I-Treatment
of I-Treatment
tobramycin I-Treatment.Drug
by I-Treatment
inhalation I-Treatment.Route
or I-Treatment
by I-Treatment
intravenous I-Treatment.Route
administration I-Treatment.Route
. I-Route

NCSE I-Effect
, O
an O
epileptic O
disorder O
in O
which O
typical O
convulsive O
activity O
is O
absent O
, O
has O
previously O
been O
reported O
in O
only O
4 I-Subject.Population
patients I-Subject
receiving I-Adverse_event.Trigger
ifosfamide I-Treatment.Drug
. O

We O
describe O
a O
case O
of O
life O
- O
threatening O
hyponatremia I-Effect
associated I-Adverse_event.Trigger
with O
sibutramine I-Treatment.Drug
use O
in O
an O
obese I-Treat_Disorder
woman I-Subject
. O

Polymyoclonus I-Effect
seizure I-Effect
resulting I-Adverse_event.Trigger
from O
accidental I-Treatment
injection I-Treatment.Route
of I-Treatment
tranexamic I-Treatment.Drug
acid I-Treatment.Drug
in I-Treatment
spinal I-Treatment
anesthesia I-Treatment
. O

Hydroxymethylglutaryl I-Treatment.Drug
coenzyme I-Treatment.Drug
A I-Treatment.Drug
reductase I-Treatment.Drug
inhibitors I-Treatment.Drug
( I-Treatment
statins I-Treatment
) I-Treatment
have O
been O
associated I-Adverse_event.Trigger
with O
myopathy I-Effect
and I-Effect
rhabdomyolysis I-Effect
. O

Propranolol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypertension I-Effect
in O
treatment O
of O
cocaine O
intoxication O
. O

This O
is O
the O
second O
report O
of O
lactic I-Effect
acidosis I-Effect
in O
a I-Subject
patient I-Subject
on I-Adverse_event.Trigger
stavudine I-Treatment.Combination.Drug
and I-Treatment
lamivudine I-Treatment.Combination.Drug
. O

We O
report O
on O
a I-Subject
patient I-Subject
with I-Subject
renal I-Subject.Sub_Disorder
artery I-Subject.Sub_Disorder
stenosis I-Subject.Sub_Disorder
who I-Subject.Sub_Disorder
had I-Subject.Sub_Disorder
only I-Subject.Sub_Disorder
1 I-Subject.Sub_Disorder
kidney I-Subject.Sub_Disorder
and O
in O
whom O
acute I-Effect
renal I-Effect
impairment I-Effect
developed I-Effect
with I-Effect
transient I-Effect
anuria I-Effect
after I-Adverse_event.Trigger
the I-Treatment
administration I-Treatment
of I-Treatment
captopril I-Treatment.Drug
. O

However O
, O
in O
the O
mid O
- O
to O
- O
late O
1980s O
, O
a O
series O
of O
letters O
to O
the O
editor O
and O
case O
reports O
announced O
an O
association O
between O
tamoxifen I-Treatment.Drug
therapy O
in O
women I-Subject.Gender
with I-Subject
breast I-Treat_Disorder
cancer I-Treat_Disorder
and O
the O
development I-Adverse_event.Trigger
of O
endometrial I-Effect
carcinoma I-Effect
. O

Simvastatin I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
following O
cyclosporine I-Treatment.Combination.Drug
treatment I-Treatment
for O
uveitis I-Treat_Disorder
. O

Based O
on O
our O
previous O
demonstration O
that O
quinine I-Treatment.Drug
could O
be O
used O
clinically O
to O
reverse I-Effect
P I-Effect
- I-Effect
glycoprotein I-Effect
- I-Effect
mediated I-Effect
resistance I-Effect
, O
we O
designed O
a O
multicenter O
, O
randomized O
trial O
aiming O
to O
determine O
whether O
quinine O
would O
improve I-Potential_therapeutic_event.Trigger
the O
survival O
of O
adult I-Subject.Age
patients I-Subject
( I-Subject
15 I-Subject.Age
- I-Subject.Age
60 I-Subject.Age
years I-Subject.Age
old I-Subject.Age
) I-Subject
with O
de I-Treat_Disorder
novo I-Treat_Disorder
acute I-Treat_Disorder
myelogenous I-Treat_Disorder
leukemia I-Treat_Disorder
( I-Treat_Disorder
AML I-Treat_Disorder
) I-Treat_Disorder
. O

Vincristine I-Treatment.Drug
induced I-Adverse_event.Trigger
cranial I-Effect
polyneuropathy I-Effect
. O

Here O
we O
describe O
another O
case O
of O
VOD I-Effect
occurring I-Adverse_event.Trigger
after O
LT O
, O
but O
in O
which O
the O
causative O
role O
was O
played O
by O
azathioprine I-Treatment.Drug
. O

A O
retrospective O
review O
of O
TTP I-Subject.Sub_Disorder
patients I-Subject
with O
quinine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thrombotic I-Effect
microangiopathy I-Effect
( I-Effect
TMA I-Effect
) I-Effect
for O
whom O
ADAMTS13 O
was O
measured O
before O
plasma O
exchange O
was O
performed O
. O

Rituximab I-Treatment.Drug
- I-Treatment.Drug
CHOP I-Treatment.Drug
induced I-Adverse_event.Trigger
interstitial I-Effect
pneumonitis I-Effect
in O
patients I-Subject
with I-Subject
disseminated I-Treat_Disorder
extranodal I-Treat_Disorder
marginal I-Treat_Disorder
zone I-Treat_Disorder
B I-Treat_Disorder
cell I-Treat_Disorder
lymphoma I-Treat_Disorder
. O

Nitrendipine I-Treatment.Drug
is I-Treatment
an I-Treatment
experimental I-Treatment
calcium I-Treatment
channel I-Treatment
blocking I-Treatment
agent I-Treatment
that O
also O
appears O
to O
cause I-Adverse_event.Trigger
the O
side O
effect O
of O
drug O
- O
induced O
gingival I-Effect
hyperplasia I-Effect
. O

The O
present O
study O
describes O
a O
patient I-Subject
who O
had I-Adverse_event.Trigger
unusual I-Effect
weight I-Effect
fluctuation I-Effect
under O
corticosteroid I-Treatment
and I-Treatment
psychotropic I-Treatment
treatment I-Treatment
such I-Treatment
as I-Treatment
mianserin I-Treatment.Combination.Drug
and I-Treatment
aripiprazole I-Treatment.Combination.Drug
. O

Clozapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
akathisia I-Effect
in O
children I-Subject.Age
with I-Subject
schizophrenia I-Treat_Disorder
. O

Patients I-Subject
with I-Subject
previously I-Subject
untreated I-Subject
NSCLC I-Treat_Disorder
were O
randomized O
to O
receive I-Potential_therapeutic_event.Trigger
either I-Treatment
tirapazamine I-Treatment.Combination.Drug
( I-Treatment
390 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m(2 I-Treatment.Dosage
) I-Treatment.Dosage
infused I-Treatment.Route
over I-Treatment.Time_elapsed
2 I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
) I-Treatment
followed I-Treatment
1 I-Treatment
hour I-Treatment
later I-Treatment
by I-Treatment
cisplatin I-Treatment.Combination.Drug
( I-Treatment
75 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m(2 I-Treatment.Dosage
) I-Treatment.Dosage
over I-Treatment.Time_elapsed
1 I-Treatment.Time_elapsed
hour I-Treatment.Time_elapsed
) I-Treatment
or I-Treatment
75 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m(2 I-Treatment.Dosage
) I-Treatment.Dosage
of I-Treatment
cisplatin I-Treatment.Drug
alone I-Treatment
, I-Treatment
every I-Treatment.Freq
3 I-Treatment.Freq
weeks I-Treatment.Freq
for I-Treatment.Freq
a I-Treatment.Freq
maximum I-Treatment.Freq
of I-Treatment.Freq
eight I-Treatment.Freq
cycles I-Treatment.Freq
. O

Drug I-Treatment
interactions I-Treatment
between I-Treatment
macrolide I-Treatment.Drug
antibiotics I-Treatment.Drug
such I-Treatment
as I-Treatment
erythomycin I-Treatment.Combination.Drug
and I-Treatment
pharmacologic I-Treatment.Combination.Drug
agents I-Treatment.Combination.Drug
that I-Treatment
prolong I-Treatment
the I-Treatment
QT I-Treatment
interval I-Treatment
have O
been O
known O
to O
cause I-Adverse_event.Trigger
TdP. I-Effect
However O
, O
clarithromycin O
is O
thought O
to O
be O
less O
frequently O
associated O
with O
drug O
induced O
TdP O
, O
because O
it O
inactivates O
hepatic O
cytochrome O
P O
- O
450 O
to O
a O
lesser O
extent O
than O
erythromycin O
. O

In O
a O
randomised O
, O
investigator O
- O
blinded O
, O
multicentre O
phase O
III O
efficacy O
trial O
, O
899 I-Subject.Population
infants I-Subject.Age
and I-Subject.Age
children I-Subject.Age
with I-Subject
acute I-Subject
uncomplicated I-Subject
Plasmodium I-Treat_Disorder
falciparum I-Treat_Disorder
malaria I-Treat_Disorder
received I-Potential_therapeutic_event.Trigger
six I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
AL I-Treatment.Drug
according I-Treatment
to I-Treatment
body I-Treatment
weight I-Treatment
over I-Treatment
3 I-Treatment.Duration
days I-Treatment.Duration
either I-Treatment
as I-Treatment
crushed I-Treatment.Route
tablets I-Treatment.Route
( I-Treatment
Coartem I-Treatment
) I-Treatment
or I-Treatment
as I-Treatment
dispersible I-Treatment.Route
tablets I-Treatment.Route
. O

A I-Subject
patient I-Subject
presented O
with O
dilated I-Effect
cardiomyopathy I-Effect
after I-Adverse_event.Trigger
many I-Treatment
years I-Treatment
of I-Treatment
overusing I-Treatment.Dosage
an I-Treatment
adrenaline I-Treatment.Drug
inhaler I-Treatment.Route
. O

Occurrence I-Adverse_event.Trigger
of O
withdrawal I-Effect
dyskinesia I-Effect
indicates O
that O
the O
neuroleptic O
effects O
of O
amoxapine I-Treatment.Drug
may O
be O
clinically O
significant O
. O

Hair I-Effect
loss I-Effect
associated I-Adverse_event.Trigger
with O
paroxetine I-Treatment.Drug
treatment O
: O
a I-Subject
case I-Subject
report O
. O

RESULTS O
: O
In O
a I-Subject
22 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Thai I-Subject.Race
woman I-Subject.Gender
with I-Subject
Graves I-Treat_Disorder
' I-Treat_Disorder
disease I-Treat_Disorder
, O
tinnitus I-Effect
, I-Effect
hearing I-Effect
impairment I-Effect
in I-Effect
the I-Effect
left I-Effect
ear I-Effect
( I-Effect
with I-Effect
progression I-Effect
to I-Effect
the I-Effect
right I-Effect
ear I-Effect
) I-Effect
, I-Effect
and I-Effect
vertigo I-Effect
developed I-Adverse_event.Trigger
after I-Treatment.Time_elapsed
3 I-Treatment.Time_elapsed
years I-Treatment.Time_elapsed
of I-Treatment
therapy I-Treatment
with I-Treatment
PTU I-Treatment.Drug
. O

Additive I-Effect
pulmonary I-Effect
toxicity I-Effect
with I-Adverse_event.Trigger
melphalan I-Treatment.Combination.Drug
and I-Treatment
busulfan I-Treatment.Combination.Drug
therapy I-Treatment
. O

We O
report O
the O
case O
of O
a O
20 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
originally I-Subject
from I-Subject
Cameroon I-Subject.Race
who I-Subject
was I-Subject
infected I-Treat_Disorder
by I-Treat_Disorder
the I-Treat_Disorder
L. I-Treat_Disorder
loa I-Treat_Disorder
parasite I-Treat_Disorder
and O
developed I-Adverse_event.Trigger
severe I-Effect
hepatitis I-Effect
, O
identified O
1 I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
after I-Treatment
a I-Treatment
single I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
ivermectin I-Treatment.Drug
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
lithium I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
CDI I-Effect
and I-Effect
NDI I-Effect
presenting O
concurrently O
. O

In O
this O
healthy I-Subject
population I-Subject
, O
the O
relative O
risk O
of O
developing I-Adverse_event.Trigger
endometrial I-Effect
carcinoma I-Effect
in O
the O
tamoxifen I-Treatment.Drug
arm O
was O
2.54 O
, O
although O
when O
stratified O
by O
age O
, O
in O
women O
over O
50 O
, O
the O
risk O
grew O
to O
4.01 O
. O

Paradoxical I-Effect
ventricular I-Effect
tachycardia I-Effect
and I-Effect
fibrillation I-Effect
after I-Adverse_event.Trigger
intravenous I-Treatment.Route
bretylium I-Treatment.Drug
therapy O
. O

OBJECTIVE O
: O
To O
describe O
a I-Subject
case I-Subject
of O
thrombocytopenia I-Effect
associated I-Adverse_event.Trigger
with O
the O
administration O
of O
lansoprazole I-Treatment.Drug
. O

A I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
optic I-Effect
neuropathy I-Effect
while O
being O
treated O
with O
isoniazid I-Treatment.Combination.Drug
and I-Treatment
ethambutol I-Treatment.Combination.Drug
. O

This O
case O
describes O
a I-Subject
52 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
a I-Effect
spontaneous I-Effect
nasal I-Effect
septal I-Effect
perforation I-Effect
after O
given O
the O
antiangiogenic I-Treatment
drug I-Treatment
, I-Treatment
bevacizumab I-Treatment.Drug
, O
for O
metastatic O
ovarian O
cancer O
treatment O
. O

Two I-Subject.Population
cases I-Subject
are I-Subject
reported I-Subject
of I-Subject
patients I-Subject
who O
developed I-Adverse_event.Trigger
a O
hematologic I-Effect
malignancy I-Effect
several I-Treatment
years I-Treatment
after I-Treatment
intravesical I-Treatment.Route
chemotherapy I-Treatment.Route
of I-Treatment
superficial I-Treatment.Treat_Disorder
bladder I-Treatment.Treat_Disorder
cancer I-Treatment.Treat_Disorder
with I-Treatment
etoglucid I-Treatment.Combination.Drug
, I-Treatment
doxorubicin I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
mitomycin I-Treatment.Combination.Drug
C. I-Treatment.Combination.Drug

Eleven I-Subject.Population
patients I-Subject
developed I-Adverse_event.Trigger
infection I-Effect
requiring O
hospitalization O
while O
taking O
leflunomide I-Treatment.Drug
including O
: O
lower I-Effect
respiratory I-Effect
tract I-Effect
infections I-Effect
( I-Effect
3 I-Effect
) I-Effect
, I-Effect
cellulitis I-Effect
( I-Effect
2 I-Effect
) I-Effect
, I-Effect
disseminated I-Effect
herpes I-Effect
zoster I-Effect
( I-Effect
2 I-Effect
) I-Effect
, I-Effect
probable I-Effect
TB I-Effect
liver I-Effect
( I-Effect
1 I-Effect
) I-Effect
, I-Effect
abdominal I-Effect
sepsis I-Effect
( I-Effect
1 I-Effect
) I-Effect
, I-Effect
mycotic I-Effect
aneurysm I-Effect
( I-Effect
1 I-Effect
) I-Effect
and I-Effect
gastroenteritis I-Effect
( I-Effect
1 I-Effect
) I-Effect
. O

Symptoms I-Treat_Disorder
and I-Treat_Disorder
endoscopic I-Treat_Disorder
lesions I-Treat_Disorder
quickly O
regressed I-Potential_therapeutic_event.Trigger
within I-Treatment
1 I-Treatment.Time_elapsed
week I-Treatment.Time_elapsed
of I-Treatment
meloxicam I-Treatment.Drug
withdrawal I-Treatment
. O

Potential O
drug I-Treatment
interaction I-Treatment
between I-Treatment
simvastatin I-Treatment.Combination.Drug
and I-Treatment
danazol I-Treatment.Combination.Drug
causing I-Adverse_event.Trigger
rhabdomyolysis I-Effect
. O

Multiple I-Effect
myeloma I-Effect
complicated I-Effect
by I-Effect
congestive I-Effect
heart I-Effect
failure I-Effect
following I-Adverse_event.Trigger
first I-Treatment
administration I-Treatment
of I-Treatment
recombinant I-Treatment.Drug
alpha I-Treatment.Drug
- I-Treatment.Drug
interferon I-Treatment.Drug
. O

Carboplatin I-Effect
hypersensitivity I-Effect
induced I-Adverse_event.Trigger
by O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
paclitaxel I-Treatment.Combination.Drug
/ I-Treatment
carboplatin I-Treatment.Combination.Drug
in O
multiple I-Subject
platinum I-Drug
- I-Subject
treated I-Subject
patients I-Subject
with I-Subject
recurrent I-Treat_Disorder
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
. O

Two O
cases O
are O
reported O
of O
patients I-Subject
who O
developed I-Adverse_event.Trigger
a I-Effect
hematologic I-Effect
malignancy I-Effect
several I-Treatment.Time_elapsed
years I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
intravesical I-Treatment.Route
chemotherapy I-Treatment
of O
superficial I-Treat_Disorder
bladder I-Treat_Disorder
cancer I-Treat_Disorder
with I-Treatment
etoglucid I-Treatment.Combination.Drug
, I-Treatment
doxorubicin I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
mitomycin I-Treatment.Combination.Drug
C. I-Treatment.Combination.Drug

CASE O
SUMMARY O
: O
A I-Subject
46 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
African I-Subject.Race
- I-Subject.Race
American I-Subject.Race
man I-Subject.Gender
experienced I-Adverse_event.Trigger
recurrent I-Effect
grand I-Effect
mal I-Effect
seizures I-Effect
during O
intravenous I-Treatment.Route
infusion I-Treatment.Route
of I-Treatment
amphotericin I-Treatment.Drug
B I-Treatment.Drug
, O
then O
petit O
mal O
seizures O
as O
the O
infusion O
was O
stopped O
and O
the O
drug O
concentrations O
decreased O
with O
time O
. O

Moreover O
, O
these O
findings O
suggest O
that O
the O
incidence O
of O
BOOP I-Effect
following I-Adverse_event.Trigger
rituximab I-Treatment.Drug
therapy I-Treatment
may O
be O
higher O
than O
has O
been O
previously O
appreciated O
. O

Two I-Subject.Population
cases I-Subject
of O
hypothyroidism I-Effect
in O
patients O
with O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
treated I-Adverse_event.Trigger
with O
recombinant I-Treatment.Drug
alpha I-Treatment.Drug
interferon I-Treatment.Drug
are O
reported O
. O

OBJECTIVE O
: O
To O
report O
the O
case O
of O
a O
young I-Subject.Age
woman I-Subject.Gender
with I-Subject
Graves I-Treat_Disorder
' I-Treat_Disorder
disease I-Treat_Disorder
in O
whom O
ototoxicity I-Effect
developed I-Effect
because O
of O
propylthiouracil I-Treatment.Drug
( I-Treatment
PTU) I-Treatment
- O
induced I-Adverse_event.Trigger
antineutrophil O
cytoplasmic O
antibody O
( O
ANCA) O
- O
associated O
vasculitis O
. O

An I-Subject
obese I-Treat_Disorder
patient I-Subject
, I-Subject
not I-Subject
diabetic I-Subject
, O
treated O
with O
metformin I-Treatment.Drug
for I-Treatment
some I-Treatment.Duration
weeks I-Treatment.Duration
, O
was O
referred O
to O
us O
with O
severe I-Effect
inferior I-Effect
digestive I-Effect
hemorrhage I-Effect
, O
diagnosed I-Adverse_event.Trigger
with O
Meckel I-Effect
's I-Effect
diverticulum I-Effect
. O

Although O
a O
lot O
of O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
torsades I-Effect
de I-Effect
pointe I-Effect
have O
been O
published O
, O
a O
review O
of O
all O
these O
cases O
and O
the O
underlying O
risk O
- O
factors O
has O
never O
been O
made O
. O

However O
, O
one I-Subject
patient I-Subject
exhibited O
severe I-Effect
hypersensitivity I-Effect
reactions I-Effect
including I-Effect
cardiac I-Effect
arrest I-Effect
and I-Effect
apnea I-Effect
, O
and O
another O
four O
patients O
developed O
eruptions O
, O
hypotension O
, O
and O
tachycardia O
soon O
after O
administration I-Adverse_event.Trigger
of O
CBDCA I-Treatment.Drug
. O

However O
, O
one O
patient O
exhibited O
severe O
hypersensitivity O
reactions O
including O
cardiac O
arrest O
and O
apnea O
, O
and O
another O
four I-Subject
patients I-Subject
developed O
eruptions I-Effect
, I-Effect
hypotension I-Effect
, I-Effect
and I-Effect
tachycardia I-Effect
soon O
after O
administration I-Adverse_event.Trigger
of O
CBDCA I-Treatment.Drug
. O

This O
report O
is O
about O
three I-Subject.Population
cases I-Subject
of I-Subject
children I-Subject.Age
who O
developed I-Adverse_event.Trigger
severe O
adverse I-Effect
reactions I-Effect
during I-Treatment
switching I-Treatment
from I-Treatment
risperidone I-Treatment.Drug
to I-Treatment
methylphenidate I-Treatment.Drug
. O

This I-Subject
patient I-Subject
, I-Subject
who I-Subject
had I-Subject
a I-Subject
history I-Subject
of I-Subject
osteoarthritis I-Subject
, O
had I-Adverse_event.Trigger
severe O
hepatitis I-Effect
5 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
being I-Treatment
started I-Treatment
on I-Treatment
diclofenac I-Treatment.Drug
for O
increasing I-Treat_Disorder
pain I-Treat_Disorder
in I-Treat_Disorder
the I-Treat_Disorder
joints I-Treat_Disorder
. O

She I-Subject.Gender
received I-Potential_therapeutic_event.Trigger
chemotherapy I-Treatment.Route
according O
to O
the O
previously O
described O
modified O
St. O
Jude O
total O
therapy O
studies O
XIII O
. O

A I-Subject
17 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
who O
had O
been O
taking O
oral I-Treatment.Route
minocycline I-Treatment.Drug
( I-Treatment
50 I-Treatment.Dosage
mg I-Treatment.Dosage
twice I-Treatment.Freq
daily I-Treatment.Freq
) I-Treatment
for I-Treatment
3 I-Treatment.Duration
weeks I-Treatment.Duration
for O
acne I-Treat_Disorder
developed I-Adverse_event.Trigger
an O
eruption I-Effect
that O
progressed O
to O
an I-Effect
exfoliative I-Effect
dermatitis I-Effect
. O

Risperidone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
obsessive I-Effect
- I-Effect
compulsive I-Effect
symptoms I-Effect
in O
two I-Subject.Population
children I-Subject.Age
. O

CONCLUSIONS O
: O
Cicatrization O
in O
the O
substantia O
propria O
of O
the O
conjunctiva O
by O
excessive O
lymphocytic O
infiltration O
after O
topically O
administered O
antiglaucoma I-Treatment.Drug
drugs I-Treatment.Drug
including I-Treatment
dipivefrin I-Treatment.Drug
is O
a O
possible O
mechanism I-Adverse_event.Trigger
of I-Adverse_event.Trigger
action I-Adverse_event.Trigger
for O
entropion I-Effect
. O

A I-Subject
patient I-Subject
with I-Subject
the I-Subject
Wolff I-Treat_Disorder
- I-Treat_Disorder
Parkinson I-Treat_Disorder
- I-Treat_Disorder
White I-Treat_Disorder
syndrome I-Treat_Disorder
presented O
with O
incessant I-Effect
orthodromic I-Effect
atrioventricular I-Effect
tachycardia I-Effect
following I-Adverse_event.Trigger
initiation I-Treatment
of I-Treatment
procainamide I-Treatment.Drug
therapy I-Treatment
. O

Hypersensitivity I-Effect
to I-Effect
carboplatin I-Effect
is O
a O
rare O
but O
real O
complication I-Adverse_event.Trigger
of O
therapy O
and O
should O
be O
considered O
in O
patients I-Subject
presenting I-Subject
with I-Subject
hyperacute I-Subject.Sub_Disorder
changes I-Subject.Sub_Disorder
on I-Subject.Sub_Disorder
ECG I-Subject.Sub_Disorder
whilst O
receiving O
carboplatin I-Treatment.Drug
therapy I-Treatment
. O

A O
well O
- O
recognized O
complication I-Adverse_event.Trigger
of O
ethambutol I-Treatment.Drug
use O
is O
optic I-Effect
neuropathy I-Effect
, O
but O
the O
potential O
ocular O
toxicity O
of O
isoniazid O
is O
often O
overlooked O
. O

A O
well O
- O
recognized O
complication O
of O
ethambutol O
use O
is O
optic O
neuropathy O
, O
but O
the O
potential O
ocular I-Effect
toxicity I-Effect
of O
isoniazid I-Treatment.Drug
is O
often O
overlooked O
. O

PURPOSE O
: O
To O
report O
that O
acute I-Treatment
lamotrigine I-Treatment.Drug
poisoning I-Treatment
may O
result I-Adverse_event.Trigger
in O
severe I-Effect
encephalopathy I-Effect
. O

Reversal O
of O
ergotamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
arteriospasm I-Effect
by O
mechanical O
intra O
- O
arterial O
dilatation O
. O

There O
have O
been O
several O
case O
reports O
of O
serotonin I-Effect
syndrome I-Effect
from I-Adverse_event.Trigger
similar O
combinations I-Treatment
of I-Treatment
antidepressant I-Treatment.Combination.Drug
and I-Treatment
atypical I-Treatment
antipsychotic I-Treatment.Combination.Drug
treatment I-Treatment
. O

We O
report O
the O
first O
case O
of O
a I-Subject
human I-Treat_Disorder
immunodeficiency I-Treat_Disorder
virus I-Treat_Disorder
type I-Treat_Disorder
1 I-Treat_Disorder
( I-Subject
HIV I-Subject
- I-Subject
1) I-Subject
- I-Subject
infected I-Subject
individual I-Subject
receiving O
combination I-Treatment
antiretroviral I-Treatment
therapy I-Treatment
, I-Treatment
which I-Treatment
included I-Treatment
ritonavir I-Treatment.Combination.Drug
, O
who O
developed I-Adverse_event.Trigger
Cushing I-Effect
syndrome I-Effect
with O
profound O
complications O
after O
epidural I-Treatment.Route
triamcinolone I-Treatment.Combination.Drug
injections I-Treatment.Route
. O

Disulfiram I-Effect
- I-Effect
like I-Effect
reactions I-Effect
with I-Adverse_event.Trigger
newer O
cephalosporins O
: O
cefmenoxime I-Treatment.Drug
. O

We O
recommend O
routine I-Treatment
follow I-Treatment
up I-Treatment
by I-Treatment
ECG I-Treatment
of I-Potential_therapeutic_event.Trigger
patients I-Subject
over I-Subject.Age
the I-Subject.Age
age I-Subject.Age
of I-Subject.Age
50 I-Subject.Age
treated O
with O
carbamazepine I-Drug
. O

A I-Subject
10 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
with I-Subject
Lennox I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
Gastaut I-Subject.Sub_Disorder
syndrome I-Subject.Sub_Disorder
who O
received O
intravenous I-Treatment.Route
lorazepam I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
atypical I-Treat_Disorder
absence I-Treat_Disorder
status I-Treat_Disorder
seizures I-Treat_Disorder
is O
reported O
. O

Ritonavir I-Combination.Drug
can O
inhibit O
the O
metabolism I-Effect
of I-Effect
fentanyl I-Effect
significantly I-Effect
, O
so O
caution I-Adverse_event.Trigger
should O
be O
exercised O
if O
fentanyl I-Treatment.Combination.Drug
is O
given O
to O
patients I-Subject
receiving I-Subject
ritonavir I-Subject
medication I-Subject
. O

This I-Subject
case I-Subject
emphasizes O
the O
importance O
of O
the O
evaluation O
of O
lithium I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
polyuria I-Effect
with O
a O
direct O
measurement O
of O
plasma O
vasopressin O
, O
interpreted O
with O
simultaneous O
plasma O
and O
urine O
osmolality O
to O
secure O
the O
correct O
diagnosis O
and O
ensure O
appropriate O
therapeutic O
management O
. O

A I-Subject
patient I-Subject
with I-Subject
chronic I-Subject.Sub_Disorder
myelomonocytic I-Subject.Sub_Disorder
leukemia I-Subject.Sub_Disorder
developed I-Adverse_event.Trigger
drug O
- O
induced O
pulmonary I-Effect
toxicity I-Effect
after O
using I-Treatment
low I-Treatment.Dosage
dose I-Treatment.Dosage
oral I-Treatment.Route
etoposide I-Treatment.Drug
. O

Alopecia I-Effect
and I-Effect
hair I-Effect
loss I-Effect
are O
rare O
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of O
psychotropic I-Treatment.Drug
drugs I-Treatment
. O

Occult O
quinine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
. O

We O
report O
the O
case O
of O
a I-Subject
17 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
who O
developed O
chest I-Effect
pain I-Effect
, I-Effect
elevated I-Effect
cardiac I-Effect
biomarkers I-Effect
, I-Effect
and I-Effect
acute I-Effect
left I-Effect
ventricular I-Effect
dysfunction I-Effect
following I-Adverse_event.Trigger
a I-Treatment.Dosage
single I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
methylphenidate I-Treatment.Drug
. O

In I-Subject
patients I-Subject
with I-Subject
swallowing I-Subject
dysfunction I-Subject
and I-Subject
pneumonia I-Subject
, O
a I-Treatment
history I-Treatment
of I-Treatment
mineral I-Treatment.Drug
oil I-Treatment.Drug
use I-Treatment
should O
be O
obtained O
and O
a O
diagnosis O
of O
ELP I-Effect
should O
be O
considered I-Adverse_event.Trigger
in O
the O
differential O
diagnoses O
if O
mineral O
oil O
use O
has O
occurred O
. O

Agranulocytosis I-Effect
induced I-Adverse_event.Trigger
by O
vancomycin I-Treatment.Drug
in O
an O
ESRD I-Subject.Sub_Disorder
patient I-Subject
on I-Subject
CAPD I-Subject
. O

First O
case O
of O
ivermectin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
severe I-Effect
hepatitis I-Effect
. I-Effect

The O
authors O
suggest O
that O
fluoxetine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
akathisia I-Effect
may I-Effect
be I-Effect
caused I-Effect
by I-Effect
serotonergically I-Effect
mediated I-Effect
inhibition I-Effect
of I-Effect
dopaminergic I-Effect
neurotransmission I-Effect
and O
that O
the O
pathophysiology O
of O
fluoxetine O
- O
induced O
akathisia O
and O
tricyclic O
antidepressant O
- O
induced O
" O
jitteriness O
" O
may O
be O
identical O
. O

The O
use O
of O
telithromycin I-Treatment.Drug
in O
patients I-Subject
receiving I-Subject
multiple I-Subject
doses I-Subject
of I-Subject
oxycodone I-Subject
for I-Subject
pain I-Subject
relief I-Subject
may O
increase I-Adverse_event.Trigger
the I-Adverse_event.Trigger
risk I-Adverse_event.Trigger
of O
opioid I-Effect
adverse I-Effect
effects I-Effect
. O

A O
case O
of O
metoclopramide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
oculogyric I-Effect
crisis I-Effect
in O
a I-Subject
16 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
with I-Subject
cystic I-Subject.Sub_Disorder
fibrosis I-Subject.Sub_Disorder
. O

Supported O
by O
a O
subtherapeutic O
quinine O
level O
, O
we O
hypothesise O
that O
a O
drug O
interaction O
with O
phenytoin I-Treatment.Combination.Drug
may O
compromise I-Adverse_event.Trigger
the O
efficacy I-Effect
of I-Effect
quinine I-Treatment.Combination.Drug
in O
the O
treatment O
of O
malaria I-Treat_Disorder
. O

Sporadic I-Effect
rippling I-Effect
muscle I-Effect
disease I-Effect
unmasked I-Adverse_event.Trigger
by O
simvastatin I-Treatment.Drug
. O

An O
objective O
causality O
assessment O
by O
use O
of O
the O
Naranjo O
probability O
scale O
revealed O
that O
NCSE I-Effect
due I-Adverse_event.Trigger
to O
ifosfamide I-Treatment.Drug
was O
probable O
. O

Cis I-Treatment.Drug
- I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
( I-Treatment
RA I-Treatment
) I-Treatment
may O
further O
increase O
the O
risk O
of O
developing I-Adverse_event.Trigger
BMTN I-Effect
. O

He I-Subject.Gender
was O
later O
skin O
tested O
to O
confirm O
allergy I-Effect
to I-Adverse_event.Trigger
MTX I-Treatment.Drug
. O

Indolent I-Effect
aspergillus I-Effect
arthritis I-Effect
complicating I-Adverse_event.Trigger
fludarabine I-Treatment.Drug
- O
based O
non O
- O
myeloablative O
stem O
cell O
transplantation O
. O

A O
case O
of O
acute I-Effect
cardiomyopathy I-Effect
and I-Effect
pericarditis I-Effect
associated I-Adverse_event.Trigger
with O
methylphenidate I-Treatment.Drug
. O

STUDY O
DESIGN O
: O
Case O
reports O
are O
presented O
of O
three I-Subject.Population
premature I-Subject.Age
infants I-Subject.Age
( I-Subject.Age
mean I-Subject.Age
gestational I-Subject.Age
age I-Subject.Age
27 I-Subject.Age
weeks I-Subject.Age
) I-Subject.Age
cared I-Subject
for I-Subject
in I-Subject
the I-Subject
intensive I-Subject
care I-Subject
nursery I-Subject
in O
whom O
clinically I-Effect
significant I-Effect
septal I-Effect
hypertrophy I-Effect
and I-Effect
left I-Effect
ventricular I-Effect
outflow I-Effect
tract I-Effect
obstruction I-Effect
developed I-Adverse_event.Trigger
during I-Treatment
dexamethasone I-Treatment.Drug
treatment I-Treatment
for I-Treatment
bronchopulmonary I-Treatment.Treat_Disorder
dysplasia I-Treatment.Treat_Disorder
. I-Treat_Disorder

A I-Subject
case I-Subject
of I-Subject
the I-Subject
Rett I-Treat_Disorder
syndrome I-Treat_Disorder
with O
acute I-Effect
encephalopathy I-Effect
induced I-Adverse_event.Trigger
during O
calcium I-Treatment.Drug
hopantenate I-Treatment.Drug
treatment I-Treatment
. O

Transient I-Effect
serotonin I-Effect
syndrome I-Effect
caused I-Adverse_event.Trigger
by O
concurrent I-Treatment
use I-Treatment
of I-Treatment
tramadol I-Treatment.Combination.Drug
and I-Treatment
selective I-Treatment.Combination.Drug
serotonin I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitor I-Treatment.Combination.Drug
. O

Adverse O
events O
associated I-Adverse_event.Trigger
with O
IFN I-Treatment.Drug
alfa I-Treatment.Drug
- I-Treatment.Drug
2b I-Treatment.Drug
use O
are O
primarily I-Effect
constitutional I-Effect
symptoms I-Effect
. O

Sustained I-Treatment
- I-Treatment
release I-Treatment
procainamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
reversible I-Effect
granulocytopenia I-Effect
after O
myocardial O
infarction O
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
M4 I-Treat_Disorder
AML I-Treat_Disorder
treated O
with O
standard I-Treatment
chemotherapy I-Treatment.Combination.Drug
followed I-Treatment
by I-Treatment
G I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
CSF I-Treatment.Combination.Drug
who O
developed I-Adverse_event.Trigger
marked I-Effect
monocytosis I-Effect
on O
day I-Time_elapsed
8 I-Time_elapsed
of O
G O
- O
CSF O
therapy O
. O

Esophageal I-Effect
candidiasis I-Effect
was O
diagnosed O
at O
endoscopy O
in O
two I-Subject.Population
patients I-Subject
receiving I-Adverse_event.Trigger
omeprazole I-Treatment.Drug
therapy I-Treatment
. O

Bisphosphonate I-Treatment.Drug
induced I-Adverse_event.Trigger
osteochemonecrosis I-Effect
of I-Effect
the I-Effect
jaw I-Effect
mimicking O
a O
tumour O
. O

OBJECTIVES O
: O
To O
describe O
the O
clinicopathologic O
features O
of O
3 I-Subject.Population
patients I-Subject
with I-Subject
CML I-Treat_Disorder
who O
rapidly O
progressed I-Adverse_event.Trigger
from I-Effect
chronic I-Effect
phase I-Effect
to I-Effect
blast I-Effect
crisis I-Effect
while O
taking O
imatinib I-Treatment.Drug
and O
to O
perform O
a O
review O
of O
the O
literature O
. O

Although O
they O
had O
only O
a I-Subject.Sub_Disorder
few I-Subject.Sub_Disorder
nodules I-Subject.Sub_Disorder
at I-Subject
diagnosis I-Subject
, O
the I-Effect
nodules I-Effect
increased I-Effect
in I-Effect
number I-Effect
and I-Effect
size I-Effect
3 I-Time_elapsed
to I-Time_elapsed
4 I-Time_elapsed
months I-Time_elapsed
after I-Adverse_event.Trigger
the O
start O
of O
methotrexate I-Treatment.Drug
therapy I-Treatment
in O
both O
patients O
. O

CONCLUSIONS O
: O
Among O
the O
many O
presentations O
of O
ifosfamide I-Treatment.Drug
neurotoxicity I-Effect
, O
clinicians O
should O
consider O
NCSE I-Effect
as O
a O
possible O
explanation O
for O
changes I-Effect
in I-Effect
consciousness I-Effect
in O
a I-Subject
patient I-Subject
receiving I-Adverse_event.Trigger
this O
agent O
. O

It O
is O
concluded O
that O
SIADH I-Effect
is O
an O
important O
side I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
lorcainide I-Treatment.Drug
therapy I-Treatment
. O

Hepatoxicity I-Effect
is I-Adverse_event.Trigger
a O
rare O
complication O
of O
SRL I-Treatment.Drug
therapy I-Treatment
and O
may O
be O
connected O
with O
some O
diagnostic O
and/or O
therapeutic O
problems O
. O

A O
previous O
study O
of O
patients O
with O
" O
quinine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
TTP I-Effect
/ I-Effect
HUS I-Effect
" O
found O
that O
ADAMTS13 I-Effect
activities I-Effect
were I-Effect
not I-Effect
abnormal I-Effect
in O
12/12 I-Subject.Population
patients I-Subject
. O

A I-Subject
teenage I-Subject.Age
girl I-Subject.Gender
with I-Subject
crescentic I-Subject.Sub_Disorder
glomerulonephritis I-Subject.Sub_Disorder
had I-Adverse_event.Trigger
antineutrophil I-Effect
cytoplasmic I-Effect
antibody I-Effect
( I-Effect
ANCA I-Effect
) I-Effect
detected O
after O
she O
had O
received O
propylthiouracil I-Treatment.Drug
( I-Treatment
PTU I-Treatment
) I-Treatment
for O
hyperthyroidism I-Treat_Disorder
without I-Treat_Disorder
cutaneous I-Treat_Disorder
vasculitis I-Treat_Disorder
. O

Digestive I-Effect
hemorrhage I-Effect
caused I-Effect
by I-Effect
a I-Effect
Meckel I-Effect
's I-Effect
diverticulum I-Effect
in O
a O
metformin I-Treatment.Drug
- O
treated I-Adverse_event.Trigger
patient I-Subject
: O
is O
there O
any O
connection O
? O

Our O
findings O
reveal O
that O
even O
in O
patients I-Subject
without I-Subject
a I-Subject
history I-Subject
of I-Subject
seizures I-Subject
, O
pregabalin I-Treatment.Drug
can O
cause I-Adverse_event.Trigger
a O
cortical I-Effect
negative I-Effect
myoclonus I-Effect
. O

We O
describe O
the O
first O
documented O
case O
of O
azathioprine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
severe I-Effect
myelosuppression I-Effect
due O
to O
thiopurine O
methyltransferase O
deficiency O
in O
autoimmune O
liver O
disease O
. O

We O
report O
five I-Population
cases O
of O
carboplatin I-Drug
( I-Effect
CBDCA I-Effect
) I-Effect
hypersensitivity I-Effect
after I-Adverse_event.Trigger
weekly I-Treatment.Freq
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
paclitaxel I-Treatment.Combination.Drug
( I-Treatment
60 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2)/CBDCA I-Treatment.Combination.Drug
( I-Treatment
area I-Treatment
under I-Treatment
the I-Treatment
concentration I-Treatment
curve I-Treatment
= I-Treatment
2 I-Treatment
) I-Treatment
therapy I-Treatment
in O
patients I-Subject
with I-Subject
recurrent I-Treat_Disorder
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
receiving O
multiple I-Treatment
platinum I-Treatment.Combination.Drug
- I-Treatment
based I-Treatment
chemotherapy I-Treatment.Route
. O

The I-Subject
patient I-Subject
was O
placed O
on O
omeprazole I-Drug
after O
his O
first O
cycle O
of O
high I-Dosage
- I-Dosage
dose I-Dosage
methotrexate I-Treatment.Drug
for O
stress I-Treat_Disorder
ulcer I-Treat_Disorder
prophylaxis I-Potential_therapeutic_event.Trigger
, O
and O
it O
was O
discontinued O
before O
the O
start O
of O
the O
first O
day O
of O
the O
patient O
's O
second O
round O
of O
high O
- O
dose O
methotrexate I-Drug
. O

Because O
the I-Subject
patient I-Subject
had O
been O
taking O
lovastatin I-Drug
for O
the O
past O
12 I-Duration
years I-Duration
, O
the O
possibility O
that O
the O
rhabdomyolysis I-Effect
may O
have O
been O
caused I-Adverse_event.Trigger
by O
a O
drug O
interaction O
between O
lovastatin I-Treatment.Drug
and O
a O
concomitant O
drug O
was O
evaluated O
. O

Ibopamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
reversible O
leukopenia I-Effect
during O
treatment O
for O
congestive I-Treat_Disorder
heart I-Treat_Disorder
failure I-Treat_Disorder
. O

A I-Subject
71 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
paroxysmal I-Treat_Disorder
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
who I-Subject
had I-Subject
a I-Subject
previous I-Subject
anterior I-Subject.Sub_Disorder
myocardial I-Subject.Sub_Disorder
infarction I-Subject.Sub_Disorder
exhibited I-Adverse_event.Trigger
granulocytopenia I-Effect
8 I-Time_elapsed
days I-Time_elapsed
following O
the O
administration O
of O
oral I-Treatment.Route
sustained I-Treatment.Drug
- I-Treatment.Drug
release I-Treatment.Drug
procainamide I-Treatment.Drug
( I-Treatment
750 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
) I-Treatment
. O

Clinicians O
should O
be O
cognizant O
of O
this O
possibility O
and O
consider O
a O
diagnosis O
of O
HDAs I-Effect
in O
patients I-Subject
with O
ongoing O
thrombosis I-Effect
who O
are O
receiving I-Adverse_event.Trigger
heparin I-Treatment.Drug
therapy O
. O

Rifampin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypothyroidism I-Effect
without I-Effect
underlying I-Effect
thyroid I-Effect
disease I-Effect
. O

Paradoxical I-Effect
precipitation I-Effect
of I-Effect
tonic I-Effect
seizures I-Effect
by O
lorazepam I-Treatment.Drug
in O
a O
child I-Subject.Age
with I-Subject
atypical I-Subject
absence I-Treat_Disorder
seizures I-Treat_Disorder
. O

Peculiar I-Effect
nail I-Effect
- I-Effect
changes I-Effect
in O
a I-Subject
70 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
occurring O
after I-Adverse_event.Trigger
approximately O
1 I-Time_elapsed
year I-Time_elapsed
of O
penicillamine I-Treatment.Drug
treatment O
are O
described O
. O

Cutaneous I-Effect
vasculitis I-Effect
secondary I-Adverse_event.Trigger
to O
ramipril I-Treatment.Drug
. O

Multiple O
mechanisms O
for O
ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
nephrotoxicity I-Effect
have O
been O
proposed O
. O

Pregabalin I-Treatment.Combination.Drug
was I-Treatment
added I-Treatment
to I-Treatment
clozapine I-Treatment.Combination.Drug
in I-Potential_therapeutic_event.Trigger
2 I-Subject.Population
patients I-Subject
with I-Subject
schizophrenia I-Treat_Disorder
, I-Subject
who I-Subject
both I-Subject
suffered I-Subject
from I-Subject
severe I-Subject
anxiety I-Treat_Disorder
symptoms I-Treat_Disorder
. O

Severe I-Effect
hyperkalemia I-Effect
as O
a O
complication I-Adverse_event.Trigger
of O
timolol I-Treatment.Drug
, O
a I-Treatment
topically I-Treatment
applied I-Treatment
beta I-Treatment
- I-Treatment
adrenergic I-Treatment
antagonist I-Treatment
. O

Amphotericin I-Treatment.Drug
B I-Treatment.Drug
overdose I-Treatment.Dosage
in O
pediatric I-Subject.Age
patients I-Subject
with O
associated I-Adverse_event.Trigger
cardiac I-Effect
arrest I-Effect
. O

Of O
particular O
interest O
is O
that O
toxicity I-Effect
only O
occurred I-Adverse_event.Trigger
during O
the O
second I-Treatment
course I-Treatment
of I-Treatment
FLA I-Treatment.Combination.Drug
and I-Treatment
sixth I-Treatment.Time_elapsed
course I-Treatment.Time_elapsed
of I-Treatment
Ara I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
C I-Treatment.Combination.Drug
containing I-Treatment
chemotherapy I-Treatment.Route
. O

The O
literature O
search O
found O
12 I-Subject.Population
cases I-Subject
of O
radiation I-Effect
recall I-Effect
caused I-Adverse_event.Trigger
by O
gemcitabine I-Treatment.Drug
. O

Two I-Subject.Population
heroin I-Subject.Sub_Disorder
addicts I-Subject.Sub_Disorder
, I-Subject
aged I-Subject.Age
34 I-Subject.Age
and I-Subject.Age
19 I-Subject.Age
years I-Subject.Age
, O
developed I-Adverse_event.Trigger
ballistic I-Effect
movements I-Effect
after O
intravenous I-Treatment.Route
heroin I-Treatment.Drug
overdose I-Treatment.Dosage
. O

Successful O
challenge O
with I-Potential_therapeutic_event.Trigger
clozapine I-Treatment.Drug
in O
a O
history O
of O
eosinophilia I-Treat_Disorder
. O

CASE O
SUMMARY O
: O
A I-Subject
57 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
with I-Subject
cardiomyopathy I-Subject.Sub_Disorder
and I-Subject
" I-Subject.Sub_Disorder
sulfa I-Subject.Sub_Disorder
" I-Subject.Sub_Disorder
( I-Subject.Sub_Disorder
trimethoprim I-Subject.Sub_Disorder
/ I-Subject.Sub_Disorder
sulfamethoxazole I-Subject.Sub_Disorder
) I-Subject.Sub_Disorder
allergy I-Subject.Sub_Disorder
documented O
as O
pancreatitis I-Effect
presented O
with O
symptoms O
consistent O
with O
pancreatitis O
after I-Adverse_event.Trigger
use I-Adverse_event.Trigger
of O
furosemide I-Treatment.Drug
. O

Acute I-Effect
intravascular I-Effect
hemolysis I-Effect
developed O
when O
a I-Subject
diabetic I-Treat_Disorder
patient I-Subject
, O
previously O
treated I-Adverse_event.Trigger
with O
glyburide O
, O
was O
started O
on O
another O
oral O
sulfonylurea O
drug O
, O
chlorpropamide I-Treatment.Drug
. O

Intravitreal I-Treatment.Route
triamcinolone I-Treatment.Drug
may O
have O
had O
an O
influence I-Adverse_event.Trigger
on O
the O
exacerbation I-Effect
of I-Effect
retinochoroiditis I-Effect
in I-Effect
the I-Effect
posterior I-Effect
pole I-Effect
of O
the I-Subject
patient I-Subject
. O

We O
evaluated O
a O
patient I-Subject
who O
developed I-Adverse_event.Trigger
a O
psychotic I-Effect
disorder I-Effect
after O
4 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
of I-Treatment
isoniazid I-Treatment.Drug
prophylaxis I-Treatment
for O
a O
positive O
tuberculosis I-Treat_Disorder
tine O
test O
. O
